ML18058B034

From kanterella
Jump to navigation Jump to search
Rev 6 to Odcm
ML18058B034
Person / Time
Site: Palisades Entergy icon.png
Issue date: 05/11/1992
From:
CONSUMERS ENERGY CO. (FORMERLY CONSUMERS POWER CO.)
To:
Shared Package
ML18058B032 List:
References
PROC-920511, NUDOCS 9209030212
Download: ML18058B034 (103)


Text

ATTACHMENT 6 Consumers Power Company Palisades Plant Docket 50-255 SEMIANNUAL RADIOACTIVE EFFLUENT RELEASE AND WASTE DISPOSAL REPORT OFFSITE DOSE CALCULATION MANUAL August 27, 1992 96 Pages

Approved PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 6 May 8, 1992

\\f4_._riager - Radiological Services RMC Administrator PRC Reviewed S-- II- '7 t..

Date 5-/Pfa;\\

Date

\\

S-ll-9a

  • .. Date.

~/,1/1z...

Date MRN

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 6 Table of Contents I.

GASEOUS EFFLUENTS....

A.

B.

ALARM/TRIP METHOD...

I.

Allowable Concentration...

2.

Monitor Response...

a.

Normal Release..

b.

Accident Releases DOSE RATE CALCULATION *****

I.

Appendix I - Calculation Basis.

a.

Equations and Assumptions for Noble Gas.......

b.

Equations and Assumptions for Iodines & Particulates:.

c.

Design Basis Quantities..............

d.

Land Use Census and DBQ Changes..........

e.

Gaseous Releases From The Steam Generator Slowdown Vent and Atmosphere Release Valves *.........

C.

DESIGN OBJECTIVE QUANTITY (DBQ) LIMITS ON BATCH AND CONTINUOUS RELEASES.........

I.

Batch Releases........*.........

2.

Continuous Releases......*........

3.

Exceeding DBO Limits..........*....

4.

Releasing! Radionuclises Not Listed in Table 1.9.

D.

OPTIONAL QUARTERLY DOSE CALCULATIONS...........

'*¥-i:(:;: _ Methodology for Optional Quarterly Dose Calculations

~IC ~:

~!=f 1 !ii ~d c~~~~r~~~~~ *~ ~p~r~a~h

  • E.

F.

G.

H.

I.

J.

GASIOUS RADWSTE TREATMENT SYSTEM OP,£RATION.

~\\.

\\\\

-I.

System Description... *....... *,..

2.

Determination of Satisfactory Operation...,.

RELEASE RATE FOR OFFSITE MPC....

\\......

PARTICULATE AND IODINE SAMPLING.

NOBLE GAS SAMPLING TRITIUM SAMPLING *.

FIGURES AND TABLES....

Page 1

1 1

2 2

3 3

3 4

7 18 19 20 20 20 21 21 22 22 22 23 24 -

25 25 26 26 27 28 28 29-60

(

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCU[ATION MANUAL Revision 6 Table of Contents II.

LIQUID EFFLUENTS...

A.

CONCENTRATION..

~

61 61 I.

RETS Requirements....................... 61.

2.

Prerelease Analysis......................

61

3.

Maximum Permissible Concentration CMPC) - Sum of the Ratios..

B.

  • c.

D.

E.

INSTRUMENT SETPOINTS.....

I.

2.
3.

DOSE I.

2.

SetDoint Determination..

Composite Samplers..

Post-Release Analysis.

Requirement *...

Release Analysis..

a.

Water Ingestion.

b.

Fish Ingestion.

c.

Annual Analysis OPERABILITY OF LIQUID RADWASTE EQUIPMENT.

RELEASE RATE FOR OFFSITE MPC *..

III.

URANIUM FUEL CYCLE DOSE *.

IV.

A.

SPECIFICATION.* * * *.

B.

ASSUMPTIONS. *. *.

C * :,:x~.g~~ ~ALC.U~TION..

RADNASTE~SYSTEM MODIFICATIONS.....

.: ~ >:t!;t~~;~;~~::~:*~~ ~~~

A.. '*:,DEfJ.rcn*ION OF MAJOR RADWASTE SYSTEM MODIFICATION.

B.

I.

. 2.

Purpose. * *

  • Definitions ***.*

FIGURES AND TABLES.........

\\

..... '~

\\

\\

.. \\..

Appendix A Relocated Technical Specifications - pending NRC approval.

Appendix B Request to Retain Soil in Accordance with 10CFR20.302

~~.

62 63 63 63 64 64 64 65 66 67 67 69 69 70 70 70 71 71 71 71 72 73-93

  • .~~-~

-~~.

I.

GASEOUS EFFLUENTS A.

ALARM/TRIP SETPOINT METHOD Specification 3.24.5.1 requires that MPC is not exceeded when averaged over a period not to exceed 1 hour1.157407e-5 days <br />2.777778e-4 hours <br />1.653439e-6 weeks <br />3.805e-7 months <br />.

Based on the definition of MPC, the dose rate in unrestricted areas due to gaseous effluents from the site shall be limited at all times to the following values:

500 mrem/y to the total body and 3,000 mrem/y to the skin from noble gases.

1,500 mrem/y to any organ from radioiodines and particulates, due to inhalation.

Specification 3.24.2.1 requires gaseous effluent monitors to have alarm/trip setpoints to ensure that offsite concentrations, when averaged over 1 hour1.157407e-5 days <br />2.777778e-4 hours <br />1.653439e-6 weeks <br />3.805e-7 months <br />, will not be greater than MPC.

This section of the ODCM describes the methodology that will be used to determine these setpoints.

The methodology for determining alarm/trip setpoints is divided into two major parts. The first consists of calculating an allowable concentration for the nuclide mixture to be released.

The second consists of determining monitor response to this mixture in order to establish the physical settings on the monitors.

1.

Allowable concentration

~i~~
s~h: * :. : ><

T~!~!o:talMPC:-fraction (Rk) for each release point will be calculated ti~J:-lt*j'oraship defined by Note 1 of Appendix B, 10 CFR 20:

-~* ***,.. *: -~ _. L**.: : -'.

\\

l by the

( 1.1)

Rev 6 5/08/92

where: *

  • MPCi =

X/Q =

F =

Actual or measured concentration, at ambient temperature and pre~sure of nuclide i (µCi/cc)

The MPC of nuclide i from 10 CFR 20, Appendix B The total MPC-fraction for release point k Most conservative sector site boundary dispersion (l.40E-06 sec/m3)

Release flow rate (83,000 cfm = 39.2 m3/sec} for stack monitor considerations; variable for other.monitors.

NOTE:

If a batch release is made while a continuous release or another batch release is in progress, the sum of all values of Rk must be less than 1.0.

2.

Monitor Response Normal radioactivity releases consist mainly of well-decayed fission gases.

Therefore, monitor response calibrations are performed to fission gas typical of normal releases (mainly Xe-133}.

Response of monitors used to define fission product release rates under accident conditions may vary from that of Xe-133, however.

Monitor response for the two categories of monitor is determined as follows:

a.

Normal Release {aged fission gasses)

Total gas concentration (µCi/cc} at the monitor is calculated. The calibration curve or constant for cpm/µCi/cc} is applied to determine cpm expected. The setting for monitor alarms is established at some factor (b) greater than 1 but less than l/R (Equation 1.1) ti~es the measure~ concentration (c):

s - b x c

. ~ ;

2 (I. 2)

Rev 6 5/08/92

b.

Accident Releases Monitors are preset to alarm at or before precalculated offsite dose rates would be achieved under hypothetical accident conditions. These setpoints are established in accordance with Emergency Plan requirements for defining Emergency Action Levels and associated actions.

Emergency Implementing Procedures contain monitor-specific curves or calibration constants for conversion between cpm and µCi/cc (or R/hr and µCi/cc), depending on monitor type, for fission product mixtures as a function of mixture decay time.

When these monitors are utilized for other than accident conditions, either an appropriately decayed "accident" conversion curve may be used, or a decayed fission gas calibration factor may be applied.

In these c~ses, setpoints are established as in 1) above.

Setpoints of accident monitors (if set to monitor normal releases) are reset to the accident alarm settings at the end of normal release. Setpoints of other release monitors are maintained at the level used at the latest relea~e* (well below the level which would allow MPC to be exceeded at the site boundary), or are reset to approximately three times background in order to detect leakage or inadvertent releases of low level gases.

B.

DOSE RATE CALCULATION

1.

Dose rates are calculated for (1) noble gases* and (2) iodines and particu]~tes. -Dose rates as defined in thh section are based on 10 CFR 50 App~ndfx* I limits of mrem per quarter and millirem per year.* All dose r:f~tfi;iys of major importance in the Palisades environs are considered.

$~;~;~~;17_*,..

3 Rev 6 5/08/92

a.

Equations and assumptions for calculating doses from noble gases are as follows:

1)

Assumptions a)

Doses to be calculated are the maximum offsite point in air, total body and skin.

b)

Exposure pathway is submersion within a cloud of noble gases.

d)

Basic radionuclide data are given in Table 1.2.

e)

All releases are treated as ground-level.

f)

Meteorological data expressed as joint-frequency distribution of wind speed, wind direction, and atmospheric st~bility for the period resulting in X/Q's and D/Q's shown in Table 1.3.

g)

Raw meteorological data consists of wind speed and direction measurements at lOm and temperature measurements at lOm and 60m.

'*h}~ ~Dose is to be evaluated at the offsite exposure points where maximum concentrations are expected to exist (overland sector

~.-

-i >-

j) site boundaries), and nearest residents.

/

\\

Potential maximum population (resldent) exposure points are identified in Table 1.4.

\\

A semi-infinite cloud ~del is used.

4 Rev 6 5/08/92

k)

For person exposures, credit is taken for shielding by residence {factor of 0.7).

l)

Radioactive decay is considered for the plume.

m)

Building wake effects on effluent dispersion are considered.

n)

A sector-average dispersion equation is used.

o)

The wind speed classes that are used are as follows:

Wind Speed Class Number Range {mLsl Midgoi nt (mLsl 1

0.0-0.4 0.2 2

0.4-1.5 0.95 3

1.5-3.0 2.25 4

3.0-5.0 4.0 5

5.0-7.5 6.25 6

7.5-10.0 8.75 7-

> 10.0 p)

The stability classes that will be used are the standard A thr:ough G classifications. The stability classes 1-7 will correspond to A=l, 8=2, **., G~7.

i~~+t;t.:~' 0 q),_ Terrain effects are not considered.

  • ;_~'t~~~~~),. Equations

~

~-:.~:... :*

/

\\

_To_ calculate the dose for any one of t~ exposure points, the following equations are used.

\\

5 Rev 6 5/08/92

For determining the air concentration of any radionuclide:

where:

=

=

Qi

=

p

=

zzk

=

uj

=

x n

=

).i

=

2wx/n i

= 1

( 1. 3)

Air concentration of radionuclide i, µCi/m3

  • Joint relative frequency of occurrence of winds in wind speed class j, stability class k, blowing toward this exposure point, expressed as a fraction.

Average release rate of radionuclide i, µCi/s.

Fraction of radionuclide remaining in plume.

Vertical dispersion coefficient for stability class k (m).

Midpoint value of wind speed class interval j, m/s.

Downwind distance, m

  • Number of sectors, 16.

Radioactive decay coefficient of radionuclide i '

-1 s.

Sector width at point of interest, m.

For determining the total body dose rate:

where:

=

(r:4)

Total body dose rate, mrem/y.

Air concentration.of radionuclide i, µCi/m3

  • 6 Rev 6 5/08/92

~

~

Total body dose factor due to gamma radiation, mrem/y per µCi/m3 (Table 1.5).

For determining the skin dose rate:

D8 = ~ Xi (DFSi + 1.11 DFYi) where:

Os

=

xi

=

DFSi =

1.11 =

( 1. 5)

Skin dose rate, mrem/y.

Air concentration of radionuclide i, µCi/m3 Skin dose factor due to beta radiation, mrem/y::

per µCi/m3 (Table 1.5).

The average ratio of tissue to air energy absorption coefficients, mrem/mrad.

Gamma-to-air dose factor for radionuclide i, mrad/y per µCi/m3 (Table 1.5).

For determining dose rate to a point in air:

n. = ~ xi (DFY i or DFB1)

(1. 6)

  • where:

Air dose rate, mrad/yr

\\

Air dose factor for beta radi~tion (Table 1.5).

b.

Equations and assumptions for calculating doses* from radioiodines and particulates are*-as follow~:

7 Rev 6 5/08/92

1)

Assumotions a)

Dose is to be calculated for the critical organ, thyroid, and the critical age groups (adult, teen, child, infant), infant (milk) and child (green, leafy vegetables).

b)

Exposure pathways from iodines and particulates are milk ingestion, ground contamination, green leafy vegetables from home gardens, and inhalation.

c}

The radioiodine and particulate mix is based on the historically observed source term given in Table l~~

d)

Basic radionuclide data are given in Table 1.2.

e)

All releases are treated as ground-level.

f)

Mean annual average X/Q's for the period January 1, 1978 - December 31, 1982 are given in Table 1.3.

S g)

Raw meteorological data for ground-level releases co~sist of wind speed and direction measurements at lOm and temperature measurements at lOm and 60m.

  • h)

Dose is to be evaluated at the potential offsite exposure points where maximum doses to man are expe~ted to exist.

- i) j)

_./

./

Real cow, goat and garden locatio~s are considered.

\\ \\

Potential maximum exposure points (T"~le.1.4) considered are the near.~st cow, goat and home garden locations in each sector *.

8 Rev 6 5/08/92

k)

Terrain effects and open terrain recirculation factors are not considered.

1)

Building wake effects on effluent dispersion are considered.

m)

Plume depletion and radioactive decay are considered for air-concentration calculations.

n)

Radioactive decay is considered for ground-concentration calculations.

o)

Deposition is calculated based on the curves given in Figure 1.2.

p)

Milk cows and goats. obtain 100% of their food from pasture grass May through October of each year.

Use default values of 0.58 for cows and 0.67 for goats for fraction of year on pasture.

q)

Credit is taken for shielding by residence (factor of 0. 7).

2)

Eguatioqs To.~alculate the dose for any one of the potential

  • maxfmum-exposure points, the following equations in Section 1.2.2 are used.
  • a}

Inhalation

/

\\

\\

Equation for calculating air concentration, X; is the same as in the Noble Gas Section (Equ~tion 1.3).

9 Rev 6 5/08/92

b)

For determining the organ dose rate:

Di = 1 x 106 I: Xi DFii BR 1

where:

Di

=

xi

=

DFii =

BR

=

lxl06 =

( 1. 7)

Organ dose rate due to inhalation, mrem/y.

Air concentration of radionuclide i, µCi/m3

  • Inhalation dose factor, mrem/pCi (Table 1.7).

Breathing rate 1400 m3/y, infant; 3700 m3/y, child; or 8000 m3/y teen and adult.

pCi/µCi conversion factor.

Ground Contamination For determining_ the ground concentration of any nuclide; 7

Gi = 3.15 x 107 E where:

G,

=

k ;..

Q,

=

DR x..

n -

I k=l (1.8)

Ground concentration of radionuclide i, µCi/m2.

Stability class.

Joint relative frequency of occurrence of winds in stability class k blowing toward this exposure point, expressed as a fraction.

Ave~age relea~~~ate of radionuclide i, µCi/s.

'\\

Relative deposition rate;\\m-1 (Fig 1.2).

Downwind distance, m.

Number of sectors, 16.

10 Rev 6 5/08/92

.. *.. ~

27rx/n

=

).i

=

tb

=

3.15xl07

=

Sector width at point of interest, Radioactive decay coefficient of radionuclide i, y-1*

Time for buildup of radionuclides ground, 15 y.

s/y conversion factor.

11

m.

on the Rev 6 5/08/92

II::

II.I

~

I II::

IM Ill. -"'

~

IC

~

j::: -

~

&Iii Q

I-c _,.,,

II::

F i1ur11 1. 2 Correc1ed 1a-3i*:=:=:::::E::::::f::=:E:i::+/-:Et+/-t:::::==:=F==t~:=t=t=;=;::t;:::::=::;:::::=;::::~;:::;:::~Ja~n~u~a~~1~9=7=7

~

10"°'

I to-&

"'1111..

1o-t

[;*

I I

~...

I I

i I

I I

I I

. I I

11

  • i:

I j I

~-. '

I Ii I I:

I l

I 11 l i !

\\

I.

\\

10-7.._ ______ °'!-...._..........a........ -----JL.-...L-....L.....L...l._,1,.,j:..U.----..

~---L~...i...1--..L-~--'

0.1.

1.0 10.0

\\

100.0 200.D PLUME TRAVEL DISTA~E (KILOMET!RSt

  • n-**

~

12 Rev 6 5/08/92

For determining the total body or organ dose rate from ground contamination:

Da = (8,760) (1X10 6 ) (0.7) I: Gi DFGi.

1 where:

DFG; =

8,760 =

lx106 =

0.7 =

{ 1. 9)

Dose rate due to ground contamination, mrem/y.

Ground concentration of radionuclide i, µCi/m2*

Dose factor for standing on contaminated ground, mrem/h per pCi/m2 (Table 1.8).

Occupation time, h/y.

pCi/µCi conversion factor.

Shielding factor accounting for a distance of 1.0 meter above ordinary ground, dimensionless.

c)

Milk and Vegetation Ingestion For determining the concentration of any nuclide (except C-14 and H-3) in and on vegetation:

where:

cv, =

Concentration QJ'radionuclide vegetation, µCi/gk.

~

k

==

Stability class

\\

13 i in and on (1.10)

Rev 6 5/08/92

fk

=

Frequency of this stability class and wind direction combination, expressed as a fraction.

Qi

=

DR

=

x

=

n

=

21rX/n

=

r

=

>.Ei

=

te =

Yv

=

e,. =

v.

i p,.

3,600 "'

Average release rate of radionuclide i, µCi/s.

Relative deposition rate, m-1 (Figure 1.2).

Downwind distance, m.

Number of sectors, 16.

Sector width at point of interest, m.

Fraction of deposited activity retained op vegetation (1.0 for iodines, 0.2 for par~~culates).

Effective removal rate constant, >.Ei = li~+ >.w, where ).i is the radioactive decay coefficient, h-1, and lw is a measure of physical loss by weathering

{).w =.0021 h-).

Period over which deposition occurs, 720 h.

Agricultural yield, 0.7 kg/m2

  • Transfer factor from soil to vegetation of radionuclide i {Table 1.6).

Radioactive decay coefficient of radionuclide i, h-1 Time for buildup of radionuclides on the-ground,.

l.3lx105 h.{l~YJ.

\\ \\

Effective surface density._ of soil, 240 kg/m2

  • s/h converston factor.

Holdup time between harvest and consumption of food

{2, 160 ho.urs fo.r stored food) 14 Rev 6 5/08/92

For determining the concentration of C-14 in vegetation:

CV14 = 1 x 103 X14 (0.11/0.16) where:

0.11 =

0.16 =

lxl03 =

Concentration of C-14 in vegetation, µCi/kg.

Air concentration of C-14, µCi/m3

  • Fraction of total plant mass that is natural carbon.

(l.ll).

Concentration of natural carbon in the atmosphere, g/m3.

g/kg conversion factor.

For determining the concentration of H-3 in vegetafion:

CV1 =

where:

CVr

=

o.r5..

i 0.5..

H =

lxl03 =

1 x 103 X1 (0.75)(0.5/H)

Concentration of H-3 in vegetation, µCi/m3

  • Air concentration of H-3, µCi/m3*

Fraction of total plant mass that is water.

(1.12}

Ratio of tritium concentration in plant water to tritium concentration in atmospheric water.

Absolute humidity of the atmosphere, g/m3

  • g/kg conversio~~actor *

\\

For determining the concentration\\qf any nuclide in cow's or goat's milk:

\\.

CHi = cvi FM, Qf exp (-A_f tf) 15 (1.13)

Rev 6 5/08/92

.,, -. *"*,.*,*.*.::.:~.-..

where:

CMi

=

cvi

=

FMi

=

~i

=

Concentration of radionuclide i (including C-14 and H-3) in milk, µCi/l.

Concentration of radionuclide i in and on vegetation, µCi/kg.

Transfer factor from feed to milk for radionuclide i, d/l (Table 1.6).

Amount of feed consumed by the milk animal per day, kg/d (cow, 50 kg/d or goat 6 kg/d).

Radioactive decay coefficient of radionuclide i, d-1.

Transport time of activity from feed to milk to receptor, 2 days.

For determining the organ dose rate leafy vegetables and milk:

from ingestion of green D = 1 x 106 I: CM1 OF 1 UM 1

where:

p =

CMi

=

. Dfi =

UM -

lxl06 (1.14)

Organ dose rate due to ingestion, mrem/y.

Concentration of radionuclide i iri vegetables or milk, µCi/kg (or liters).

Ingestion dose factor, mrem/pCi (Table 2.1).

Ingestion rate for milk, 330 l/y; for vegetables 26 kg/yr (child), no in_gestion by infant.

\\

\\

pCi/µCi conversion factor\\

d)

. Meat Ingestion {Beef),

To calculate the concent~ation of'a nutlide in animal flesh:

16 Rev 6 5/08/92

~~- *- -

where:

(1.15)

Concentration of nuclide i in the animal flesh, pCi/kg.

Fraction of animal's daily intake which appears in each kg of flesh, days/kg (Table 1.6).

Concentration of radionuclide i in the animal's feed (Equation 1.10).

Amount of feed consumed by the cow per da~,

50 kg/d.

Average time from slaughter to consumption, 20 days.

To determine the organ dose from ingestion* of beef:

u, Ingestion dose factor for age group, mrem/pCi (Table 2.1) for nuclide i.

Ingestion rate of meat for age group, ~gLy (child-41, teen~65, adult-110).

\\ \\

-e)-

Organ Dose Rates For determining the total body and organ dose rate from iodines and particulate~:

(1.16)

(1.17) 17 Rev 6 5/08/92

where:

0

=

o,

=

DG

=

D"

=

Dv

=

OF

=

Total organ dose rate, mrem/y.

Dose rate due to inhalation, mrem/y.

Dose rate due to ground contamination, mrem/y.

Dose rate due to milk ingestion, mrem/y.

Dose rate due to vegetable ingestion, mrem/y.

Dose rate due to beef ingestion, mrem/y.

3)

The maximum organ dose rate, maximum total body dose rate, and maximum skin dose rate calculated in the previous section (Sec 1.2.2) are used to calculate design basis quantities as described in Section 1.3.

c.

Design Basis Quantities The design basis quantity of a radio~uclide emitted to the atmosphere is the amount of that nuclide, when released in one year, which would result in a dose not exceeding any of the following:

I) 15 millirem to any organ of an individual from iodines and particulates with half-life greater than 8 days.

2) 15 millirem to skin of an individual from noble gas..
3) 5 millirem to the total body of an individual from noble gas.

Design basis quantity (Ci) is the smallest value for each nuclide, calculated by dividing the dose limits (a thro.ugh c above) by the appropriate dose ~alculated from the amount of radionuclide (Ci) used to cortservative-ly estimate the doses of

-Section 0, as listed in Table I.I (or ~\\hypothetical 1 Ci/year);

the result is then multiplied by the amount of radionuclide

.used.

18 Rev 6 5/08/92

d.

D DBQ = DM (Cc) c where:

DAI

=

DC

=

cc

=

DBQ =

Appendix I dose limit (mrem or mrad).

Calculated dose (mrem o~ mrad).

Quantity of nuclide resulting in dose De (Ci).

Design Basis Quantity (Ci).

(1.18)

The limiting values for Design Basis Quantities for radionuclides released to the atmosphere are given in Table 1.9.

The inverse of the ratio Cc/De in the above equation (ie, De/Cc) is a useful value, since it represents the most limiting dose per unit quantity of each nuclide released.

Use of the De/Cc ratio in quarterly evaluation of offsite dose is discussed in Section D.

Values of D/Cc are given in Table 1.9.

Land Use Census and DBO Changes Specifications 4.11.3 and 4.11.4 describe the requirements for an annu~l land use census and revision of the ODCM for use in the following calendar year. Areas of the ODCM which will be r~viewed, and changed if appropriate, are Table 1.4 (Land Use Census data by Sector), Table I.4a (Critical Receptors), and Table 1.9 {Gaseous Design Basis Objective Annual Quantities).

Changes will be effective on J~nuary I of the year following the*

year of the survey.

/

19 Rev 6 5/08/92

  • ~ '

r

e.

Gaseous Releases From the Steam Generator Slowdown Vent and Atmosphere Release Valves Releases from the steam generator blowdown vent and atmospheric relief valves are difficult to quantify as there are no sampling capabilities on these steam release systems.

however, neither system is a normal release path.

The steam generator blowdown vent is normally routed to the main condenser and recirculated.

Radioactive releases will be calculated by analyzing steam generator blowdown liquid and assuming that 100 percent of Noble Gases, 10 perce~t of the Iodines and 1 percent of the Particulates will be released to the environment in the steam phase.

Voiumes wili be released to the environment in the steam phase.

Volumes will be calculated using water balances ~r alternate means as available.

C.

DESIGN OBJECTIVE QUANTITY (DBQ) LIMITS ON BATCH AND CONTINUOUS RELEASES

1.

Batch Releases Prior to each batch release (waste decay tank release or Containment purge), the quantity of each nuclide identified is summed with the quantity of that nuclide released since the first of the current calendar year. The cumulative total for each nuclide then is divided by the design objective quantity for each nuclide (from Table 1.9), and t~e resultant fractions are summed in order to assu~e that the sum fraction of all nuclides does not exceed 1.0:

< 1. 0 (1.19) 20 Rev 6 5/08/92

The amount in any calendar quarter should not exceed 0.5. This is checked by subtracting the value obtained at the end of the previous quarter from the value obtained from the cumulative total to date, including the batch to be released.

2.

Continuous Releases Low level continuous releases from the vent gas collection header and other low level sources are totaled on a weekly basis and summed with any batch releases for the week in order to establish the cumulative DBQ fraction from batch plus continuous released for the year-to-date. Calculations are performed in the same manner as for batch releases described in C.1.0.

3.

Exceeding DBO Limits As discussed under B.1.3, the DBQ is a very conservative estimate of activity which could give doses at Appendix I limits. Because different organs are summed together and doses to different people are summed, the DBQ typically overestimates dose by about a factor of five. Thus, if calculations of DBQ fraction exceed 1.0 for year-to-date or 0.5 for the quarter, technical specifications probably still would not be exceeded.

However, further discretionary releases should be deferred until an accurate assessment of dose is made by use of GASPAR computer code or by analysis of appropriate release data via the-segment gaussian dose model used i-n emergency planning {inhalation dose, total body external dose, and boundary dose in air). See also Section D.1.2.

I- ~*~>d-,,>::;*..

i.f -:ouid: be noted that Palisades Plant to date {based on review of s*~~lan~ual.effluent data) has never exceeded the annual or quartel!ly DBQ:

7

f.t~ction, despite its conservatism. _-Thus, it is not expected

_that an alternate to the DBQ method will be reqll'.~ed unless the plant is 1n a significantly off-normal condition.\\

\\

21 Rev 6 5/08/92

4.

Releasing Radionuclides Not Listed in Table 1.9 Table 1.9 contains all nuclides identified to date as routine constituents of gaseous releases at Palisades Plant, plus those common to PWRs in general, even if not previously detected at Palisades.

From time to time, however, other nuclides may be detected.

If the unlisted nuclide constitutes less than 10% of the MPC-fraction for the release, and all unlisted nuclides total less than 25% of the MPC-fraction, the nuclide may be considered not present.

If the unlisted nuclide constitutes greater than 10% of the MPC-fraction, or all unlisted nuclides together constitute greater than 25%, then each nuclide should be assigned a DBQ equal to the most conservative value listed for the physical form of the nuclide involved (noble gas, halogen or particulate).

Should a nuclide not listed in Table 1.9 begin to appear in significant quantities on a routine basis, revision to this ODCM should be made in order to include a design basis quantity specific to that nuclide.

D.

OPTIONAL QUARTERLY DOSE CALCULATIONS

1.

Methodology for Ootional Quarterly Dose Calculations THt~~::~:-~:~tion may be used in place of, or in addition to, the Design

..,.,,,",._(....,, -...

B~:~'~[$1;;Qµantity (DBQ) fraction calculation described by Eq~ii~i~pl.19:. This optional conservative calculation relates th-e-o*ecf fra-C:t ion to the doses from which it was ori gi na 11 y derived.

Use of this method may assist in identification of t'tt_e critical dose

  • pathway or characteristics of the assumed criticat individual

\\

(infant, child, teen and adult), since Table 1.9 indicates these parameters.

22 Rev 6 5/08/92

a.

Simplified Conservative Approach This method utilizes a limiting dose concept such that the limiting dose for each nuclide is summed with the limiting dose for each other nuclide, regardless if such sum is physically possible. It also assumes critical pathways, such as milk and vegetables, are in effect even in winter when the pathway is absent.

As such, the method is highly conservative and significantly over-estimates dose.

If limits appear to be exceeded by this method, Section D.I.2 (a concise method, but requiring computer support) will be utilized.

~:

1.

Assumptions a)

All assumptions of Section I.I are utilized.

b)

Limiting doses for each gaseous nuclid~ are summed, regardless of limiting decay mode (gamma or beta).

c)

Limiting doses for each particulate and *iodine nuclide are summed, regardless of dose point location, exposure pathway or organ affected.

d) : Doses are sununed for detected nucl ides such that all nuclides which contribute greater than IO%

individually or 25% in aggregate, to the MPC of released radioactivity, are included in the dose calculation.

2.

Equations

,/

For determining gaseou~--~ffluent ~e:

\\

. \\

23 Rev 6 5/08/92

i DG = L A1G(Dc/Cc)1G < 5 milli:rad/qua:rte:r, 10 m:rad/y:r 0

where:

DG

=

{ 1. 20)

Dose from gaseous effluents {mrad).

Quantity of gaseous nuclide i released {Ci).

Dose per Ci factor for gaseous nuclide i

{mrad/Ci).

The limit for this mixture is conservatively taken *as that for gamma exposure (5 mrem/quarter, 10 mrem/year) although as indicated in Table 1.9, a majority of the gaseou~

effluents are beta-limiting and on an individual basis have the higher limit of 10 millirem/quarter and 20 millirem/year.

For determining tritium, particulate and iodine dose to organs:

i DTPI = L ~Ii (Dc/Cc)TPii < 7. 5 mrem/q, 15 mrem/y

{1.21)

b.

where:

. ATPlf

=

Dose from particulates and iodines (mrem).

Quantity of particulate or iodine nuclide i released {Ci).

Dose per.Cf faf'tor for 'Rarticulate or iodine nuclide i (mrad/Ci)..

\\

\\

.Realistic Calculation This methodology is to be use~ if the ~ighly conservative calculations described in C.1~1, C.1.l or D.1.0 yield values that appear to exceed applicable limits.

24 Rev 6 5/08/92

Doses for released particulates, iodines and noble gases will be determined by use of the NRC GASPAR computer code.

The computer run will utilize the annual average joint frequency meteorological data based. on not less than 3 years of meteorological measurement, and will reflect demographic and land use information from the land use survey generated in the most recent prior year. Where appropriate, seasonal adjustments will be applied to obtain realistic dose estimates since both recreational and agricultural activities can vary greatly in relation to season of the year.

An alternative to GASPAR for offsite dose calculation is the use of the Palisades Segmented Gaussian Piume Emergency offsite dose calculation program. This dose model allows evaluation !f dose under the actual meteorological conditions present at the time of release. It is anticipated that the system may be us:ed in major short-term releases such as Containment purges are to be made under conditions which depart significantly from mean annual conditions.

E.

GASEOUS RADWASTE TREATMENT SYSTEM OPERATION The gaseous radwaste treatment system (GRTS) described below shall be maintained and operated to keep releases* ALARA.

I.

System Descriptiog AJ~low diagram for the GRTS is given in Figure 1-1. The system consists o -.*-:* :f.~e * \\:faste-gas compressor packages, six gas decay tanks, and the

t*~ed piping, valves, and instrumentation. Gaseous wa.stes are

.::.,.~"<".i'~'.~J!;~~*.fr~m,:the following:.degassing of the reactor.coola~t and.purging O'.("~'tft~:i::VQ.~;ume control tank pr1or to a coJd shutdown, d1Splacing of cover

. gases caused by liquid accumulation in**ihe tanks\\connected to the vent header, and boron recycle process operation.

\\

  • 25

\\

\\

Rev 6 5/08/92

Design of the system precludes hydrogen explosion by means of ignition source elimination {diaphragm valves, low flow diaphragm compressors and system electrical grounding), and minimization of leakage outside the system.

Explosive mixtures of hydrogen and oxygen have been demonstrated compatible with the system by operational experience over the past 13 years.

2.

Determination of Satisfactory Ooeration Design basis quantity fraction will be calculated for batch and continuous releases as described in Section I.C. These calculations will be used to ensure that the GRTS is operating as designed.

Because the plant was designed to collect and hold for decay a vast majority of the high level gases generated within the primary system, and because the 13-year operating history {to date of writing the initial ODCM) of the plant has demonstrated the systemts consistent performance well below Appendix I limits, no additional operability requirements are specified.

F.

RELEASE RATE FOR OFFSITE MPC (500 mrem/yr) 10 CFR 20.106 requires radioactive effluent releases to unrestricted areas be in concentrations less than the limits specified in Appendix B, Table II when averaged over a period not to exceed one year.

{Note:

there are no unrestricted areas anywhere within the site boundary as defined by Figure 1-1.j Concentrations at this level if present for one year will-result in a dose of 500 mrem wholebody or 1500 mrem organ or 3000 mrem sk_in du~: to external exposure or inhalation depending on the nucl id4!,{;$.)~:r~Jeas-ed~

10 CFR 50.36a requires that the release of radioa~~~{y~?~aterials be kept as low as reasonably _achievable.

However, the s~'.~~;i~~ij~~f:~rt"he~-, _states that the 1 i censee is permitted the fl exi bi-1-i-ty of ope"ra~lo~~,~<to~ assure a dependable source ~f-power even under unusual operating--conditions, to release quantitfes---of materi'l higher than a smali percentage of 10 CFR 20.106 limits but still wit~in those limits.

Appendix I to 10 CFR 50 provides the numerical guideline~

26 Rev 6 5/08/92

~

on limiting conditions for operations to meet the as low as reasonably achievable requirement.

The GASPAR code has been run to determine the dose due to external radiation and inhalation. The source term used is listed in Table I.I.

The meteorology data is given in Table I.3. Dose using annual average meteorology, to the most limiting organ of the person assume to be residing at the site boundary with highest X/Q, is 2.I5E-02 mrem (for one year).

The release rate which would result in a dose rate equivalent to 500 mrem/year (using the more conservative total body limit) is the curies/year given in Table I.I multiplied by 500/2.I5E-02 or I.II Ci/sec.

G.

PARTICULATE AND IODINE SAMPLING

~articulate an iodine samples are obtained from the continuous sample stream pulled from the plant stack. Samples typically are obtained to; represent an integrated release from a gas batch (waste gas decay tank or Containment purge, for example), or a series of samples are obtained to follow the course of a release.

In any event, sample intervals are weekly, at a minimum.

Because HEPA filters are present between most source inputs to the stack and the sample point, releases of particulates normally are significantly less than pre-release calculations indicate. This provides for conservatism in establjshing setpoints and in estimation of pre-release design basis quantity fraction.

However, for the sake of maintaining accurate ;elease ~otals, monitor results (for gase~) and sample results (for pa_rtJc~lates ~nd iodines) utilized rather than the pre-release estimat~$~\\:,_for cumu.lative records.

,'}~~}~g~>. -..

Garnma.::'.~i!!J\\Yti"cal results for particulate and halogen filters are combined for dete~ination of total activity of particulates and halogens released.

Beta and alpha counting also is performed on the part,culate filters. Beta yields'of the ganima isotopes detected on particulate fllters are applied to determine "identified" beta, an the "identified" count ~ate is 27 Rev 6 5/08/92

subtracted from the observed count rate to give "unidentified" beta. The "unidentified" beta is assumed to be Sr-90 until results on actual Sr-90

{chemically separated from a quarterly composite of filters) are obtained.

H.

NOBLE GAS SAMPLING I.

J.

Noble gases will be sampled from Waste Gas Decay Tanks prior to release and the Containment prior to purging. Analysis of these samples will be used for accountability of noble gases. Off gas will be sampled at least weekly and used to calculate monthly noble gas releases. Nonroutine releases will be quantified from the stack noble gas monitor {RE 2326) which has a LLD of lE-06 µCi/cc (if RE-1815 is used because RE-2326 is out of service, the LLD will be 5E-05 µCi/cc}.

tRITIUM SAMPLING Tritium has a low dose consequence to the public because of low production rates. The major contributors to tritium effluents are evaporation from the fuel pool and reactor cavity {when flooded).

Because of the low dose impact, gaseous tritium sampling will not be required. Tritium effluents will be estimated using conservative evaporation rate calculations from the fuel pool and reactor cavity.

FIGURES AND TABLES

\\,

.* \\

28 Rev 6 5/08/92

01 0

o co ct>

l.O NO'l PALISADES GASEOUS !FFLUENTS W~JtGAS 5URGFTANk STEAM GfNF.RATOll ILOWIJOWN TANK VENT r*--------,

1 AUX I

WfST SAFE

, GUARD SU,,LY RE ttH I

\\

fUU tfAl'tDLG AllEA HEPA INORMAU HEPA/CWAACOAL IRF.fUfllNGI r----------,

RAil-SUPPLY -....1Jl'L..I WA5Tt ARFA ADOif N ft£ 51t1 1 BLOG 1

RAD-L'-',-,._ _

WASTE AR Rt ll!Ot" l

I I _..

RE 1't3 HEPA STACK NOllU HEP'A Rf Cll31 CONTAIN*

MENT BLDG r---------.,

1 FU£L

¢ GAS ltE 1111 AREA t>t-- SU..'LY AE rm:i*

AUDIT "RE HIOll. 61' 1 ANO 57'J TRIP SUPPL y ANO ONF. OF r.. o EXHMJSTEllS.

FLOW IS NOT TFRMINATEO PALISADES EFFLUENT FLOW PATHS GASEOUS

TABLE 1.1 PALISADES GASEOUS AND LIQUID SOURCE TERMS. CURIES/YEAR (1)

Nuclide Gaseous(2}

Liquid(2}

H-3 5.5 159 Kr-85 4.1 NA Kr-85m 0.12 NA Kr-87 8.4E-02 NA Kr-88 2.lE-01 NA Ar-41 3.lE-02 NA Xe-13lm 2.2 NA Xe-133 1493 NA Xe-133m 0.43 NA Xe-135 1.11 NA Xe-135m 0.3 NA 1-131 0.025 3.21E-03 1-132

  • 2.91E-03 NA 1-133 6.5E-03 4.7E-05 1-134 4.8E-04 NA 1-135
  • . l.84E-02 NA Na-24 l.SE-06 NA Cr-51 2.5E-04 3.9E-03 Mn-54 4.lE-04 7.8E-03 Co-57 2~1E-06 3.2E-05 Co-58 8.6E-04 2.9E-02 Fe-59 6.6E-06 4.lE-04

- Co-60 l.lE-03 l.24E-02 Se-75 3.7E~Oa NA Nb-95 2.4E-05 4.53E-04 Zr-95 4.7E-06 l.79E-04 Mo-99 l.SE-07 NA Ru-103

.3E-07

.lE-05 Sb-127 NA 3.5E-05 Cs-134 4.SE-05 0.7

._cs-136-NA l.8E-06

  • 0~::* ~-z-J:s::..137.

2.6E-04 l.36E-02

~tea.. 140 2.BE-07 NA

-~~

~..:

~~

.;~

_.;~,[:a-140 7.5E-07 l.lE-04

);~,.,-j((Jrfidentified beta

3. 9E-04 3.lE-03
-".:**.,. ~.... ~-~-, -~---.-.

/

. ( 1}

Data derived from taking the effluents rel~ased duri'~ July-December 1978 through January-June 1982 and dividing by 4.

\\

' \\

(2}

Nuclide values listed as NA have not been observed at detectable levels in these waste streams.

30 Rev 6 5/08/92

-~..:-

r TABLE 1. 2 BASIC RADIONUCLIDE DATA NUCLIDE HALF-LIFE LAMBDA BETA1 GAMMA1 (days) ilLil CMEV/DIS)

(MEV/DIS) 1 Tritium 4.49E 03

1. 79E-09 5.68E-03 0.0 2

C-14 2.09E 06 3.84E-12 4.95E-02 0.0 3

N-13 6.94E-03 l.16E-03 4.91E-Ol

1. 02E 00 4

0-19 3.36E-04 2.39E-02 l.02E 00 LOSE 00 5

F-18 7.62E-02

1. OSE-04 2.SOE-01 l.02E 00 6

NA-24 6.33E-Ol l.27E-05 5.SSE-01 4.12E 00 7

P-32

1. 43E 01 5.61E-07 6.95E-Ol 0.0

.8 AR-41 7.63E-02

1. OSE-04 4.64E-Ol l.28E 00 9

CR-51 2.78E 01 2.89E-07 3.86E-03 3.28E-02 10 MN-54 3.03E 02 2.65E-08 3.BOE-03 8.36E-Ol 11 MN-56 l.07E-Ol 7.SOE-05 8.29E-Ol l.69E 00 ::

12 FE-59 4.SOE 01

1. 78E-07
l. lBE-01 l.19E 00 13 C0-58 7.13E 01 l.12E-07 3.41E,.02
9. 78E-Ol
  • 14.

C0-60

1. 92E 03 4.18E-09 9.68E-02 2.SOE 00 15 ZN-69m 5.75E-Ol l.39E-05 2.21E-02 4.16E-Ol 16 ZN-69 3.96E-02 2.03E-04 3.19E-Ol 0.0 17 BR-84 2.21E-02 3.63E-04 l.28E 00
1. 77E 00 18 BR-85 2.08E-03 3.86E-03 1.04E 00 6.60E-02 19 KR-85m l.83E-Ol 4.38E-05 2.53E-Ol l.59E-Ol 20 KR-85 3.93E 03 2.04E-09 2.51E-Ol 2.21E-03 21 KR-87 5.28E-02
1. 52E-04 l.32E 00 7.93E-Ol 22 KR-88 l.17E-Ol 6.86E-05 3.61E-Ol l.96E 00 23 KR-89 2.21E-03 3.63E-03 l.36E 00 l.83E 00 24 RB-88 l.24E-02 6.47E-04 2.06E 00 6.26E-Ol 25 RB-89 l.07E-02 7.SOE-04 l.OlE 00 2.0SE-00 26 SR-89. __

5.20E 01 1.54E-07 5.83E-Ol 8.45E-05 27 SR-90

1. 03E 04 7.79E-10
1. 96E-Ol 0.0 28 SR-9l 4~03E-Ol
1. 99E-05 6.50E-Ol 6.95E-Ol 29 SR 92,. -

lA3E-Ol

7. lOE-05
1. 95E-Ol l.34E 00 30

~~!!4~

5.56E-03 1.44E-03 9.20E-Ol 2.24E 00 31 2.67E 00 3.00E-06 9.36E-Ol 0.0 32 3.47E-02 2.31E-04 2.73E-02 5.3oE-or*

33 5.88E 01 l.36E-07 6.06E-Ol 3.61E-03 34 Y-92,.

l.47E-Ol 5.46E-OS--

1.44~~

2.50E-Ol 35 Y-93

-4.29E-Ol l.87E-05 1.17E 0 8.94E-02 36 ZR--95 6.50E 01 l.23E-07 l.16E-O 7.35E-Ol 37 NB-95m 3.75E 00 2.14E-06 l.81E-Of, 6.06E-02 38 NB-95 3.SOE 01 2.29E-07 4.44E-02 '

7.64E-Ol 39 M0-99 2.79E 00 2.87E-06 3.96E-Ol.

1. 50E-Ol 40 TC-99m 2.SOE-01 3.21E-05 l.56E"-02 l.26E-Ol 41 TC-99 7.74E 07 l.04E-13 8.46E-02 0.0 42 TC-104 l.25E-02 6.42E-04 l.60E 00 l.95E 00 31 Rev 6 5/08/92

TABLE 1.2 (continued)

BASIC RADIONUCLIDE DATA NUCLIDE HALF-LIFE LAMBDA BETA1 GAMMA1 (days) ill.tl (MEV/DIS)

(MEV/DISl 43 RU-106 3.67E 02 2.19E-08

1. a1E-a2 a.o -

44 TE-132 3.24E 00 2.48E-a6

1. aaE-al 2.33E-al 4S 1-129 6.21E a9 l.29E-1S S.43E-a2 2.46E-a2 46 1-131 S.aSE ao 9.96E-a7
1. 94E-al 3.SlE-al 47 I-132
9. sa.-a2 8.37E-aS 4.89E-al 2.24E aa 48 I-133 8.7SE-al 9.17E-a6 4.aSE-al 6.a2E-Ol 49 1-134 3.61E-a2 2.22E-a4 6.16E-al 2.S9E ao sa 1-135 2.79E-al 2.87E-OS 3.68E-al I.SSE oa SI XE-13lm
l. ISE al 6.SaE-07
1. 43E-Ol 2.0lE-02 S2 XE-133m 2.26E aa 3.SSE-a6
1. 9aE-al 4.15E-a2, S3 XE-133 S.27E ao
1. S2E-a6 l.3SE-al 4.6aE-a2-~

S4 XE-13Sm 1.asE-a2 I 7.43E-a4 9.SSE-a2 4.32E-al 7

  • SS XE-135 3.83E-al 2.a9E-aS 3.17E-al
2. 47E-al:

S6 XE-137

2. 71E a3 2.96E-a3
1. 77E aa I.SSE-al 57 XE-138 9.84E-a3 8.1SE-a4 6.6SE-al
l. laE ao S8 CS-134 7.48E a2 I.a7E-as l.63E-al I.SSE aa S9 CS-135
l. IOE a9 7.29E-15 S.63E-02 a.a 6a CS-136 l.3aE a1 6.17E-07 l.37E-al
2. lSE oa 61 CS-137
l. laE 04 7.29E-Ia
1. 71E-al 5.97E-Ol 62 CS-138 2.24E-a2 3.S8E-a4 I.2aE aa 2.30E aa 63 BA-139 5.76E-a2 l.39E-04

-8.96E-Ol 3.S3E-02 64 BA-140 l.28E 01 6.27E-07 3.15E-Ol

1. 71E-al 65 LA-140 1.68E 00 4.77E-06 5.33E-Ol 2.31E 00 66 CE-144 2.84E 02 2.82E-08 9.13E-02
1. 93E-02 67 PR-143 l.36E 01 5.90E-07 3.14E-Ol 0.0 68 PR-144 l.20E-02 6.68E-04 l.21E 00 3.lSE 00

\\

1 Average energy per disintegration values were obtained from ICRP Publication No 38, Radionuclide Transformations: Energy *and Intensity of Emissions 1983 and NUREG/CR-1413 (ORNL/NUREG-70), a Radionuclide '-Decay Data Base - Index and Summary Table, DC Kocher, _May 1980.

32 Rev 6 S/aB/92

---~-- ------------------------------

1 uSlllC ~~- - l~~~. VUSIOll z.o TABLE 1.3

~

  • UN DATI*

OZ*Y~*90

,.... LISADIS XDGDGell..... USIM8 01/0l/IJ

  • lZlll/17 NIT DATA.....

- a*OUND L!YIL *IL!ASI - TOP a, CDNTAIH*U!JIT IUILDIHO NO DICAT, UNDIPUT!I ANNUAL A't!UOl CHI/Q < SEC/"!T9 COID>

DISTANCI! IN NILIS FIQlll 1'141 SIT!.

Sl!CTOI O.Z.H O.JH 0.751 1.00I 1.5DI z.oao Z.500 J.OOI l.5DI 4.aoo 4.SOQ s

1.120!*06 l.Ol2!*06 5.6271!*17 l.7071!*07 Z.0571!-07 1.l5tl!-07 9.1611*01 7.5fl!-OI 6.0tl!-01 5.0141!-0I 4.257!-oa

SSH z.~Ol!-06 9.1091!-07 4.9171!*07 3.Z441!*07 1.1011!-07 l.ZOll!-07 1.7611!-0I,,7731!-0I 5.452!-0I 4.5ZO!-O& l.alZ!-01 SH Z.944!*0* t.492!*07 5.0,51!*07 3.l44!*07 1.1611!*07 l.Z46!*07 9.llZ!*OI 7.06Zl!*OI 5.6951!*01 4.1291!-0I 4.016e-~1 MSH J.50Z!-06 1.llZ!-06 5.lll!-07 3.1101-01 Z.llll!-07 1.4211!-07 1.0501!-07 l.17ll!*OI *. 6161!-0I 5.512!-0I 4.695!-oa M

5.0l41!*06 1.6071!*06 l.4l51!*07 5.517!*07 l.0511!*07 Z.047!*07 l.5041!*07 1.170!*07 9.4711!-0I 7.189!*01 6.717!-~&

MHN 6.6951-06 Z.ll61*06 1.1221*06 7.1191*07 4.0441-07 Z.7061-07 1.9191-07 1.5411-07 1.ZSZl-07 l.04l!-07 a.aa5e-~a tlH 7.6aU-06 2.4071!-06 1.2571!-06 1.uu-01 4.5551!-07 l.OUl!-07 Z.ZUl-07 1.7'71!-07 l."1!01!-07 1.199!-07 l.02ZE-07 HNH 9.3341!-06 2.1111-06 1.4911-06 9.7191-07 5.4461-07 s.*101-07 Z.7271!-07 Z.1361!-07 1.7311-07 l.4541!-07 l.Z,lE-07 ti 1.067!-0S l.ZHl!-06 1.7111-06 1.un:-06 6.Ull!-07 4.U7!-07 S.106!*07 2.un:-01 1.91ll!-07 1.Ul!-07 1.421E-07 NH!

4.4041!*06 1.4021!*06 7.46Sl!*07 4.9031!*07 Z.7211!*07 1.1241!*07 l.lll!*07 1.0l91!*07 1.4011!*01 6.990!*01 5.946E*O&

NI!

5.1121!-06 1.6951!-06 9.2401!-07 6.0471!-07 S.1251!*07 z.1111-01 1.5741!*07 1.2061!-07 9.641!-0I 7.944!-oa 6.7JO!-CS ENI 4.Z051*06 1.3741-06 7.413!-07 4.ll41!*07 z.,551-07 1.74ll!*07 l.ZS91!-07 9.,621-01 7.729!*01 6.l75E-oa 5.S&lE-~S J.9701*06 l.l2Zl*06 7.1501*07 4.6491*07 Z.5401*07 1.660!-07 1.1951!-07 9.1461-01 7.2911!*01 6.005!-aa 5.J59!-0S

!SI!

3.l791!-06 l.lZll-06,,0471!*07 l.9SOl!-07 Z.1471!-07 l.S911-07 l.0041!-07 7.6591-01 6.0991!-0I 5.009!-oa 4.Z:SE-aa SI!

l.9191-06. 1.Z961-t6 6.9721-17 4.5291!-07 Z.4751-07 1.6141-07 l.1*01-01 1.1641*01 7.0651-01 5.107!-0I 4.&&aE-0&

SS!

- s.~-06 1.l171-06 7.1151-07 4.6221-17 Z.5241-07 1.6511-07 l.lltl-1? t.lDll-01 7.2,11!-0I 5.9141-01 5.044!-0S ANNUAL AVl!IACll atl'e CSEC/tel!T!Jt C\\1111>

DISTANCI I* NIL!S l'ICIR TMI SITI.

Sl!CTOI 5.000 7.501 10.011 15.000 Z0.001 ZS.ODI J0.001 lJ.001 40.001 45.000 so.ooo s

3.6661!-0I z.0101-011.3141*011.11*1-at 5.llZl-Ot l.917!-0t S.057!-0t 2.4121-0t Z.07Z!-Ot l.769!-09 1.535E-09 SSH J.lOll-01 1.5141-01 l.Z,11*01 7.1~71!*0t 4.9Stl-Ot l.65tl*Ot Z.1671!-0t'Z.Sl51-0t l.9551-at l.6731-09 1.456!-09 SH 3.~7l!QCC 1.917!Qt; 1.l4Za~ea 7.75ZE-i9 5.2721-ii 3.ilii*Ot J.0751-lt z.5091*1* 2.1041-0t l.IOll!-09 t.571E-a9 HSH 4.0611!-0I Z.l521-0I l.*011-01 9.3411!-0t 6.40Zl*Ot 4.7141-0t S.7761-tt s.otsl-lt z.,041-0t 2.Zl91-0t 1.956!-09 H

5.4201!-0I l.3'41*01 2.2111*0* 1.ll61-0I 9.1541-0t 6.1*11-tt 5.lttl-tt 4.4251-lt J.7Z41-at S.20Z!-O[ 2.797!-09 MllH 7.6991!*01 4.4541*01 S.Olll*ll 1.7711*01 1.2151*01 t.OISl*tt 7.17Zl*Ot 5.1791-lt *.95Zl!*Ot 4.2591-0t. l.722!-09

-Nw s.a111-01 5.1141-01 s.5s11-01 z.0121-01 1.4J41-01 1.0161-01 1.szs1-1t 1.ooz1-1t 5.*011-01 5.a9or-at.-4.456E-a9 NHN 1.0111!*07 6.ll71*01 4.3501*01 2.5721*01 1.7711!*01 l.3l71!-0I l.O*ll*OI l.7SOl*Ot 7.5711!*09 6.J6Zl-Ot S.S75E-09 N

1. 2361!*07 7. 2591-01 4. HOl*OI z. uu-aa 2. 0*61!-0I l. 540!-0I 1. ZZSl!*OI l. 0011-aa I. 5151!-at 7.1471-0t 6. 441 E-09 Nrt!

5.1471!-0I Z.9'51-01 Z.0111!*11 1.170l!*OI 7.9Hl*ot 5.9'4l*Ot 4.Utl*ot S.1441!*0t l.ZSZ!-01 Z.7751-at 2.4221!*09

11 5.7571!-0I 1.2211-11 Z.1471-11 l.ZUl-01 l.U7!-ot 6.00tl*ot 4.HJ!*ot S.7t61-tt S.16'1!-ot Z.70Gl-at Z.l4ZE-09 Ertl!

4.6211!-0I Z.6041*01 1.1s11-11 t.1901-lt *.,611-0t 4.1211-ot S.1451-0t S.lZll-Ot Z.611!-0t Z.ZlOl*Ot l.93&!-09 I

4.S4Sl-OI 2.4Z5!*01 1.60tl-11 9.01*1-ot *.otzl-Ot *.4771-0t S.4151-0t Z.12Jl-lt Z.l541-0t Z.0061!-0t l.740E-09

!SI!

l.6111!-0I Z.0061-01 l.l271-0I 7.45'1-lt 4.9151-lt l.65'1-0t Z.1421-tt z.zttl-lt l.t1s1-a* 1.630!-09 1.412!-09 SE 4.1931!-0I Z.lS5!*01 1.5411!-0I l.7Zll*Ot S.1441-0t 4.Zt21-0t S.l40!*0t 2.705!-tt Z.2551-0t 1.t221!-09 l.oooE-09 SS!

4.llll!-01 Z.4261-01 1.6141*11 t.1451-lt 6.1511-0t 4.5SOl*tt J.5J41*1t 2.1671*** 2.lt4l*Ot z.a*ll*Ot l.174!-09

~!NT AND IUILDINO,AIA"!Tl!JtSa P. !L !ASI! Hl!IGMT Wl!Tl!ltS>

OIAfll!T!!

CMl!Tl!RS> *

!XIT 'il!LOCJ:TT CltlTIJIS>

ALL GROUND L!Vl!L RILl!ASIS.

51.U O.OI O.OI

"'usHK cof'!PuTo.. aDI - xa.aot. vm1* z.1 Rl!P. WIMI MIJ:GllT Clt!Tl!IS>

10.0 IUILDlNO HllGHT CM!TlltS>

51.l ILDG.NIN.CAS.SIC.Aa.A

<Sl.NITlllS>

ZOll.O Hl!AT !IUSSIClll IATI CCAVSIC>

I. I 11111 llATI* IZ**~*tl

..... "LISADU XDGllGlll.-..... usz* IVIVU - 12'JVl7 MT DATA....

GROUND L!Vl!L R!Ll!ASI ~~f* GP CGllTAl.-r IUILll*

. NO ll!CAY.

UND!PL!TDhP/~><

CHI/; ( Sl!C/M!T!R c:vaiiiYi!ilf UCll slillar lliltl!CTIOJI

. S*l

.:-C~~,~~a Z*S l'IGR SITI s

5.1171!-07 SSW 5.1051*t7 SH 5.2141!*07 HSN 6

  • 1ZOl*07 If l.UH-t7 HMM 1.1741*9'
1. sn1-"

NIM 1.57' *N rt 1.7,.l*H HNI

7. 7Ul*t7 HI!

t. 555.~7

!Ill 7.672 -t7 I 7.HW' l!S 6

  • 251 -t1 sl 1.2u -t7 SI
7.

-t1 Z.UJI~'

1.151 *t7 1.tll..,

Z.19' -17

-J.UJ ~7

  • .1771*17 4.7051*17 5.Ut!-n 6.414 -t1 Z.Ht *17 J.4211*17 2.7J41-t1 Z.Ull-t1 Z.Zlll-t1 Z.54tl-t7 Z.HU-t1 Slilar ICIUllllAllU IN NILIS l'llCll THI HTI S-4 4*5 5*11,

11*11 4.ZU!*OI S.14Zl*OI

  • .OZH*OI
4. 7051-0I
  • . 7JZl*ll 1.HH*ll 1.GZ41*t7 1.Z4'1*t7 l.424.-t7 J.Ht -ti

. 6.7211-tl J.Jt7 -ti S.0741*tl 4.22*=*

4.Hl -ti s.ut 33 1.1u1-tt 7.441...

Zl*SI Sl-41 Z.4'0l!*Ot Z.l4Zl!*ot Z.5Ul*ot J.1021-ot

    • 4361!-0t 5.ltSl*lt 7.0ZOl*tt a.nu-at
1. 01111-11 S.ISH*tt J.Htl*ot J,U41-tt Z.U41*1t Z.lDll-tt 2.1u1-"

Z.177 *tt 4Q*51J

1. 772!-09 1.'76E*H
1. 106!-09 2.24ZE*09 l.207!*09 cr..26'!-at 5.0911!-0t

'. S71!*09 7.S5U*09 Z. 7&01!-0t Z.105!-ot Z.Zl4!*09 z.011~-at 1.614!-at

1. 926!-09 Z.0471!-0t Rev 6 5/08/92

. -. ". '".-* :-... ~~~-

1uSMC ca.uTAM - ~-. VUSIOtl z. o TABLE 1.3

  • u11 DATI* oz-1t-t1
  • - "LISA.DU XUlllOUI -

UU* OVOVU

  • 1Z..SV17 "IT DAT& um G*OUllD Ll!Vn *l!L!ASI -

TUI' a, COllT&I""UT IUILDillG Z. ZU DAY DIC.A Y, UllDIPUTD ANNUAL AVUAOI CHI.IQ CSIClllllT!I CUID>

DUTAl!CI II "lLl!S l'lCllll THI SlTI!

SICTDI 0.251 o.511 0.751 1.011 1.501 z.011 Z.501 s.001 J.501 4.000 4.500 S

S.1171!*06 l.OSOl*G6 5.6131!*17 J.6951*07 Z.0441*17 l.S49!*07 9.776!*01 7.514!*01 6.017!*01 4.965!*01 4.191!-0I SSN

  • Z.799!*06 9.092!*07 4.9041!*17 J.ZJZl*17 1.7911!*07 l.19Z!*l7 1.671!*01 6.6971*01 5.JIO!*OI 4.45Z!*OI J.768!-0I SN Z.94Z!*06 9.4761!*07 5.052!*17 J.SSSl*07 1.1591*07 l.ZS71!*07 t.OS4!*01 6.919!*01 5.627!*01 4,,,51!-0I l.955!-0I NSN 3.499!*06 1.110!*06 5.IZZl!*07 J.116!*07 Z.119!*17 l.411!*07 1.041!*07 1.0161*01 6.5S4!*01 5.4341!*01 4.620!-0I N

5.0291*06 1.,04!*06 1.4121*07 5.4961*07 S.040!*07 2.0J11!*07 1.4901*07 1.157!*07 9.344!*01 7.765!*01 6.602!-0I NHN 6.,901!*06 Z.ll21*06 1.120!*06 7.2971*07 4.026!*07 Z.690!*07 l.974!*07 l.5ll!*07 1.Zl9!*07 l.Oll!-07 S.76lE-OI HM 7.674!*06 Z.40ll*06 1.Z551*06 1.1161*17 4.JS4!*07 l.0451*17 Z.Z451*07 1.7501*17 1.419!*07 l.lll!-07 1.008!*07 NNH 9.3Zll*06 Z.5141*06 1.4951*06 9.7611!*07 S.4Zll*17 J.6591*17 Z.7071*17 Z.117!*17 1.7201*07 1.438!*07 l.2Z7E-07 rl 1.06'!-05 l.29H*H 1.7011*16 l.UZl-H 6.1641!*17 4.1Ul*17 S.Gl41*17 Z.414!*07 1.9'll!-D7 1.6421!*07 l.40lE-07 NII!

4.400!-06 1.UOl!-06 7.4451*07 4.117!*17 Z.7151-17 1.1121!*17 l.l27!*17 1.0ZH-11 1.son-oa 6.900!-0I 5.UOE-OS NI!

5.101!*06 l.69S!*06 9.2211*07 6.0S0!*07 S.llZ!*07 Z.1,11*07 1.56Sl*07 l.19,!*G7 9.546!*01 7.154E-OI 6.&lSE-OS ENI 4.ZOll!-06 l.S71!-06 7.JtS!-07 4.117!*07 Z.6411-07 1.7SOl-07 l.Z41!*07 9.5551-01 7.6291*01 6.250!-oa S.Z91E-08 E

l.967!*06 l.l20!-06 7.lSS!-07 *.,l51-07 Z.5Zll*07 1.6501*07 1.1161*07 9.057!-0I 7.Zl5!-0I 5.927!-oa 4.9S4E-OS

!SI!

S.S761*06 l.lZll!-06 6.assl-17 S.9171-17 Z.1S6!*17 1 *.sat!-17 t.9551-al 7.5151-11 6.0Z71-0I 4.9421!-0I 4.l49E-08 SI S.9151!*06 l.2t41*06 6.9561*17 4.515!*17 Z.4'.Sl-17 1.6141*17 1.1511-17 l.77tl-tl 6.tlJ!*OI 5.7SS!*OI 4.817!*01 SS!

.S.9941*06 l.llJI-.. 7.1011*17 4.60tl-t7 Z.5141*17 1.6411*17 1.1111*17 t.1271-11 7:1971*11 J.9171*01 *.9101!*01 ANNUAL AVllAGI CHI.It CSICl"ITll CUID>

DISTAllCI II "1&.l!S """ TMI SITI S!CTOI 5.001 7.50t 10.HI 15.011 za.001 u.aat SO.HI SJ.Ill 41.DH 45.0H

50. 000 s

S.6G.S!*OI z.0111-01 l.J.S7!*01 7.4921-lt 4.9661-lt s.,051-lt Z.7711-lt z.Z161*1t 1.IZ41*0t l.5S41*09 1.lll!-09 SSN S.2461*01 1.1sz1-01 l.ZZll-11 6.lt71*1t 4.StJl*lt.S.S411*1t z.1111:** Z.11611-lt 1.7061-0t 1.457!*09 l.ZlZ!-09 SH S.4121*11 1.957!*11 1.Zt71*01 7.J79!*tt 4.f!?!*t! !.61Zl*tt Z.71~~....;t Z.Z~7E--Wi l.i5il*ii 1.561!*01 1.141!-09 HSH S.9961-0I z.zt11-11 1.5451*11 1.1771*** S.91tl*lt 4.4111-lt S.4Z7s-lt Z.7671*** 2.Zt71-at 1.947!*09.1.671!-09 Ii 5.70H*OI.S.ZHl*ll 2.ZOZl*H 1.ZHl*ll 1.4t71*tt 6.Z4Zl*lt 4.1411*19 5.ttJl*lt S.Z.17!*19 Z.7Ul*ot.. Z.l54!*09

1. 5SZ!*OI *.sszr-oa Z.Ut!*H 1.HZl-tl 1.1451*11 l.42tl*lt,,*5'11-tt 5.5171-lt 4.4101-ot 5. 74Sl*Of';l.ZZ9!*09 flN 1.742!*0I 5.056!*01 S.4SJl*OI l.HOl*tl 1.SSZl*OI 1.GOU!*OI 7.IUl*H 6.SSJl*tt 5.Z77!*ot 4.4H!*ot*2s.579!*09 NNM i.our-01 6.zazr-01 4.zur-ea -z.44n-oa 1.Hu-111 LZ4t!*aa 9.7141-tt 1.ul!-ot,.u11-ot s.u41!-o9i'.4.1961!-a9 N

1.Zl91*07 7.l04!*0I 4.1501°01 Z.U41!*0I l.UU*OI l.4lH*OI 1.lZH*H t.Utl*lt 7.U7!*ot 6.5Z61!*ot.;5.652!-09 NH!

  • 5.0Ul-01 Z.HSl*OI 1.9411-0I 1.117!*11 7.5ZZl-ot 5.531!*11 4.Zt7!-0t J.4HE*ot Z.1771-ot z.ul!-ot:z.1001-09 r11 5.nu-oa 5.uar-oa z.acn-01 1.usr-oa 1.1211-tt 5.,ur-at 4.sur-tt s.4Hl-tt z.14H*ot z.snl!-ot"z.osaE-ot 1111 4.5421-01 z.5su-oa 1.'7s1-11 t.5451-tt *a.1151-tt 4.41H-1t s.4441-H z.75Zl!*lt z.zue-ot 1.9os1-ot 2.uar-09 4.Z71!*01 Z.S641*11 l.Jss1-1* 1.6551!-tt 5.6tSl*lt 4.116l*lt 5.1541-lt Z.51,1-lt Z.0661!-0t 1.735!-0t l.41l!-09

!5!

l.550!-ol 1.9551-01 1.212 *II 7.0111-tt 4.66ll*lt 5.l671*1t z.1111-** Z.OSJl*Ot 1.617!-0t 1.4161-09 1.2101!-0*

SI 4.125!*01 Z.Z711*01 1.4tl!*ll l.510l*lt 5.4111*1t 5.9661*19 J.0411*1t Z.4211*19 1.tt*l!*at 1.677!*09 1.435!-09 SS!

4.Z7Z!-al Z.l751-al 1.5'tl*tl 1.7711-tt 5.lltl*tt 4.ZS11*1t S.2511-tt Z.6111*19 Z.15ll*Ot 1.llJl*Ot 1.5571!*09

¥EMT A11D

~UILDINO ll'AllArtl!Tl!IS*

~ELEASE HUOMT Wl!TDS>

OIAllET!~

ct:l!T!ltS>

!XlT V!LQCITY Cl'llT!ISJ

~LL GROUND Ll!Y!L R!L!ASl!S.

51.11 a.GI O.OI

~USMC COl'IPUT!ll CODI

  • XGlllGe1 Vml.. I.I Rl!P. MIND HIJOllf OllT!IS)
11. O IUIL.1111111 HllOllf Cl'llTllSI 51.1 ILDl."11.CIS.SIC.Alll CSl."'1'111> Ziii.i HUT llUISlllll UTI CCAVSll:>

I. I IUll DATI* lz-ts-tl

  • HH ll'AUSADU XOG~~~~.usz** IVIVIS
  • 1ZISVl7 MT DATA -

. GROUND Ll!Y!L HL!ASI "'""Tilt~OP' ClllT&lllBW'* IUIL.111*

2.ZH DAT DICAT. Utl-.,ITD.

CHI.It CSICll'tlT!I CUIDj~ji:;'Uae S-

,..:::if::;:~ ~'!.::~:;.* -

DU!CTIOlt

  • 5*1

. *_:-<:9\\;>z.:'

Z*S S_,. IOUllll&llD II NILD flUll Tiii SITI

.S-4 4-!I 5*11 11 FROlt SIT!

S

.s.:OZ!*07 SSN

5. H U-t7 SN 5.Z71!*17 MSW

'

  • 1041*17.

1.1111-11 NHN 1.1711-M tr.t l. UH*M Nllt

1. 57 Sl*M

.N 1.7tll-M ICtll 7

  • 7'51*11 NI!

9

  • SlH-17 I

7.S7l -t7 t.HSl-H 1.7511*11 t.1N(f

-1.041 -t7 1.JH ~

l.91t 7

z.a.1 i-11

  • Z.7ZS 5.114_ -

1.J71 6.0441*11 J,41Jl*H 1.u11-11 6.JJI...

t.J7t...

1.244 7

1.414 1.7ff..,

l.t

  • _.,

7.H *ta 4.ZOH*tl l.7771-tl 5.H41*tl 4.Ull*ll 6.6171*11 1.71Sl*H 2.0108 11 1.zs1 -e1 l.415 5.1741-tl

,.U41-tl 5.5Ml*M 4.UZ II Zl*!I 40-50 1.uzl' IS 6.Z4 -t7 SI 7.Zll 7

SM 7.Ut 1.517117 l.Ut 17 1.111 1.IN 1.HS i-11 1.H

lllll:::

7.U :-u 6.1 7.1

7.

4... 1:

4.IJ...

4.H S0*41 Z.ZZJ!*ot Z.0771!*09 z.zsH*ot Z.7771*09 5.HH*lt 5.SZ41*1t 6.555!*1t 7.'741*1t 9.lHl*lt J.4791-lt J.4641-tt Z.7Ul*lt Z.5Z71*1t Z.0641*11 Z.UH*tt Z.6Ul*lt

1. 533!-09 l.44l!-09
1. '7 l!-09 l.Ul!-09
z. 746!*09 l.750!-09
4. 4961-09 5.U41!*09 6.5S7!*09 Z.443!*09 Z.JH!*H
l. 901!-at
l. 7401-at l.ttZO!*ot l.HZ!*ot 1.1191-tt Rev 6 5/08/92 34

26/Bo/s 9 Aa~

61*1tn*t H*IUC't H*HZt't 61*1SH't 61* tH't H*HLl't H*HH't H*IZL6'*

H*liH'*

H*H**"S H*IHl'Z H*Htt'Z 60*16tli'1 H*ICCZ't H*H\\lt't H*lltZ't

.,.. u 5£ I' I C:llS,,W:))

11'1 mHSDll.lftll Cl'HH CAJ.l.IW'H> mY':&C'811W'CICl11 t'lli CSll.LJW>

.LllDlilN llMJl1lftl

,., lllllJA 'IOCllDX - IClD:> IJJ.n4'10~ :sl!Nsn[

ID. D cmuw>

.UI:>OUA J.tlG CID' D

<Alil.Lill>

liiJ.:i:!':'lC Cl' D1 CAJ.LIW>

.LMOUll INlM '411*

Ot'lli CS11JJ.JU>

lMOJJM i1SV313o tAJ.LIWYVY~ DNiai1nc CHY J.Ni~.

Dt*ift9'L DT*ltDZ'6 ll*lliZt't ll*lllt't ft*Jltl't lt*JLS*'Z lt*l*Cli'S ID*lltt'S ll*llilD'1 IO*IDOL't IO*JltZ'f iSS 01-i.,,l'L D1-il1D9'1 *D-ilSSD't **-1tzr*1 11-IZtL't lt-16tS'Z 60*1t*r*r IO*lt*r*s ll*IDCD't ID*ISSt't ID-ilttt*r

s Dl*il6SO'f Dl*ilZIZ'L Dl*il*Z6'1 ll*ltZt't ft*ISl*'t ll*ISLl'1 ll*il*lil'Z ll*lltli'* ll*l*Zl'I IO*l*D*'t ID-i16L9'Z ilSil 01-il6.,,.l Dl*ll*6'1 ID*ilt60'1 ll*lliLS't lt*JCll't ll*Jlit*'Z IO*ltlt'S ID*Jttli'li IO*IDLD't ID*iltlt't ID*ilZZZ'f Ot-i.,SZ'I Dt*ilHl'6 ID*ilDtZ't H*ilttli't H*JIH't H*ilLH'Z H*ilLDl'S ID*JnD't H*ilHT't IO*iltZl't ID-iltt.,*r illl3 60-ilrtO'.t H*illitz't ID*ilH*'I H*ilZH't H*IH*'Z H*ilLCZ'C H~ilUt'* H*ilLh'L IO*IDO't ID*IUZ'Z ID-il"LZ'*

ill~

60-ilS,O'T *D-lt*Z't *D-IStS't 10-1111*1 IO*ilrt**z ll*ILZZ'C 11-ilLIS'* 10-ILlt'L ID*llCC't 10-ltLD'Z ID-16tl'S JNN 60-ilou;,z H*ltU'S H*ilDDO'* 60*106't H*JllZ't H-nn*1 IO-ltL1'1 ID-Utl'l to-1sn*r ID*IHD~s ID*UL1"6 H

60-ilSt,~Z *D*llfl'Z *D-ISt**r lt*lflZ'* ll*IZh'S 11-IZSZ'L IO*IZZD't IO*IOIS'.l ll*llll'Z ID*ID**** ID*iLZD'I MNN 60-il,Z6~1 6D*iLIZ'Z ID-i6tL'Z ll*Jlr**r 11-111r** *t-llZl'S 10-IZSZ'I ID-llLZ't 11-ilLliS'Z ID-Jrzt*r ID-lllS't MH 60-ilS09'T ID*ltH't ID-llU'Z H*llLl'Z lt-Jrlt'S H*HU't H*llH't H*ILID't ID*lltD'Z IO*Htt'C to-a.u*s MilM 60-i,6T'T *o-arz**t ll*illZL't ***ll*t*z 11-1sst*z ***IZlt'C ll*llZZ'li ll*lltt'I ID*IDZli't 10-1zsr*z ID*il*tr**

H Ot-uo~** H-:;n:1w1 H*HU't lt-llU"t... *U'1 H-nts*z....,,,., 11-aru*s ll*IHD't IO*Jht't ID*ilLtD'S MS:M Dt*iltSL't ot-16t0'1 11-1cz1** **-1czz*1 **-ltL!i't ll*llitt*z 11-llZD'C ll*JtCl't iO*itz*** iO*liit"i iO*ICLi'Z

~s Dt-il,ZZ't Dt*iltS'l'L ot-ilDID'I ll*ltrt't ll*JS,*'t I0-11Ll'1 11-1rz1*z 11-1*s*** ID*l*Z'l'I IO*ittr*t ID*ISli*'Z MSS Cl*iLt Dt*ilD06'L ot-lllit'i ***IDtZ'1 11-1rtr*1 ll*lttt'Z ****, ***, 10-11r1** 10-1coz** 10-1,.**t ID*l6tL'Z s

ODD'O' DOD'S*

IDD'O'I 11o*cr llD'IS llD'r?

llO'IZ llO'lit lll'Ot IDC'L IDO'C IOl:>JS I.LIS JIU.... sanw II l:lllUSJll

<DI~ &lllt....:DS> llJ'JIC IOYIJAY iYnllNY tO-iOOl'S IO*l6LS'* 10-Jtet'S lt-lttZ'L lt-Jftt** Ll*llitr't Ll*lt*t*z Ll*lr**** Ll*JLrr*t tO*IZDZ't tl-IZIL'f ass t0-i019't to-;z,,*., 10-1s***s ID-IZZD'L ID*JLLS'i Ll*l*rr*t Ll*lllO'Z Ll*ltt6'C LO*llDZ'f tD*ISlt't tO-illDL'S IS I0-31£1't 10-aose*s IO*Jt*t** IO*ilLtD't ID*lttt't LD*ltit't Ll*ltZl'T ll*ILS'l'S Ll*ISIS'S tO-JCZD't tD-ilL6t'S JSi IO*i60t"S IO*iS6S't IO*iltlf'S ID*illi*Z'l 10*11tf'6 LO*IZLS'T Ll*ISSt'Z Ll*Jtto** LO*lltf'9 tD*JLDZ't tD*ilfiL'f i

80-36,0'., tO*iSLt"' IO*i60D't ID*IDC9'L LD*JltD't LD*ID***t Ll*iltliZ'Z LD*ILZZ"* LO*l1Df't tD*l'ICZ't tD*i16L6'S JNi 10-3£,0'S fO*i6L0'9 10-ilZDS'L ID*l6CS'6 LD*ilZLZ't LD*ilSDl't LD*ltZl'Z LD*lllZ'S LD*ilDfZ't tD*ilL*i"T tD*ILfl

IN 10-;L,,., IO*il9,t'5 tD*l*rs*t ID-ISSZ'I LO*JtlD't LD-itDS't LD*l*tr*z to-111z** LD*lt*f'f tD*iDIZ't tO*ll91

JMN L0-30£0'1 LD*ltLZ'T LD*lt'lli'l LD*HZ6't LD*ilttli'Z LD*H***r Ll*IHZ'li Ll*USt'I tD*l'IZli't tD*IDtD'S so-Joto*t u

t0-3L9t'6 LD-IStt'l LD-IZlif't LD*IZ6t't LD*l'IDZ'Z LD*IZ*D't Ll*IDZt"* Ll*IZtC'I tO*l*rr*t tD-ltCt'Z tO*IZSl'i HNN IO-i669'L 10-1r't'6 tO*ifTT't LO*IDO*"t Ll-JIZl'T Ll*lrrs*z tl*IStt'S Ll*IZlt'L tD*IDZt'T tO-ll6t'Z tD*IL9Z'L MN 10-3169"9 ID*ilTl6'L IO*lfbt'6 LO*l9ZZ'1 LD*llDt't LO*ILCZ'Z LO*IDS'l'S Ll*IZD'l't Ll*IZ66'6 tD*l6*6't tD*lliCS'9 HMM tO-itSO'i IO*il6ZO't tD*IZtt*L ID*lli9Z'6 LD*llitZ't LO*Jtlf't Ll*IS61i'Z ll*l*Zt"* Ll*ilttS'L tD*iLfT tD*ilffL"'

M to-arrc*r 10-ilbtZ"* IO*il**t*s ID*ilZL ID*l*l'l'I LO*ilDlt'T LO*ILDl't LO****r*r LD*ll6t'S tD*liTD't tD*ilttr*r MSM 10-arzc*r ID*i91f'f 10-16? ID*lf6i'i to-artt'L LD*IDSD't LD*l*IS't LD*l*Z*'Z LD*ilttSI LD-1'199'1 tD-19RL'Z MS t0-3,Rt'Z 10-1ss,*r ID*illSZ"* ID-IStt'S ID*ilLD'L 10-1sz*** LO*ISSli'T LD*ILCl'Z LO*illLS'* LO*l*tr*t to-JDli9'Z MSS 10-;soz*r ID*l**t*r ID*ltSL"* IO*ICtD't ID*Jlt6'L LO*ISZt't Lt****t't LD*IZtZ'C LD*Jtto*s Ll*IDZ'l'6,..JZ1i6'Z s

oos*,

IDC'S IDD'S IDli'Z llD'Z IDC'T llD't ICL'D IOli'O ICZ'D IDJ.!lilS IUS INJ. ltDU nuw Nt l:>MUUG

<Utn:i GJ.Jlt"'3S> lll'lM:I JIOYlliAY iwnNNY a111aa

  • .lf:llO.I.YO IDD.*

11em1un1.1JGM1Ctu.11e:> 1110 4D.L - 1sniaw i:aA:ai uno~

..... Y.LYQ.lllW lll'tSl'?t - CIJ'tOl'tO.. zsn..... lt90CltDX SlaYS:t1Y~.....

D. z NDtnJA *netox -

IDD~GJ.n..a:> :.ten

£"1 31BVl

26/BO/S g 11a~

?t*HU'i Zt*ID9S Z1*il6.1.l'tr Zl*ill.t.lr'S' Zl-il.1.16 'tr

?l*Ui

Zl*ilUSS'

'2'1-:iUD'.I.

21-ilHt '.I.

21-ilZS't. Sl Zl*ilCzt' 9 2l*llS'G6'S' 2l*ilC5Z 2l*ilhZ'Z 2l*iltrS'S' '2 2l*il11Z'S' Zt*HH'I lt*lfH'l.

Z1*11H'I zt*ll..H'I n-u.0*1 11*111.lr'G' n-11n*t tt*lttt't lt*Hfl'I Zt*Jlll'I Zl*iilllSf Zt*J0.1.6 'S Zt*HH'S zt*IUl'f Zt*JHt' 5

    • ----..-or
  • 1111 '

.>, nn*as*m*u.,*111111

  • .*., lift *mm HIN
  • tr

.l.llllllN INll11ftl I* n

.&lllllN UIM '11111 H*IZ 11j'~*t I-tn:i I

  • IH't 11 m*t

'3"t 1 t*r**

It* tUl

'l Hl."'l 11-IHli"t 11*1Hi't 1t*IZU'I

'l1*1HD'f H* Hi'i

, -n-1**1.*r 1t* ZH'l.

Hf,H'f H

n*r H* Hl.'Z 11-11n*r lt*llCl"Z 11-1n1.*r 1t-1n1*1 lt*ltH'to lt*lltt'lr lt*atzr*r 1t-11.er*r lt*Hti'Z 11-110**1 lt*HIZ't lt*ILU't lt*lttl't

  • am1111 1101 111101D,,,

...... z. *l!Wll llftl 1*1 *H1DA 'IDHDX - IDD:> lli.lft4'1ole:l :n1N£n,._

21-1,11** Zt*llll'i Zt*lftSl. rt-****** 'l1-11'2't tt-IS,l.'t tt*IZS,'Z tt-11*r** 'lt*l*D,'I 11-11.1.r*t D1*116l'2 ass Zl*IS'S't'" zt-itZ6'f zt-IZtlr'l. r1-1rrr** 'l'l*lll.Z't tt-IZLL't tt-IZlr,'Z tt-1'"'" tt-ltr,*1 11-ILl.St Dt*illOt'Z ilS 21-il.1.56'f Zt*ilLlrl'lr Zl*ill,D'f Zt-JSDl'L 'lt*llfD't 'lt*ltS*'I 11-:ar,1*2 tt*JlrLS'f tt-IZl.O'.t. ot-ILZt't ot-aoor*2*

IS3 21-;z*w** n-nn*s z1-1n1*, z1-12u*1 n-u,1*1 n-11u*1 n-11z1r*z n-ano** n-11u*.t. 11-auz*t n-*21**2 ii Zi-il"D'tr* zt-IS'6'1r Zt-IZDZ Zt*ILLl'L tt*IHD'1 tt*lfttr't n-anz*z n-nu*r tt*llZZ'.I. Dt-11Zst'1 ot-nsr*z INl!

21-ilL,Z'li: n-an**, Zt-IUD't n-1.1.u*1 n-1ttr*1 n-ilLH't n-aut*z tt*Htr.t.'* n-atH"I Dt-llt6"'1 01-HSD'S' ilN 21-;o.1. *z 21-aur*r z1-a.1.u*1r zt-nn*s zt-1rzz*.1. n-1100*1 n-aru*t n-1n1r*z n-nu** n-12n*.1. ot-llH' 1 a11N Z1-ilt1.l.'S' Zl*ISDD'.t. 21-11,.1.*1 t1*11Z1't t1-1z1s*t tt-ltlO'Z t1-1,z1*r tt-JS,1'S lt*IZZO't 11-112,*1 Dt*l*ZSS'

~

21-il.1.Zl'i Z1*i16ft'L lt-ILil't tt-11*1*1 11* trr*t 11-1trt*z t1*1tt1'S' rt-lto,Z'S !t*!!;G't eteJOtt't ;t-i.l.ii'i MNN n-16u*~ 21-;zn*, 21-nn*t !tean:*, n-anr*i n-HH't n-112.1.*z n-uos** n-1.1.11*1 ot-atz**t u-:aou*z

.i.;11 2l*iZ,6'* 21-IDID11-111,*.1. Zt-111.1.*1 tl*ltolf't rt-lltl't r1-1r1.1.*z tt*ISltr'to tt*JDll'I Dt*l*t*'t 01~1r11*z

.WIH Zl-i9D2'S' 21*JIZ6'[ zt-llt*** zt-l*Zt z1-1rz**1 tt-iS.t.T'T tt*ltS.t.'t tt*Jtll'Z tl*JO[t'S t1-1Zt1'6 a1-1r,1*1 21-iS66"i Zt*IZ***2 Zt-lfiD'S zt-1tr1*r z1-1rrz*r zt-19DS.t. tt-IDID't lt*IDDl't tt-IZ,S'S tt-*.t..t.f'i 01-11s1*1 MtH 21-itli'l Z1-i.t.22'Z Zt*ltll'Z z1-1,1s*r Zt*l,L.1.'lr zt-IS'' zt-ID*6'6 tt-IZ*,*t r1-a11r2*r tt-16.t.l'S Dt-a.1.so*1 MS Zl*ilZ6i'l 21-ae1r*z Zl-1206'2 z1-1rrt*r Zt-lt.1.l'lr Z1-llt6'f tt-1rro*1 tl*IOlt'l 11-IZISS' tl*ID6SS' 01-1001*1 MSS 21-iD19'Z Zl-ill61't Zl*iZDD'tr Zt*iltot'S Zt*ISSI Zt-1.1.,S'I tt*llZtr't tt*ILSS'2 tt*I*,,.* tt*l*r**.1. Dt*i.l.tS't s

oc*os OO'i!>

DO'Dtr ID'SS' ID'DS' ID'iZ ID'D2 IO'Sl IO'Dt DS'.I.

oo*s I.LIS lil0¥.:1 01-nrr

  • r Dl*HH *r Dl*ilDVCZ 01-:azz1*r Dl*ilZ.,~*z D t-il'169' S' Di*il2t6*t Oi*ittc*~

Oi*llS6D

01-uos*r Cl*ilLl.,'t 0 l*iS'li2'. z Dl*ilDD"' 1 01-ilLLZ'l 01-aorr*t 01-nre* 1 Oli..,

CJizw II SJ:)NY!CJD NDll)i~lC Ol-i16l1'!> DT*l*Dt'S Dt-iS.1.6 lt*l'Z' ll*l*Z*'l 60-ll.tot'Z 61*110.1.'"60-119,'t tD-ISllr't tD-1,t!>'~

ISS Ol*ilS61'* 01-1szr*s lt*ltDD'.I. 11*1*96 *D-i6Ztr't 61*1.l.SSZ ID-ILZt'tr ID-1169'.I. 10*166,'1 IO*ltrS'

as 01-;,r,*r 01-11sr*1r DT*Jtf.l.'S 11-i2t6'.I. **-IDtt't IO*llZ6'1 6D*IOll'S 60-ISDS 10-llZZ'l to-aor,*s

s; Dl*i,St'S' 01-***1*1r 01-1.1.r**, lt-IZll'I 6D*l*lS't 11-1,,1*2 ID*li*r** ID-1,.1.D'.I. ID*llLSt 10-ISLD

i Ol*iD1S'S' D1*1'5"'" 11*11,l'S 11*1.1.ID't 6D*lflt't ID*llZL6't ID*ltS6'S ID*i2to*'t ID*liiZ't tD*IOl.l.'S' iN~

Dl*lt,,.* 01-IZ6L'S 11-1.1.t' 11-ltSD't 61-ISSS't 11*1*" ll*IZtrt'S 6D*l*.1.r*1 IO*JtS9't 10-1r21*,

u Dl*i.l.lt'Z 01-112o*r Dl*llrtl'f 11-110*1 Dt*IZS't'I H*lttrf't......,., ll*IDISlr IO*IDSS'I tO-U21i"2 Jtm Ol-JS'96'* 01-iOOt'f Dt*iSIZ'I 61-IS*t*t *1-111,*t 11-111.1.*z *1-1r1s*s ll*ltOt'I ID-1*.l.t't ID-19!>Z'S N

Dt-ilSD'S Dl*IDZ!> Ol*Jttolr'I 60*1S'l'l 61*lltZL't 11-lttol'Z ll*IDDt'S ll*IZl2'1 IO*llOR'l ID*lt*SS MNN 01-aorr** Ot*l.1.6!>'5 Dl*llZZ'.t. lt-lfll'6 IO*IS.1.lr'l **-itS'*'Z 61-IDll'to 60*il.t.lr6'.I. tD-lll*s*t 10-iLtS

MN 01-11or** 01-11,,., 01-1111*.1. lt*lfZ6'1 ID-11,*'l ID*IDZtr'Z IO*l*s1** 61-ISDl'.1. ID-iDtrSl to-arcs*,

MNH 01-itlt'Z Dt*i12tSS 01-JSlrt'tr Ot*IDttr'f Dt-Jtltr'I 10-ar't 10-1,rt*r 60*1.l.Dt'i 60*1,.6'1 tD*i1,6'Z H

01-iOtt't D1-Jt61'2 01-illt'Z ll-JSl6'S 11-*****s ll*llll'6 10-*****1 *1-1s.1.1*r 60-lftl't 10-112:*1 MSH 01-ill.1.i'l 01-;roo*z 01-llrtf'Z lt*ISs,*r 11-ilLLt'S lt*IS,l'I ll*lttt't ll*ifll'Z *0-10.,... tD-11'9'1 MS Ot*lt*t*t Dl*IStO'Z lt-IZ*.1.*z 11-ltol.1.'f 11-111c*r lt*llZZ'I 60-ltSR'l ID*l*to*r 60-itll'S tD-ltS.l.'1 MSS Dl*il,2'2 01*15.l.1'2 Dl*ltlt'f 11*111Z'C lt*ltlt'.I. ll*ltLZ'l ll*IZSS'2 ll*i.l.St'to 11*1"0'1 ll*itr6t'Z S

DD.'

DS. r DO. r IS. z DD. z

°'. t OD. l S.I.. D

°'. 0 fl. 0 i.l?S,.,...

Cl11W NJ Cll:>NY.LCJa NDll)i*la CID.l!JJC INIMllMl>CI Al S.LNID' lllXI' lY CZ-a*w> WlllY.1.r*n.., llOJ!ZCDlllO IAJlY1JW DNJllUnl.&JIJWHJY.LJID:> ~o 11111 - asnuw 1ilt.1i 1111\\0WEl

..... Y.LWll.LIM "lt"'21 - fl'11'1D DN1cn...... lltOll*DX CJIYCI1Y4.....

£"1 318\\fl

TABLE 1.4 1991 PALISADES LAND USE CENSUS TABLE 10.11-1 Distance to the nearest residence, garden, dairy/beef cattle and goat SECTOR RESIDENCE GARDEN BEEF CATTLE DAIRY COW N

> 5 mi

> 5 mi

> 5 mi

> 5 mi NNE 1.6 mi 3.8 mi

> 5 mi

> 5 mi NE I.8 mi I.8 mi

> 5 mi

> 5 mi ENE 1.3 mi 1.5 mi 4.0 mi 4.0 mi E

I.O mi I. I mi 3.5 mi

> 5 mi ESE 1.0 mi I.O mi 3.I mi 4.0 mi SE

.9 mi I. I mi 3.8 mi 4.3 mi SSE

.75 mi I.5 mi

> 5 mi

> 5 mi s

.5 mi

.5 mi

> 5 mi

> 5 mi SSW

.75 mi I.5 mi

> 5 mi

> 5 mi 37 in each sector.

GOAT

> 5 mi

> 5 mi

> 5 mi 3.8 mi

> 5 mi

> 5 mi

> 5 mi

> 5 mi

> 5 mi

> 5 mi Rev 6 5/08/92

Distance Sector (Miles)

SSE 0.48 s

0.50 ESE 3.10 ENE 4.00 ENE 3.80 NOTE:

  • Based on TABLE l.4a 1991 PALISADES LAND USE CENSUS TABLE 10.11-3 Critical Receptor Items Location/Description Item Site Boundary N/A Residence, Palisades Park Residence/

3/4 mile West of 29th Garden Avenue and Blue Star intersection.

Newel, 73419 30th Ave Beef Covert, (So.uth side of Cattle road).

Cecil Hodge, 1s911 12nd Dairy Street, 3.8 mile South of 16th Avenue and 72nd Street intersection (west side of 72nd Street).

Harlett, 19487 72nd Street Goat 1/4 mile South of 72nd Street CR 380 intersection.

Palisades 5-year composite meteorological 38

\\ \\

\\

  • X/Q ( s ec/m3 l
1. 40E-06 l.OOE-06
?

7.40E-08

.,.t_

  • ~f.

6.40E-08 6.90E-08 data, 1983-19.87.

Rev 6 5/08/92

ELEMENT H c Na p

Cr Mn Fe Co Ni Cu Zn Rb.

Sr y

Zr Nb Mo Tc Ru Rh Ag Te I

Cs Ba La Ce Pr Nd w

Np TABLE 1.6 STABLE ELEMENT TRANSFER DATA Fm - MILK (COW)

Fm - MILK (GOAT)

F - MEAT CDAYS/Ll (DAYS/Ll CDAYS/KGl

1. OE-02 1.7E-01 1.2E-02
1. 2E-02
1. OE-01 3.lE-02 4.0E-02 4.0E-02 3.0E-02 2.SE-02 2.SE-01 4.6E-02 2.2E-03 2.2E-03 2.4E-03 2.SE-04 2.SE-04 8.0E-04 l.2E-03
1. 3E-04 4.0E-02 1.0E-03 l.OE-03
1. 3E-02 6.iE-03 6.7E-03 5.3E-02 l.4E-02 l.3E-02 8.0E-03 3.9E-02 3.9E-02 3.0E-02 3.0E-02 3.0E-02 3.lE-02 8.0E-04 1.4E-02 6.0E-04 I.OE-OS I.OE-OS 4.6£-03 S.OE-06 5.0E-06 3.4E-02 2.5£-03 2.SE-03 2.8E-01 7.SE-03 7.5E-03 8.0E-03
2. 5E-0.2 2.5E-02 4.0E-01 1.0E-06 1.0E-06 4.0E-01 1.0E-02 l.OE-02
1. SE-03 S.OE-02 S.OE-02.

1.7E-02 1.0E-03

1. OE-03.

7.7E-02 6.0E-03 6.0E-02 2.9E-03 1.2E-02 3.0E-01 4.0E-03 4.0E-04 4.0E-04 3.2E-03 5.0E-06 S.OE-06 2.0E-04 l.OE-04 l.OE-04 1.2E-03

.. 5. OE:'."_06.::

5.0E~06 4.7E-03

.;.._ * -* 5

  • OE.:..06 *.

S.OE-06 3.3E-03

  • );<<'.:s* *. OE'.:.04 5.0E-04 l.3E-03
  • -~:::t*oE-06 5.0E-06 2.0E-04 40 B.

CVEG/SOILl 4.8E-OO 5.SE-00 5.2E-02

l. lE-00 2.SE-04 2.9E-02 6.6E-04 9.4E-03
1. 9E-02
1. 2E-Ot 4.0E-Ofi 1.3E-Ol~-
1. 7E-Oi 2.6E-03 1.7E-04 9.4E-03 l.2E-01 2.SE-01 5.0E-02 1.3E+Ol 1.5E-Ol l.3E-OO 2.0E-02 l.OE-02 S.OE-03 2.SE-03 2.SE-03 2.SE-03 2.4E-03 1.8E-02 2.SE-03 Rev 6 S/08/92

Kr-85m Kr-85 Kr-87 Kr-88 Kr-89 Xe-131m Xe-133m Xe-133 Xe-135m Xe-135 Xe-137 Xe-138 Ar-41

1.
2.
3.

TABLE 1. 5 DOSE FACTORS FOR SUBMERSION IN NOBLE GASES*

DFR1 DFY2 1.17 ( +3 )3

1. 23 ( +3) 1.61(+1) 1.72(+1) 5.92(+3) 6.17(+3)
1. 47 ( +4) 1.52(+4)
1. 66( +4)
i. 73 ( +4) 9.15(+1) 1.56(+2) 2.51(+2) 3.27(+2) 2.94(+2) 3.53(+2) 3.12 ( +.3) 3.36(+3) 1.81 ( +3) 1.92(+3).
1. 42( +3)
1. 51 ( +3) 8.83(+3) 9.21(+3}

8.84(+3}

9.30(+3}

/

\\

DFS1

1. 46( +3) 1.34(+3) 9.73(+3) 2.37(+3) 1.01(+4) 4.76(+2) 9.94(+2) 3.06(+2) 7.11 ( +2)
1. 86 ( +3)
1. 22( +4) 4.13(+3) 2.69(+3}

' \\

\\

\\

DFB2 1.97(+3) 1.95(+3)

1. 03 ( +4) 2.93(+3)
1. 06( +4) 1.11(+3) 1.48(+3) 1.05(+3) 7.39(+3) 2.46(+3)

I. 27( +4) 4.75(+3) 3.28(+3}

  • Dose factors for exposure to a semi-infinite cloud 'of noble gases.

Values were obtained from USNRC Regulatory Guide 1.109, Revision 1 (October 1977).

"\\

39 Rev 6 5/08/92

TABLE 1. 7 INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THY~OID KIDNEY LUNG GI-LLI H3*

BElO Cl4 N13 Fl8 NA22 NA24 P32 AR39 AR41 CA41 SC46 CR51 MN54 MN56 FESS FE59 COS7 COSS C060 NI59 NI63 NI6S CU64 ZN6S ZN69M+D ZN69 SE79 BR82 BR83i-D BR84 BRSS KR83M KRSSM KR85 KR87 KR88+D KR89 RB86 RB87 RB88 RB89+D SR89+0 SR90+o*

SR9l+D SR92+D

0.

4.62E-07 9.49E-04 l.2SE-04 1.89E-OS 3.79E-06 4.39E-08 4.39E-08 3.92E-06 0.

7.37E-05 7.37E-OS 7.S4E-06 7.S4E-06 1.4SE-03 8.03E-05

0.
0.
0.
0.

7.48E-OS 0.

3.75E-04 S.41E-04

0.
0.
0.

l.81E-05

0.

1.lOE-09 l.41E-05 8.39E-06 9.69E-06 l.68E-OS

. 0.

4.6SE-07

0.

8.71E-07

0.

S~73E-06 l.81E-OS S.44E-06 2.42E-04 l.46E-05 l.71E-09 2.03E-10

0.

l.34E-09 1.38E-OS 4.47E-05 8.98E-09 l.84E-08 3.85E-ll 6.91E-ll

0.

2.25E-06

0.
0.
0.
0.
0.
0.
0.
0.
0.

0 *.

0.
o.
0.

0..

~':Jic,J~36E-04 o *. ::"..

_., 7:.*. -UE-05

0. -. : " 3~98E-07
0.

2.29E-07 2.84E-04 0.

2.92E-02 0.

6.83E-08 0.

7.SOE-09 0.

4.62E-07 2.6SE-05 3.79E-06 4.39E-08 3.33E-07 7.37E-05 7.54E-06 S.53E-OS

o.
0.

8.16E-06.

1. 69E-04 6.39E-08 3.56E-06 1.SSE-10 2.38E-06 6.77E-06 4.SSE-07
1. 30E-06 8.41E-06
3. lOE-06 8.29E-06 8.79E-ll S.53E-10 2.22E-OS
1. 67E-09 5.13E-12 4.20E-07 9.49E-06 2.72E-07 2.86E-07 1.46E-08
o.
o.
o. o.
0.
0.

6.JOE-05 2.64E-05 2.0SE-07 1.47E-07 8.ISE-06 1.SSE-03 2.47E-09 2.79E-10 4.62E-07 4.62E-07 4.62E-07

0.
0.

l.49E-03 3.79E-06 3.79E-06 3.79E-06 4.39E-08 4.39E-08 4.39E-08

0.
o.
0.

7.37E-05 7.37E-OS 7.37E-OS 7.S4E-06 7.54E-06 -7.S4E-06

o.
o.
o.
0.
0.

l.OOE-08

0.
0.

3.14E-08 O.

0.

6.94E-02

0.

3.S6E-04 0.

4.llE-08 9.4SE-09 9.17E-06 O.

3.56E-06 7.14E-04

0.

7.86E-10 8.9SE-06

0.
0.

6.21E-05

0.
0.

7.25E-04

0.
0.

2.71E-04

0.
0.

S.SSE-04

0.
0.

3.22E-03

0.
0.

S.48E-05

0.
0.

l.49E-04

0.
0.

5.80E-_06

0.

2.84E-09. 6.64E-06

0.

2.32E-OS 4.62E-04

0.

7.45E-09 1~91E-05

0.

2.87E-ll l.05E-06

0.

2.47E-06 2.99E-04

o.
o.
o.
0.
o.
o.
o.
0.
o.
o.
0.
0.
0.
0.

2.50E-09

0.
0.

l.31E-08 O.

0.

l.16E-08

0.
0.

6.59E-08

0.

O.

l.38E-07 O.

O.

8.67E-08

o.
o.
o.

O.

,*O.

O.

o.

/ o.

\\ o.

o.
o.
o.
0.

O.

\\.l.45E-03 O.

O.

\\S.03E-03

0.

O.

~.76E-05

0.
0.

I. 70E-05 Includes a SO% increase to account for percutaneous ~ranspiration.

41 4.62E-07 1.73E-05 3.79E-06 4.39E-08

6. lOE-07 7.37E-05 7.54E-06
l. lSE-05
o.
0.

2.96E-07 2.19E-05 2.55E-07 5.04E-06 5.12E-05 1.a2e:;-07

1. 77&-05 3.47E-06 7.95E-06 2.28E-05 6.34E-07 l..73E-06 3.58E-05 1.07E-05 3.67E-05 2.92E-05 9.44E-06 3.46E-06
o.
o.
0.
o.
o.
0.
o.
0.
o.
o.

2.17E-06 2.99E-07 2.42E-07 4.87E-08 4.57E-OS 9.36E-05 S.24E-05 1.00E-04 Rev 6 5/08/92

._j ___ -

~::;_.....

TABLE 1.7 (continued)

INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 2.35E-06 0.

6.30E-OS

0.
0.

l.92E-04 7.43E-05 Y91M+D 2.91E-10 O.

9.90E-12

0.
0.

l.99E-06 l.6SE-06 Y91 4.20E-04 O.

l.12E-05

0.
0.

l.75E-03 5.02E-05 Y92 l.17E-OS 0.

3.29E-10

0.
0.

l.75E-05 9.04E-05 Y93 l.07E-07 O~

2.91E-09

0.
0.

5.46E-05 l.19E-04 ZR93+0 2.24E-04 9.51E-05 6.lSE-05

0.

3.19E-04 l.37E-03 l.48E-05 ZR95+0 S.24E-05 l.99E-05 l.45E-05

0.

2.22E-05 l.25E-03 l.55E-05 ZR97+0 l.07E-07 l.S3E-OS S.36E-09

0.

I.SSE-OS 7.SSE-05 l.OOE-04 NB93M l.38E-04 3.59E-05 l.15E-05

0.

3.6SE-05 2.09E-04 2.47E-06 NB95 l.12E-05 4.59E-06 2.70E-06

0.

3.37E-06 3.42E-04 9.05E-06 NB97 2.44E-10 5.21E-ll l.SSE-11

0.

4.07E-ll 2.37E-06 l.92E-05 M093

0.

6.46E-06 2.22E-07

0.

l.54E-06 3.40E-04 3.76E-06 M099+0

0.

l.ISE-07 2.31E-OS

0.

l.S9E-07 9.63E-05 3.4SE-05 TC99M 9.98E-13 2.06E-12 2.66E-ll

0.

2.22E-ll 5.79E-07 l.45E-06 TC99 2.09E-07 2.6SE-07 S.SSE-OS

0.

2.49E-06 6.77E-04 7.S2E-06 TCIOl 4.65E-14 5.SSE-14 5.SOE-13

0.

. 6.99E-13 4.17E-07 6.03[.-07 RU103+0 l.44E-06 0.

4.S5E-07

0.

3.03E-06 3.94E-04 l.15E~05 RUIOS+D S.74E-10 0.

2.93E-10 O.

6.42E-10 l.12E-05 3.46E~05 RU106+0 6.20E-05 0.

7.77E-06

0.

7.61E-05 S.26E-03 l.17E~04 RHIOS S.26E-09 5.41E-09 3.63E-09

0.

l.50E-OS 2.0SE-05 l.37E~05 PD107

0.

4.92E-07 4.llE-OS

0.

2.75E-06 6.34E-05 7.33E-07 PD109

0.

3.92E-09 l.05E-09

0.

l.2SE-OS l.68E-05 2.S5E-05 AGllOM+D 7.13E-06 5.16E-06 3.57E-06

0.

7.SOE-06 2.62E-03 2.36E-05 AGlll 3.75E-07 1.45£-07 7.75E-OS

0.

3.05E-07 2.06E-04 3.02E-05 CD113M

0.

6.67E-04 2.64E-05

0.

5.SOE-04 l.40E-03 l.65E-05 CDllSM

0.

l.73E-04 6.19E-06

0.

9.41E-05 l.47E-03 5.02E-05

, SN123 2.09E-04 4.21E-06 7.2SE-06 4.27E-06 0.

2.22E-03 4.0SE-05 SN125+0 l.OlE-05 2.SIE-07 6.00E-07 2.47E-07 0.

6.43E-04 7.26E-05 SN126+0 8.30E-04 l.44E-05 3.52E-05 3.84E-06 0..

4.93E-03 l.65E-05 SB124 2.71E-05 3.97E-07 8.56E-06 7.lSE-08 0.

l.89E-03 4.22E-05 SB125+0 3.69E-05 3.41E-07 7.78E-06 4.45E-08 0.

l.17E-03 l.OSE-05 SB126 3.0SE-06 6.0lE-08.

l.llE-06 2.35E-08 0.

6.SSE-04 5.33E-05 SB127 2.82E-07 5.04E-09!

8.76E-08 3.60E-09 0.

l.54E-04 3.78E-05 TE125M 3.40E*06 l.42E-06 4.70E-07 l.16E-06 0.

3.19E-04 9.22E-06 TE127M+D l.19E-05 4.93E-06 l.48E-06 3.48E~06 2.68E-05 9.37E-04 l.95E-05 TE127 l.-59E:~09 6.SlE:~lO 3.49E-10 1.32E-09 3.47E-09 7.39E-06 1. 74E-05 TE129M+D L'OlE~os*.' 4.35E-:06

1. 59E-06
3. 91E-06 2. 27E-05 1. 20E-03 4. 93E-05 TE129 s;:i~~E(~:t~t:** 2.4aE:.n l.34E-ll 4.82E-ll l.25E-10 2.14E-06 l.88E-05 TE131M+D 7'.f62E;;oa.> -3.93E-08 2.59E-08 6.38E-08 l.89E-07 l.42E-04 8.51E-05 TE131+0 fa:21£,~:11*~ 5.87E-12 3.57E-12 l.13E-ll 2.SSE-11 l.47E-06 5.S-7-E~06 TE132+D 2ii~6'E~07 1.69E-07 l.26E-07 l.99E-07.-7.39E-07 2.43E-04 3.ISE-05 TE133M+D 6~t3E.~Jl 3.59E-ll 2.74E-11 5.52E-ll/ l.72E-l0 3.92E-06 l.59E-05 TE134+0 3.lSE-11 2.04E-ll l.68E-ll 2.91E-ll 9.59E-Ii 2.93E-06 2.53E-06 1129
2. l&E-05 1.5'9E-05 l.16E-05
1. 04E-02 l.88E-05 \\ 0.

2.12E-07 1130

4. 54E-06 9. 91E-06
3. 98E-06 l.14E-03 l.09E-05 \\0.

l.42E-06 1131+0 2.71E-05 3.17E-05 l.40E-05 l.06E-Ol 3.70E-05 0.

7.56E-07

\\

42 Rev 6 5/08/92

TABLE 1.7 (continued)

INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 l.21E-06 2.S3E-06 8.99E-07 l.21E-04 2.82E-06 0.

l.36E-06 1133+0 9.46E-06 l.37E-OS 4.00E-06 2.S4E-03 l.60E-OS 0.

l.S4E-06 1134 6.SSE-07 l.34E-06 4.7SE-07 3.18E-OS l.49E-06 0.

9.21E-07 113S+O 2.76E-06 S.43E-06 l.98E-06 4.97E-04 6.0SE-06 0.

l.31E-06 XE131M

0.
0.
0.
0.
0.

6.77E-09 0.

XE133M

0.
0.
0.
0.
0.

8.89E-09 0.

XE133

0.
0.
0.
0.
0.

7.41E-09 0.

XE13SM

0.
0.
0.
0.
0.

8.0SE-09 0.

XE13S

0.
0.
0.
0.
0.

I.80E~oa 0.

XE137

0.
0.
0.
0.
0.

8.30E-08 0.

XE138+0

0.
0.
0.
0.
0.

9.78E-08 0.

CS134M+O l.32E-07 2.lOE-07 l.llE-07

0.

8.SOE-08 2.00E-08 l.16E-07 CS134 2.83E-04 5.02E-04 S.32E-05

0.

l.36E-04 5.69E-05 9.53E-07 CS13S l.OOE-04 8.66E-05 4.73E-06

0.

2.SSE-OS l.OlE-OS 2.18E~07 CS136 3.4SE-OS 9.61E-OS 3.78E-OS

0.

4.03E-OS 8.40E-06 l.02E~06 CS137+0 3.92E-04 4.37E-04 3.2SE-OS

0.

l.23E-04 S.09E-OS 9.S3E~07 CS138 3.61E-07 S.SBE-07 2.84E-07

0.

2.93E-07 4.67E-08

  • 6.26E~07 CS139+0 2.32E-07 3.03E-07 l.22E-07
0.

l.6SE-07 2.S3E-08 l.33E~oa BA139 l.06E-09 7.03E-13 3.07E-ll

0.

4.23E-13 4.2SE-06 3.64E-OS BA140+0 4.00E-OS 4.00E-08 2.07E-06

0.

9.S9E-09 l.14E-03 2.74E-OS BA141+0 l.12E-10 7.70E-14 3.SSE-12

0.

4.64E-14 2.12E-06 3.39E-06 BA142+0 2.84E-ll 2.36E-14 l.40E-12

0.

l.36E-14 l.1IE~06 4.9SE-07 LA140 3.61E-07 l.43E-07 3.68E-08

0.
0.

l.20E-04 6.06E-OS LA141 4.85E-09 l.40E-09 2.45E-10

0.
0.

l.22E-OS 5.96E-OS LA142 7.36E-10 2.69E-10 6.46E-ll

0.
0.

5.87E-06 4.25E-OS CE141 l.98E-05 l.19E-05 l.42E-06

0.

3.75E-06 3.69E-04 l.54E-OS CE143+0 2.09E-07 I.38E-07 l.SSE-08

0.

4.0JE-08 8.JOE-05 3.5SE-05 CE144+0 2.28E-03 8.65E-04 I.26E-04

0.

3.84E-04 7.0JE-03 l.06E-04 PR143 l.OOE-05 3.74E-06 4.99E-07

0.

I.41E-06 3.09E-04 2.66E-05 PR144 3.42E-ll l.32E-ll l.72E-12

0.

4.SOE-12 I.15E-06 3.06E-06 N0147+0 5.67E-06 5.SIE-06

  • 3.57E-07
0.

2.25E-06 2.JOE-04 2.23E-05 PM147 3.91E-04 3.07E-05: l.56E-05

0.

4.93E-05 4.55E-04 5.75E-06 PM148M+D 5.00E-05 l.24E-05 9.94E-06

0.

1.45£-05 l.22E-03 3.37E-05 PM148 3.34E-06. 4.82E-07 2.44E-07

0.

5.76E-07 3.20E-04 6.04E-05 PM149 3.10E~07 4.0SE-08 1.78E-08 O~

4.96E-08 6.50E-05 3.0IE-05 PM151 7.52E;;;08 l.lOE-08 5.SSE-09

0.

I.JOE-OS 3.25E-05 2.58E-05 SM151 3.38E~'04 6.45E-05 l.63E-05

0.

5.24E-05 2.98E-04 3.46E-06 SM153 l.53Ei07 l.lSE-07 9.06E-09

0.

2.47E-08 3.70E-05 1.93[::05 EU152 7.8~E:i'04. 1.77E"".04 1.72E-04

0.

5.94E-04 1.48E-03 9.BSE-06 EU154 2.96E.;.03-3.46E-04 2.45E-04

0.

/l.14E-03 3.05E-03 2.84E-05 EU155 5.97E-04 5.72E-05 3.46E-05

0.

. l.58E~04 5.20E-04 S.19E-05 EUIS6 l.S6E-05 9..59E-06 l.S4E-06

0.

4.48E-06\\6.12E-04 4.14E-OS TB160 l.12E-04 0.

l.40E-OS

0.

3.20E-05 J.llE-03 2.14E-05 H0166M l.45E-03 3.07E-04 2.SIE-04

0.

4.22E-04 2.0SE~03 l.65E-05 WISI 4.86E-08 l.46E-08 l.67E-09

0.

o~

1~33E-05 2.63E-07 WISS l.57E-06 4.83E-07 5.SSE-08

0.
0.

4.48E-04 l.12E-OS Wl87 9.26E-09 6.44E-09 2.23E-09

0.
0..

2.83E-05 2.54E-05 43 Rev 6 5/08/92

TABLE 1.7 {continued)

INFANT INHALATION DOSE COMMITMENT FACTORS (MREM,50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THY OID KIDNEY LUNG GI-LLI PB210+D 8.62E-02 2.02E-02 3.43E-03

0.

6.85E-02 l.76E-Ol 3.79E-OS 81210+0

0.

l.33E-05 l.ISE-06

0.

l.03E-04 9.96E-03 3.27E-05 P0210 2.98E-03 5.63E-03 7.12E-04

0.

I.30E-02 2.40E-Ol 4.36E-OS RN222+D

0.
0.
0.
0.
0.

9.88E-06 0.

RA223+D l.56E-03 2.26E-06 3.12E-04

0.

4.16E-05 2.25E-Ol 3.04E-04 RA224+D l.77E-04 4.00E-07 3.54E-05

0.

7.30E-06 7.91E-02 3.42E-04 RA225+D 2.57E-03 2.88E-06 5.13E-04

0.

5.31E-05 2.57E-Ol 2.87E-04 RA226+D 2.48E-Ol l.46E-05 2.05E-Ol

0.

2.94E-04 7.83E-Ol 3.05E-04 RA228+D l.60E-Ol 7.61E-06 l.80E-Ol

0.

l.53E-04 l.09E-OO 5.19E-05 AC225 3.69E-03 4.72E-03 2.48E-04

0.

3.49E-04 l.96E-Ol 2.71E-04 AC227+D 5.29E+OO 8.76E-Ol 3.28E-Ol

0.

l.86E-Ol l.62E+OO 5.27E-OS TH227+D l.82E-03 3.03E-05 S.24E-05

0.

l.13E-04 3.27E-Ol 3.53E-04 TH228+D 8.46E-Ol l.lOE-02 2.SGE-02

0.

5.61E-02 4.65E+OO 3.62E-04 TH229 l.34E+Ol l.82E-Ol 6.62E-Ol

0.

8.99E-Ol l.22E+Ol 3.29E-04 TH230 3.46E+OO l.79E-Ol 9.65E-02

0.

8.82E-Ol 2.18E+OO 3.87E~05 TH232+D 3.86E+OO l.53E-Ol-2.29E-Ol

0.

7.54E-Ol 2.09E+OO 3.29E~os TH234 l.33E-05 7.17E-07 3.84E-07

0.

2.70E-06 l.62E-03 7.40E.-05 PA23l+D.

9.lOE+OO 3.00E-01 3.62E-01

0.

l.62E+OO 3.BSE-01 4.61E-05 PA233 6.84E-06 l.32E-06 l.19E-06

0.

3.68E-06 2.19E-04 9.04E-06 U232+D 2.57E-Ol

0.

2.13E-02

0.

2.40E-02 l.49E+OO 4.36E-05 U233+D 5.44E-02 0.

3.83E-03

0.

l.09E-02 3.56E-Ol 4.03E-OS U234 5.22E-02 0.

3.75E-03

0.

l.07E-02 3.49E-Ol 3.95E-05 U235+D 5.0lE-02 0.

3.52E-03

0.

1.0lE-02 3.28E-Ol 5.02E-OS U236 5.0lE-02 0.

3.GOE-03

0.

1.03E-02 3.35E-01 3.71E-05 U237 3.25E-07 0.

8.65E-08

0.

8.08E-07 9.13E-05 1.31E-05 U238+D 4.79E-02 0.

3.29E-03

0.

9.40E-03 3.0GE-01 3.54E-05 NP237+D 3.03E+OO 2.32E-01 l.26E-01

0.

7.69E-01 3.49E-Ol 5.lOE-05 NP238 2.67E-06 6.73E-08 4.16E-08

0.

l.47E-07 9.19E-05 2.58E-05 NP239 2.65E-07 2.37E-08 l.34E-08

0.

4.73E-08 4.25E-05 l.78E-05 PU238 5.02E+OO 6.33E-01 l.27E-01

0.

4.64E-Ol 9.03E-Ol 4.69E-05 PU239 5.SOE+OO 6.72E-01:

l.34E-Ol

0.

4.95E-Ol 8.47E-Ol 4.28E-05 PU240 6.49E+OO 6.71E-Ol; l.34E-Ol

0.

4.94E-Ol 8.47E-Ol 4.36E-05 PU241+0 l.SSE:::-01 6.69E-03 3.llE-03

0.

l.lSE 7.62E-04 8.97E-07 PU242 5.09E+OO 6.47E-01 l.29E-Ol

0.

4.77E-Ol 8.15E-Ol 4.20E-05 PU244 5.95E+OO -}.40E-Ol l.48E-Ol

0.

S.46E-Ol 9.33E-Ol 6.26E-05 AM241 l.~4.E:f'00/.8.4'4[,.pl l.31E-Ol

0.

7.94E-Ol 4.06E-Ol 4.78E-OS AM242M l.~OE+oo,::, 8-~24E:-Ol l.35E-Ol

0.

8.03E-Ol l.64E-Ol 6.0lE-05 AM243 1:82E+oo*~: s~IOE-01 l.27E-Ol

0.

7.72E-Ol 3.85E-Ol 5.60£'."_05 CM242 a-.~s8E~02'. 7:44"E-02 5.70E-03

0.

l.69E-02 2.97E-Ol 5.lOE-05 CM243 l.73E+oo,::.:T. 94.E-Ol

1. OGE-01
o.
3. 91E-Ol
4. 24E-Ol
5. 02E-05 CM244 1.43E+OO 7.04E-Ol 8.89E-02 O.

3.21E-0'1 4.0SE-01 4.86E-05 CM245 2.26E+OO 8.SOE-01 l.36E-Ol

0.

5.23E-O~\\ 3.92E-Ol 4.53E-05 CM246 2.2.4E+OO 8.79E-Ol l.36E-Ol

0.

5.23E-Ol \\J.99E-Ol 4.4SE-05 CM247+D 2.lSE+OO 8.64E-Ol l.33E-Ol

0.

5.lSE-01

~.92E-Ol S.85E-05 CM248 l.82E+Ol 7.12E+OO l.lOE+OO

0.

4.24E+OO 3.23E+OO 9.43E-04 CF2~2 4.26E+OO 0.

l.OlE-01

0.
0.

l.37E+OO l.85E-04 44 Rev 6 5/08/92

TABLE 1.7 (contd}

CHILD INHALATION DOSE COMMITMENT FACTORS (MREM~SOY PER PCI INHALED IN FIRST YR)

ISOTOPE BONE

. LIVER TOTAL BODY TH ROID KIDNEY LUNG GI-LLI H3*

0.

3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 BElO 8.43E-04 9.83E-05 2.12E-05

0.
0.

7.41E-04 1.72E-05 C14 9.70E-06 1. 82E-06 1.82E-06 l.82E-06 1. 82E-06

1. 82E-06 1.82E-06 N13 2.33E-08 2.33E-08 2.33E-08 2.33E-08 2.33E-08 2.33E-08 2.33E-08 FIB 1.88E-06 0.

1.85E-07

0.
0.
0.

3.37E-07 NA22 4.41E-05 4.41E-05 4.41E-05 4.41E-05 4.41E-05 4.41E-05 4.41E-05 NA24 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 P32 7.04E-04 3.09E-05 2.67E-05

0.
0.
0.

1.14E-05 AR39

0.
0.
o.
0.
0.

4.89E-09 0.

AR41

0.
0.
0.
0.
0.

1.68E-08 0.

CA41 7.06E-05 0.

7.70E-06

0.
0.

7.21E-02 2.94E-07 SC46 1.97E-04 2.70E-04

1. 04E-04
0.

2.39E-04 0.

2.45E-05 CR51

0.
0.

4.17E-08 2.31E-08 6.57E-09 4.59E-06 2.93E-07 MN54

0.

1.16E-05 2.57E-06

0.

2.71E-06 4.26E-04 6.19E-06 MN56

0.

4.48E-10 8.43E-11

0.

4.52E-10 3.SSE-06 3.33E-05 FESS 1.28E-OS 6.SOE-06 2.lOE-06

0.
0.

3.00E-OS 7.7SE-07 FES9 S.S9E-06 9.04E-06 4.SlE-06

0.
0.

3.43E-04 1. 91E"05 C057

0.

2.44E-07 2.BSE-07

0.
0.

l.37E-04 3. S8E;;;06 COSS

0.

4.79E-07 8.S5E-07

0.
o.

2.99E-04 9.29E-06 C060

0.

3.S5E-06 6.12E-06

0.
0.

l.91E-03 2.60E-05 NI59 1.66E-05 4.67E-06 2.83E-06

0.
0.

2.73E-OS 6.29E-07 NI63 2.22E-04 1. 25E-05 7.56E-06. 0.

0.

7.43E-05 1. 71E-06 NI65 8.08E-10 7.99E-11 4.44E-11

o.
0.

2.21E-06 2.27E-05 CU64

0.

S.39E-10 2.90E-10

0.

1.63E-09 2.59E-06 9.92E-06 ZN6S 1.15E-05 3.06E-05

1. 90E-OS
0.
1. 93E-05 2.69E-04 4.41E-06 ZN69M+D 4.26E-09 7.28E-09 8.59E-10
0.

4.22E-09 7.36E-06 2.71E-05 ZN69 l.81E-11 2.61E-ll 2.41E-I2*

0.

l.SSE-11 3.84E-07 2.75E-06 SE79

o.

l.23E-06 2.60E-07

0.

I. 71E-06 1. 49E-04 3.43E-06 BR82

0.
o.

S.66E-06

0.
0.
0.
0.

BR83+D

o.
0.

I. 28E-07

0.
0.
0.
0.

BR84

0.
0.
1. 48E-07
0.
0.
0.
o.

BR85

0.
0.

6.84E-09

0.
0.
0.
o.

KR83M

o.
0.
o.
0.
0.

I. 22E-09 o.

KRSSM

o.
0.
o.
0.
0.

6.SSE-09 o.

KRBS

0.
o.
o.
0.
0.

S.66E-09 0.

KR87

0.
0.
o.
0.
0.
  • 3.38E-08 o.

KR88+D

o.
o.
0.
o.
0.

6.99E-08 0.

KR89

0.
0.
o.
0.
0.

4.5SE-08 0.

RB86 0 **.'

  • S.36E-05 3.09E-OS
0.
0.
0.

2.16E-06 RB87

0.
  • 3.16E-05 l.37E-05
0.
0.
0.

2.96E-07 RB88

0.

l.52E-07 9.90E-08

0.
0.

\\ 0.

4.66E-09 RB89+D

0.

9.* 33E-08 7.83E-08

0.
0.

\\ 0.

5.llE-10 SR89+D 1.62E-04 0.

4.66E-06

0.
0.

'S. 83E-04 4.52E-05 SR90+D 2.73E-02 0.

I.74E-03

0.
0.

3.* 99E-03 9.28E-05 SR9l+D 3.28E-08 0.

I. 24E-09

0.
0.

I.*44E-OS 4.70E-05 SR92+D 3.54E-09 0.

1.42E-10 0.

0.

6.49E-06 6.S5E-05

  • Includes a 50% increase to account for percutaneous transpiration.

4S Rev 6 5/08/92

TABLE 1.7 {contd}

CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 l.llE-06 0.

2.99E-08

0.
0.

7.07E-05 7.24E-05 Y91M+D l.37E-10 0.

4.98E-12

0.
0.

7.60E-07 4.64E-07 Y91 2.47E-04 0.

6.59E-06 O.

0.

7.lOE-04 4.97E-05 Y92 5.SOE-09 0.

l.57E-10

0.
0.

6.46E-06 6.46E-05 Y93 5.04E-08 0.

l.38E-09

0.
0.

2.0lE-05 l.OSE-04 ZR93+D 2.07E-04 7.80E-05 5.55E-05

0.

3.00E-04 7.lOE-04 l.47E-05 ZR95+D 5.13E-05 l.13E-05 l.OOE-05

0.

l.61E-05 6.03E-04 l.65E-05 ZR97+D 5.07E-08 7.34E-09 4.32E-09

0.

l.05E-08 3.06E-05 9.49E-05 NB93M l.27E-04 3.17E-05 l.04E-05

0.

3.44E-05 l.04E-04 2.45E-06 NB95 6.35E-06 2.48E-06 l.77E-06

0.

2.33E-06 l.66E-04 l.OOE-05 NB97 l.16E-10 2.08E-ll 9.74E-12

0.

2.31E-ll 9.23E-07 7.52E-06 M093

0.

3.76E-06 l.35E-07

0.

l.06E-06 l.70E-04 3.78E-06 M099+D

0.

4.66E-08 l.ISE-08

0.

l.06E-07 3.66E-05 3.42E-05 TC99M 4.81E-13 9.41E-13 l.56E-ll

0.

l.37E-11 2.57E-07 l.30E-06 TC99 l.34E-07 1.49E-07 5.35E-08

0.
  • l.75E-06 3.37E~04 7.75E~06 TClOl 2.19E-14 2.30E-14 2.91E-13
0.

3.92E-13 l.58E-07 4.41E~09 RU103+D 7.SSE-07 0.

2.90E-07

0.

l.90E-06 l.79E-04 l.21E~os RUlOS+D 4.13E-10 0.

l.50E-10

0.

3.63E-10 4.30E-06 2.69E~05 RU106+D 3.68E-05 0.

4.57E-06

0.

4.97E-05 3.87E-03 l.16E-04 RHlOS 3.91E-09 2.lOE-09 l.79E-09

0.

8.39E-09 7.82E-06 l.33E-05 PD107

0.

2.65E-07 2.SlE-08

0.

l.97E-06 3.16E-05 7.26E-07 PD109

0.

l.48E-09 4.95E-10

0.

7.06E-09 6.16E-06 2.59E-05 AGllOM+D 4.56E-06 3.08E-06 2.47E-06

0.

5.74E-06 l.48E-03 2.71E-05 AGlll l.81E-07 5.68E-08 3.75E-08

0.

1.71E-07 7.73E-05 2.98E-05 CD113M

0.

4.93E-04 2.12E-05

0.

5.13E-04 6.94E-04 l.63E-05 CD115M

0.

7.88E-05 3.39E-06

0.

5.93E-05 5.86E-04 4.97E-05 SN123 l.29E-04 2.14E-06 4.19E-06 2.27E-06 0.

9.59E-04 4.0SE-05 SN125+D

~.95E-06 9.94E-08 2.95E-07 l.03E-07 0.

2.43E-04 7.17E-05 SN126+D 6.23E-04 l.04E-05 2.36E-05 2.84E-06 0.

3.02E-03 1.63E-05 SB124 l.SSE-05 2.00E-07 5.41E-06 3.41E-08 0.

8.76E-04 4.43E-05 SB125+D 2.66E-05 2.05E-07; 5.59E-06 2.46E-08 0.

6.27E-04 1.09E-05 SB126 l.72E-06 2.62E-08: 6.16E-07 l.OOE-08 0.

2.86E-04 5.67E-05 SB127 l.36E~07 l.09E-09 4.70E-08 l.SlE-09 0.

6.17E-05 3.82E-05 TE125M l.82E-06 6.29E-07 2.47E-07 5.20E-07 0.

l.29E-04 9.13E-06 TE127M+D 6.72E~O~ 2:31E-06 8.16E-07 1~64E-06 l.72E-05 4.00E-04 l.93E-05 TE127 7.49E*;~l0~" 2. S7E..:10 l.65E-10

5. 30E-10
1. 91E-09 2. 71E-06
1. 52E-05 TE129M+D 5.f9E*~06>. *i..s5E-06
8. 22E-07
1. 71E-06 'l.36E-05 4. 76E-04 4. 91 E-05 TE129 2.. *64E~Tr
  • 9*.45E-12.

6.44E-12 l.93E-ll 6.94E-ll 7.93E-07 6.8~E_~06 TE131M+D 3~'63£;.;_08'-.:.l.60E-08 1.37E-08 2.64E-08 l.08E-07 5.56E-05 8.32E-05 TE13l+D 5~87E:-l2* 2.28E-12 l.78E-12 4.59E l.59E-11 5.55E-07 3.60E-07 TE132+D l.30E-07 7.36E-08 7.12E-08

8. 58E~08" 4. 79E-Oi l.02E-04 3. 72E-05.

TE133M+D 2.93E-ll 1.51E-ll l.50E-ll 2.32E-ll l.OlE-10\\ l.60E-06 4.77E-06 TE134+D l.53E-ll 8.SlE-12 9.40E-12 l.24E-ll 5.71E-ll \\l.23£-06 4.87E-07 1129 l.OSE-05 6.40E-06 5.71E-06 4.28E-03 l.08E-05 O.

2.lSE-07 1130 2.21E-06 4.43E-06 2.28E-06 4.99E-04 6.61E-06 O~

l.38E-06 1131+0 l.30E-05 I.JOE-OS 7.37E-06 4.39E-O~ 2.13E-05 O.

7.68E-07 46 Rev 6 5/08/92

"*:* *,. --.*P TABLE 1.7 (contd)

CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG Gl-LLI 1132 1133+0 1134 1135+0 XE131M XE133M XE133 XE135M XE135 XE137 XE138+0 CS134M+O CS134 CS135 CS136 CS137+0 CS138 CS139+0 BA139 BA140+D BA141+0 BA142+0 LA140 LA141 LA142 CE141 CEI43+D CEI44+D PR143 PR144 ND147+D

.PM147 PM148M+D PM148 PM149 PM151 SM151 SM153 EU152 EU154 EU155 EU156 TB160 H0166M Wl81 WISS Wl87 5.72E-07 l.IOE-06 4.48E-06 5.49E-06 3.17E-07 5.84E-07 l.33E-06 2.36E-06

0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.

6.33E-08 8.92E-08 l.76E-04 2.74E-04 6.23E-05 4.13E-05 l.76E-05 4.62E-05 2.45E-04 2.23E-04 l.71E-07 2.27E-07 l.09E-07 l.lSE-07 4.98E-10 2.66E-13 2.00E-05 l.75E-08 5.29E-ll 2.95E-14 l.35E-ll 9.73E-15 l.74E-07 6.0SE-08 2.28E-09 5.31E-10 3.50E-10 l.llE-10 l.06E-05 5.28E-06 9.89E-08 5.37E-08 l.83E-03 5.72E-04 4.99E-06 l.SOE-06 l.61E-ll 4.99E-12 2.92E-06 2.36E-06;

3. 52E:-:_04
2. 52E-05 :

3.31E-05 6.SSE-06 l.61E-:-.06_ l.94E-07 l.*4.7,EFOt -l.'56'E~os 3;~2

~i;E~oa~'~. 4:.. 33E-o9 3.14£~0-4*: -. 4. 75E-05 7'~;21.E~~OS:'.>.4. 51E.,.08 t~.4'2E~CJ.4';f:.. 1.37E;.04 2 :14e;o3:r,*- -2~49E~o4 5.60£.:04-4.0SE-05 7.89E-06 (.23E-06 7.79£-05 0.

l.34E-03 2.SlE-04 2.66£-08 6~52E-09 8.31E-07 2.0SE-07 4.41E-09 2.61E-09 5.07E-07 2.0SE-06 2.69E-07 l.12E-06

0.
0.
0.
0.
0.
0.
0.

6.12E-08 6.07E-05.

4.45E-06 3.14E-05 3.47E-05

1. 50E-07 5.SOE-08 l.45E-ll l.17E-06
1. 72E-12 7.54E-13 2.04E-08 l.15E-10 3.49E-ll 7.83E-07 7.77E-09 9.77E-05 2.47E-07 8.lOE-13 l.84E-07 l.36E-05 6.SSE-06 l.25E-07 8.45E-09 2.82E-09 1.49E-05 4.35E-09 l.61E-04 2.27E-04 3.ISE-05 8.75E-07 9.67E-06 2.37E-04 8.99E-10 2.91E-08 1.17E-09 5.23E-05 1.04E-03 l.37E-05 2.14E-04
0.
o.
o. o.
0.
0.
o.
o.
o.
o.
o.
0.
0.
0.
o.
0.
o. o.
o. o.
0.
o.
0.
o.
o. o.
o.
0.
o.
o.
0.
0.
0.
o. o.
o.
0.
o.
o.
o.
o.
o.

o

  • 47 l.69E-06 0.

8.65E-07 9.13E-06 0.

l.48E-06 8.92E-07 0.

2.58E-07 3.62E-06 0.

l.20E-06

0.

3.30E-09 0.

0.

4.36E-09 0.

0.

3.66E-09 0.

0.

4.48E-09 0.

0.

9.09E-09 0.

0.

4.07E-08 0.

0.

5.17E-08 0.

4.94E-08 8.35E-09 7.92E-08 8.93E-05 3.27E-05 l.04E-06 l.53E-05 5.22E-06 2.17E-07

'2.58E-05 3.93E-06 l.13E;os 7.63E-05 2.SIE-05 9.78E~07 l.68E-07 l.84E-08 7.29E~08 9.0SE-08 9.36E-09 7.23E~l2 2.33E-13 l.56E-06 l.56E-05 5.71E-09 4.71E-04 2.75E-05 2.56E-14 7.89E-07 7.44E-08 7.87E-15 4.44E-07 7.41E-10

0.

4.94E-05 6.IOE-05

0.

4.48E-06

  • 4.37E-05
0.

2.35E-06 2.0SE-05 2.31E-06 l.47E-04 l.53E-05 2.26E-08 3.12E-05 3.44E-05 3.17E-04 3.23E-03 l.OSE-04 8.llE-07 1.17E-04 2.63E-05 2.64E-12 4.23E-07 5.32E-08 l.30E-06 8.87E-05 2.22E-05 4.45E-05 2.20E-04 5.70E-06 9.74E-06 5.72E-04 3.SSE-05 3.30E-07 l.24E-04 6.0lE-05 2.75E-08 2.40E-05 2.92E-05 7.35E-09 l.24E-05 2.SOE-05 4.89E-05 l.48E-04 3.43E-06 l.37E-08 l.37E-05 l.8ZE=05 5.73E-04 9.00E-04 l.14E-05

/l.09E-03 l.66E-03 2.98E-05 1.SlE-0~ 2. 79E-04 5.39E-05 2.72E-06 2.54E-04 4.24E-05 2.32E-05

~.34E-04 2.28E-05 4.01E~04 l.13E-03 l.63E-05

0.

5~71E-06 2.61E-07

0.

l.86E-04 l.llE-05

0.

l.llE-05 2.46E-05 Rev 6

,5/08/92

TABLE 1.7 {contd}

CHILD INHALATION DOSE COMMITMENT FACTORS (MREM~SOY PER PCI INHALED IN FIRST YRl ISOTOPE BONE LIVER TOTAL BODY TH ROID KIDNEY LUNG GI-LI PB210+D 8.03E-02 l.85E-02 3.18E-03

0.

6.31E-02 8.74E-02 3.75E-05 81210+0

o.
5. llE-06 5.65E-07
o.

5.76E-05 3.70E-03 3.21E-05 P0210 l.70E-03 2.76E-03 4.09E-04

0.

8.85E-03 l.05E-Ol 4.32E-05 RN222+D

0.
0.
0.
0.
0.

4.82E-06 0.

RA223+D 7.69E-04 8.89E-07

1. 54E-04
0.

2.36E-05 8.48E-02 3.00E-04 RA224+D 8.44E-05 1. 53E-07. l.69E-05

0.

4.06E-06 2.92E-02 3.34E-04 RA225+D

1. 28E-03 1.14E-06 2.56E-04
0.

3.02E-05 9.74E-02 2.84E-04 RA226+D 2.34E-Ol 7.66E-06 l.92E-Ol

0.

2.03E-04 3.90E-Ol 3.02E-04 RA228+D

1. 49E-01 3.94E-06 l.68E-01
0.

l.04E-04 5.37E-01 5.14E-05 AC225 1.81E-03 1.87E-03 l.21E-04

0.
1. 99E-04 7.37E-02 2.67E-04 AC227+D 4.96E+OO 8.05E-01 3.07E-01
0.
1. 77E-01 8.04E-Ol 5.22E-05 TH227+D 9.24E-04 1. 26E-05 2.67E-05
0.

6.67E-05 l.26E-Ol 3.49E-04 TH228+D 8.06E-Ol 1.04E-02 2.72E-02

0.

5.41E-02 3.34E+OO 3.59E-04 TH229 l.28E+Ol

1. 76E-01 6.31E-Ol
0.

8.68E-Ol l.04E+Ol 3.27E-04 TH230 3.30E+OO 1. 73E-Ol 9.20E-02

0.

8.52E-01 l.85E+OO 3.84E-05 TH232+D 3.68E+OO 1.47E-Ol 1.28E-01

0.
  • 7.28E-Ol
1. 77E+OO 3. 21E;~o5 TH234 6.94E-06 3.07E-07*

2.00E-07

0.

1.62E-06 6.31E-04 7.32E~05 PA23l+D 8.62E+OO 2.86E-01 3.43E-01

0.

l.56E+OO 1. 92E-Ol 4. 57E".;05 PA233 4.14E-06 6.48E-07 7.25E-07

0.

2.38E-06 9. 77E-05 8.95E;:06 U232+D 2.19E-Ol 0.

1. 56E-d2
0.

1.67E-02 7.42E-Ol 4.33E-05 U233+D 4.64E-02 o.

2.82E-03

0.

7.62E-03 1. 77E-Ol 4.00E-05 U234 4.46E-02 0.

2.76E-03

0.

7.47E-03 1. 74E-Ol 3.92E-05 U235+D 4.27E-02 0.

2.59E-03

o.

7.0lE-03 1. 63E-Ol 4.98E-05 U236 4.27E-02 0.

2.65E-03

0.

7.16E-03 l.67E-Ol 3.67E-05 U237 l.57E-01 0.

4.17E-08

o.

4.53E-07 3.40E-05 l.29E-05 U238+D 4.09E-02 0.

2.42E-03

0.

6.55E-03 l.53E-01 3.51E-05 NP237+D 2.88E+OO *2. 21E-01 l.19E-01

0.

7.41E-Ol

1. 74E-01 5.06E-05 NP238
1. 26E-06 2.56E-08
1. 97E-08
0.

8.16E:-08 3.39E-05 2.SOE-05 NP239

1. 26E-07 9.04E-09 6.35E-09
0.

2.63E-08 1.57E-05 1.73E-05 PU238 4.77E+OO 6.0SE-01

1. 21E-01
0.

4.47E-Ol 6.0SE-01 4.65E-05 PU239 5.24E+OO 6.44E-Ol 1.28E-Ol

o.

4.78E-01 5.72E-Ol 4.24E-05 PU240 5.23E+OO 6.43E-01; 1.27E-Ol

0.
4. 77£"-0l
5. 71E-Ol 4.33E-05 PU24l+D l.46E-Ol 6.33E-03 1 2.93E-03
0.
1. lOE-02 5.06E-04 8.90E-07 PU242 4.85E+OO 6.20E-Ol
1. 23E-Ol
0.

4.60E-Ol 5.SOE-01 4.16E-05 PU244 5.67E+OO 7.lOE-01 1.41E-Ol

o.

5.27E:-Ol 6.30E-Ol 6.20E-05 AM241

l. 7c4E+O<t. 7 ~ SSE~Ol
1. 24E-Ol
0.

7.63E-01 2.02E-Ol 4.73E-05 AM242M l.7,9E*.OO~ 7~65E-01 1.27E-Ol

0.
7. 71E-01 8.14E-02 5.96E-05 AM243 I.*72E"+OO.:-: 7.53E-Ol 1.20E-01
0.

7.42E-01

1. 92E-01 5.SSE-05 CM242 6.,3J,i~~(),2, 4. 84E-02 4.20E-03
o.

1.34E-02 1.31E-Ol 5.06E-05 CM243 1.,61£+.0lt 7". 33E-Ol 9.95E-02

0.

.. 3. 74E-Ol 2.lOE-01 4. ga*t-o5 CM244 1.33E~o*o: 6.48E-Ol 8.31E-02

o.

,.3.06E-Ol 2.02E-Ol 4.82E-05 CM245 2.l4E+OO 8.16E-Ol

1. 28E-01
0.

5.03E-Ol 1. 95E-Ol 4.49E-05 CM246.

2.13E+OO 8.lSE-01 1.28E-01

o.
5. 03E:.o~\\ 1. 99E-Ol
  • 4.41E-05 CM247+D 2.07E+OO 8.02E-01
1. 26E-Ol
0.

4.95E-~l,1.~SE-01 5.SOE-05 CM248 1.72E+Ol 6.61E+OO 1.04E+OO

0.

4.08E+OO 'l.61E+OO 9.35E-04 CF252 3.92E+OO 0.

9.33E-02

0.
0.

6.62E-Ol l.84E-04

\\

48 Rev 6 5/08/92

TABLE 1.7 (contd)

TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG Gl-LLI H3*

0.

I.S9E-07 I.S9E-07 I.S9E-07 I.S9E-07 I.S9E-07 I.S9E-07 BEIO 2.78E-04 4.33E-OS 7.09E-06

0.
0.

3.84E-04 I.77E-OS CI4 3.2SE-06 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 NI3 8.6SE-09 8.6SE-09 8.6SE-09 8.6SE-09 8.6SE-09 8.6SE-09 8.6SE-09 FIS 6.S2E-07 0.

7.IOE-08

0.

O.

0.

3.89E-08 NA22 I.76E-OS I.76E-OS I.76E-OS I.76E-OS I.76E-OS I.76E-OS I.76E-OS NA24 I.72E-06 l.72E-06 I.72E-06 I.72E-06 I.72E-06 I.72E-06 I.72E-06 P32 2.36E-04 1.37E-OS 8.9SE-06

0.

O.

0.

1.I6E-OS AR39

0.
0.
0.
0.
0.

4.00E-09 0.

AR4I

0.
0.
0.
0.

. 0.

1.44E-08 0.

CA4I 4.0SE-OS 0.

4.38E-06

0.
0.

I.OIE-OI 3.03E-07 SC46 7.24E-OS I.4IE-04 4.ISE-OS

0.

I.3SE-04 0.

2.98E-OS CRSI

0.
0.

lo69E-08 9.37E-09 3.84E-09 2.62E-06 3.7SE-07 MNS4

0.

6.39E-06 I.OSE-06

0.

I.S9E-06 2.48E-04 8.3SE-06 MNS6

0.

2.I2E-IO 3.ISE-II

0.

2.24F-IO I.90E-06 7.ISE~06 FESS 4.ISE-06 2.98E-06 6.93E707

0.
0.

I.SSE-OS 7.99E~07 FES9 I.99E-06 4.62E-06 I.79E-06

0.
0.

I.9IE-04 2.23E-OS COS7

0.

1.ISE-07 1.ISE-07

0.
0.

7.33E-OS 3.93E~06 COSS

0.

2.S9E-07 3.47E-07

0.
0.

I.68E-04 I.I9E-OS C060

0.

I.89E-06 2.48E-06

0.
0.

I.09E-03 3.24E-OS NIS9 S.44E-06 2.02E-06

  • 9.24E-07
0.
0.

I.4IE-OS 6.48E-07 NI63 7.2SE-OS S.43E-06 2.47E-06

0.
0.

3.84E-OS I.77E-06 NI6S 2.73E-IO 3.66E-II I.S9E-II

0.
0.

I.I7E-06 4.S9E-06 CU64

0.

2.S4E-IO I.06E-10

0.

8.0IE-IO I.39E-06 7.68E-06 ZN6S 4.82E-06 I.67E-OS 7.SOE-06

0.

I.OSE-OS I.SSE-04 S.83E-06 ZN69M+D I.44E-09 3.39E-09 3.IIE-IO

0.

2.06E-09 3.92E-06 2.I4E-OS ZN69 6.04E-12 l.lSE-11 8.07E-13

0.

7.S3E-12 I.98E-07 3.S6E-08 SE79

0.

S.43E-07 8.71E-08

0.

8.13E-07 7.71E-05 3.53E-06 BR82

0.
0.

2.28E-06

0.
0.
0.
0.

BR83+0

0.
0.

4.30E-08

0.
0.
0.
0.

BR84

0.
0.

5.4IE-08

0.
0.
0.

O.

BRSS

0.
0.

2.29E-09

0.
0.
0.
0.

KR83M

0.
0.
0.
0.
0.

9.97E-10 O.

KR85M

0.

O.

O.

0.

O.

5.46E-09 0.

KRSS

0. *..
  • o *.. ;
0.
0.
0.

4.63E-09 0.

KR87 o~:'f;£f'{;;*'.;',:.' o*.

o.
0.
o.

2.82E-08 o.

KRSS+O o*.\\'.~f,~~§,J::~<*.. 0"..

0.

0.

0.

5. 81 E-08 0.

KR89 O:/~.

\\.. O"...

0.
0.
0.

3.SSE-08 0.

RBS6 O*~*:;;,

'~f8<:::2.~~ar:.os 1.osE-os
o.
o.
o.

2.21r:-os RB87 o*:t>/**:*~~:\\{t~~40E-05 4.SSE-06

0.

.0.

0.

3.0SE-07 RB88 o.' ' '.' '&:a2E.:.oa 3.40E-08

0.

',.*" o.

\\ 0.

3.65E-1S RB89+0

0.

4.40E-08 2.91E-08

0.

O.

\\\\0.

4.22E-17 SR89+0 S.43E-05 0.

I.S6E-06

0.

O.

,3.02E-04 4.64E-OS SR90+0 l.35E-02 0.

8.3SE-04

0.

O.

2.06E-03 9.56E-05 SR91+0 l.lOE-08 0.

4.39E-10 O.

0.

T.59E-06 3.24E-OS SR92+D l.19E-09 O~

5.0SE-11

0.
  • 0.

3.43E-06 l.49E-OS

  • Includes a SO% increase to account for percutaneous transpiration.

49 Rev 6 S/08/92

TABLE 1.7 {contd)

TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN "FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 Y91M+D Y91 Y92 Y93 ZR93+D ZR95+D ZR97+D NB93M NB95 NB97 M093 M099+D TC99M TC99 TClOl RU103+D RU105+D RU106+D RH105 PD107 PD109 AGllOM+D AGlll CD113M CD115M SN123 SN125+D SN126+D SB124 SB125+D SB126 SB127 TE125M TE127M+D TE127 TE129M+D TE129 TE131M+D TE13l+D TE132+0 TE133M+D TE134+0 1129 1130

. 1131+0 3.73E-07 0.

4.63E-ll O.

8.26E-05 0.

1.84E-09 0.

l.69E-08 0.

6.83E-05 3.38E-05 l.82E-05 5.73E-06 l.72E-08 3.40E-09 4.14E-05 l.36E-05 2.32E-06 l.29E-06 3.92E-ll 9.72E-12

0.

l.66E-06

0.

2.llE-08 l.73E-13 4.83E-13 4.48E-08 6.58E-08 7.40E-15 l.05E-14*

2.63E-07 0.

l.40E-10 0.

l.23E-05 0.

l.32E-09 9.48E-10

0.

l.17E-07

0.

6.56E-10 l.73E-06 1.64£-06 6.07E-08 2.52E-08

0.

2.17E-04

0.

3.48E-05 4.31E-05 9.44E-07 l.66E-06 4.42E-08 2.18E-04 5.39E~06 5.38E-06 9.92E-08 9.23E-06 l.OlE-07:

6.19E-07 l.27E-08i 4.64[~08 9.92E-10 6.lOE-07 2.SOE-07 2.25E-06 1.02E-06

2. Sl.E~~~lO 1.1.4E-10 L;1:4E:;0~6 8. 23E-07 8-.87E+l2* 4.22E-12
1. 23*E~:oa
  • 1. s1 E-o9 1.97E~i2*
  • 1.04E-12 4.SOE-08 3.63E-08 l.OlE-11 7.33E-12 5.31E-12 4.35E-12 3.53E-06 2.94E-06 7.SOE-07 2.24E-06 4.43E-06 6.14E-06
1. OOE-08
1. 77E-12 2.21E-06 5.36E-ll 4.65E-10 l.84E-05 3.94E-06
1. 57E-09 3.41E-06 7.0SE-07 3.55E-12 4.52E-08 4.03E-09 6.24E-12
1. 79E-08 l.03E-13 l.12E-07 5.42E-ll
1. 55E-06 6.24E-10 8.39E-09 l.66E-10 9.99E-07
1. 26E-08 7.lOE-06 l.14E-06 l.40E-06 9.99E-08 8.24E-06 2.lOE-06 2.lSE-06 2.23E-07 l.75E-08 8.34E-08 2.73E-07 5.52E-ll 2.81E-07 2.20E-12 5.03E-09 6.30E-13 2.74E-08 5.71E-12 3.64E-12 4.90E-06 8.96E-07 3.30E-06
0.
0.

3.66E-05

0.
0.

4.00E-07

0.
0.

3.67E-04

0. *
0.

3.35E-06

0.
0.

l.04E-05

0.

l.16E-04 3.67E-04

0.

8.42E-06 3.36E-04

0.

5.15E-09 l.62E-05

0.

l.59E-05 5.36E-05

0.

l.25E-06 9.39E-05

0.

l.14E-ll 4.91E-07

0.

5.06E-07 8.81E-05

0.

5.14E-08 l.92E-05

0.

7.20E-12 l.44E-07

0.
  • 8.35E-07 l.74E-04
0.

l.90E-13 8.34E-08

0.

9.29E-07 9.79E-05

0.

l.76E-10 2.27E-06

0.

2.38E-05 2.0lE-03

0.

4.04E-09 4.09E-06

0.

9.39E-07 l.63E-05

0.

3.36E-09 3.19E-06 O.

3.13E-06 8.44E-04

0.

8.17E-08 4.00E-05

0.

2.43E-04 3.59E-04

0.

2.82E-05 3.03E-04 7.SSE-07 0.

4.96E-04 3.45E-08 0.

l.26E-04 l.42E-06 0.

l.72E-03 l.22E-08 0.

4.81E-04 8.80E-09 0.

3.42E-04 3.SOE-09 0.

l.SSE-04 5.21E-10 0.

3.31E-05 l.75E-07 0.

6.70E-05 5.48E-07 8.17E-06 2.07E-04 l.77E-10 9.lOE-10 l.40E-06 5.72E-07 6.49E-06 2.47E-04 6.48E-12 3.32E-ll 4.12E-07 9.06E-09 5.49E-08 2.97E-05 l.55E-12. "7.72E-12 2.92E-07 3.07E-08 2.44E-a7 5.61E-05 8.18E-12 5.07E-l~ 8. 71E-07

4. 46E-12 2. 91E-ll \\ 6. 75E-07 3.66E-03 5.26E-06 \\0.

l.86E-04 3.44E-06 0.

l.83E-03 l.OSE-05 0.

50

-~----

6.99E-05

3. 77E-09 5.llE-05 2.06E-05 7.24E-05
1. 60E-05 l.86E-05 7.88E-05 2.52E-06
1. 21E-05 2.71E-07 3.99E-06 3.36E-05 7.66E-07
7. 99[-06 l.09E-16 l.36E~05 l.13E-05
1. 20E-04 l.23E-05 7.49E-07 l.96E-05 3.41E-05 3.00E-05
1. 68E-05 5.lOE-05 4.16E-05 7.29E-05 1.68E-05 4.98E-05
1. 24E-05 6.0lE-05 3.94E-05 9.38E-06
1. 99E-05 l.OlE-05 5.06E-05 2.02E-07
7. 76[-05 l.89E-09 5.79E-05
1. 23E-07 l.37E-09 2.29E-07 l.14E-06
8. llE-07 Rev 6 5/08/92

~ ~-

TABLE 1.7 {contd}

TEEN INHALATION DOSE COMMITMENT FACTORS (MREM~50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY T YROID KIDNEY LUNG GI-LLI 1132

1. 99E-07 5.47E-07 1.97E-07
1. 89E-05 8.65E-07 0.

1.59E-07 1133+0 I. 52E-06 2.56E-06 7.78E-07 3.65E-04 4.49E-06 0.

1. 29E-06 1134 l.llE-07 2.90E-07
1. OSE-07 4.94E-06 4.58E-07 0.

2.SSE-09 1135+0 4.62E-07 1. lSE-06 4.36E-07 7.76E-05 1.86E-06 0.

8.69E-07 XE131M

0.
0.
0.
0.
0.

2.70E-09 0.

XE133M

0.
0.
0.
0.
0.

3.59E-09 0.

XE133

0.
0.
0.
0.
0.

2.99E-09 0.

XE135M

0.
0.
0.
0.
0.

3.88E-09 0.

XE135

0.
0.
0.
0.
0.

7.SSE-09

0.

XE137

0.
0.
0.
0.
0.

3.33E-08 0.

XE138+0

0.
0.
0.
0.
0.

4.38E-08 0.

CS134M+O 2.20E-08 4.35E-08 2.35E-08

0.

2.54E-08 4.56E-09 2.02E-08 CS!34 6.28E-05 l.41E-04 6.86E-05

o.

4.69E-05 l.B3E-05

1. 22E-06 CS135 2.0SE-05 l.82E-05 4.47E-06
0.

7.30E-06 2.70E-06 2.23E-07 CS136 6.44E-06 2.42E-05 1.71E-05

0.
1. 36E}06 CS137+0 8.38E-05 l.06E 3.89E-05
0.

3.BOE-05 l.SlE-05 1. 06E-06 CS138 5.82E-08 1. 07E-07 5.SSE-08

0.

8.28E-08 9.84E-09 3.38E-ll CS139+0 3.65E-08 5.12E-08

1. 97-E-08
0.

4.34E-08 4.86E-09 I. 66E-.:.23 BA139 I. 67E-10 l.lBE-13 4.87E-12

0.

l.llE-13 8.0SE-07 8.06E-07 BA140+0 6.84E-06 8.38E-09 4.40E-07

0.

2.BSE-09 2.54E-04 2.86E-05 BA141+0 I. 78E-ll 1.32E-14 5.93E-13

0.

1.23E-14 4.llE-07 9.33E-14 BA142+0 4.62E-12 4.63E-15 2.84E-13

0.

3.92E-15 2.39E-07 5.99E-20 LA140 5.99E-08 2.95E-08 7.82E-09

0.
0.

2.68E-05 6.09E-05 LA141 7.63E-10 2.35E-10 3.87E-ll

0.
0.

2.31E-06

1. 54E-05 LA142 l.20E-10 5.31E-ll 1.32E-ll
0.
0.
1. 27E-06
1. SOE-06 CE141 3.SSE-06 2.37E-06
2. 71E-07
0.
1. llE-06 7.67E-05 I. SSE-OS CE143+0 3.32E-08 2.42E-08 2.70E-09
o.

l.OBE-08 l.63E-05 3.19E-05 CE144+0

6. llE-04 2.53E-04 3.28E-05
0.
1. SlE-04 l.67E-03 I. OSE-04 PR143 I. 67E-06 6.64E-07 8.28E-08
o.

3.86E-07 6~04E-05 2.67E-05 PR144 5.37E-12 2.20E-12 2.72E-13

0.

l.26E-12 2.19E-07 2.94E-14 N0147+0 9.83E-07 l.07E-06

  • 6.41E-08
0.

6.28E-07 4.65E-05 2.28E-05 PM147 l.lSE-04 1. lOE-05 i 4.SOE-06

0.

2.lOE-05 1.14E-04 5.87E-06 PM148M+D 1.32E-05 3.35E-06 2.62E-06

0.

5.07E-06 3.20E-04 4.lOE-05 PM148 5.44E-07 8.88E-08 4.48E-08

0.

1.60E-07 6.52E-05 6.14E-05 PM149 4.9JE~08 6~8~E~09 2.84E-09

0.

l.31E-08 1. 24E-05 2.79E-05 PM151 l.2(lE7P8.. 1. 99E-09 1.0lE-09

0.

3.57E-09 6.56E-06 2.27E-05 SM151 l.OJE!~;o4;-.2.lOE-05 4.86E-06

0.

2.27E-05 7.68E-05 3.53E-06 SM153 2 ~,*3*E~.08:~ *.. 2

  • 0 lE-08 1.47E-09
0.

6.56E-09 7. llE-06 1. 77E-05 EU152 2~-96E;~;04':.. 7.19E-05 6.30E-05

0.

3.34E-04 5.0lE-04 I.3sr=-os EU154

9. 43£:..0IJ:'
  • I. 23E;.04 8.60E-05
0.

_ 5.44E-04 9.12E-04 3.34E-05 EU155 2.00E~o4* l.96E-05 l.21E-05

0.

7.65E-05 1.SlE-03 5.97E-05 EU156 2.70E-06 2.03E-06 3.30E-07

0.

l.36E-06\\ l.37E-04 4.56E-05 T8160 3.04E-05 0.

3.79E-06

0.
1. 20E-05 \\ 2. 97E-04 2.60E-05 H0166M 4.40E-04 l.36E-04 9.87E-05
0.

2.00E-04 *6.24E-04 1. 68E-05 Wl81 8.90E-09 2.SSE-09 3.0lE-10

0.
0.

Z.95E-06 2.69E-07 WISS 2.78E-07 9.17E-08 9.73E-09

0.
0.

9.60E-05 l.14E-05 Wl87 I. SOE-09 1.22E-09 4.29E-10

o.
o.

5.92E-06 2.21E-05 51 Rev 6 5/08/92

TABLE 1.7 {contd}

TEEN INHALATION DOSE COMMITMENT FACTORS (MREM~SOY PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY T YROID KIDNEY LUNG GI-LLI PB210+0 3.09E-02 8.28E-03 1.07E-03

0.

2.95E-02 4.52E-02 3.87E-05 81210+0

0.

2.26E-06 1.89E-07

o.

2.74E-05 l.91E-03 3.19E-05 P0210 5.68E-04 1. 22E-03 l.37E-04

o.

4.21E-03 5.41E-02 4.45E-05 RN222+0

0.
0.
0.
o.
o.

3.94E-06 0.

RA223+D 2.57E-04 3.93E-07 5.14E-05

0.

l.12E-05 4.39E-02 3.04E-04 RA224+0 2.83E-05 6.77E-08 5.65E-06

o.

l.93E-06 l.51E-02 3.29E-04 RA225+0 4.28E-04 5.04E-07 8.56E-05

o.

1.44E-05 5.04E-02 2.89E-04 RA226+0 l.33E-Ol 3.38E-06 9.87E-02

o.

9.67E-05 2.02E-Ol 3.llE-04 RA228+0 5.34E-02 I. 74E-06 5.88E-02

0.

4.97E-05 2.78E-Ol 5.30E-05 AC225 6.04E-04 8.25E-04 4.06E-05

o.

9.47E-05 3.81E-02 2.70E-04 AC227+0 2.49E+OO 3.69E-Ol l.48E-Ol

o.
1. 07E-Ol 4.16E-Ol 5.38E-05 TH227+0 3.09E-04 5.56E-06 8.93E-06
o.

3.IBE-05 6.50E-02 3.57E-04 TH228+0 2.60E-Ol 4.37E-03 8.78E-03

o.

2.45E-02 l.69E+OO 3 *.70E-04 TH229 9.06E+OO l.36E-Ol 4.45E-Ol

o.

6.67E-Ol 5.0SE+OO 3.36E-04 TH230 2.34E+OO I.34E-Ol 6.49E-02

0.

6.55E-Ol 8.98E-Ol 3.95E-05 TH232+0 2.61E+OO l.14E-Ol 9.21E-02

o.

S.60E-Ol 8.60E-Ol 3.36E-05 TH234 2.32E-06 I.35E-07

6. 71E-08
0.

7.73E-07 3.26E-04 7.49E;;.05 PA231+0 5.32E+OO 2.00E-01 2.07E-Ol

0.

l.12E+OO 9.91E-02 4.71F05 PA233 l.68E-06 3.24E-07 2.89E-07

o.

I. 22E-06 5.39E-05 l.OOE-05 U232+0 7.31E-02 0.

5.23E-03

0.

7.94E-03 3.84E-Ol 4.46E-05 U233+D l.55E-02 0.

9.42E-04

0.

3.63E-03 9.ISE-02 4.12E-05 U234 l.48E-02 o.

9.23E-04

0.

3.55E-03 8.99E-02 4.04E-05 U235+D I. 42E-02

0.

8.67E-04

o.

3.34E-03 8.44E-02 5.13E-05 U236 l.42E-02 0.

8.86E-04

o.

3.41E-03 8.62E-02 3.79E-05 U237 5.25E-08 0.

l.40E-08

o.

2.16E-07 l.76E-05 I. 29E-05 U238+0 l.36E-02 0.

8. IOE-04
o.

3.12E-03 7.89E-02 3.62E-05 NP237+D I. 77E+OO l.54E-Ol 7.21E-02

o.

5.35E-Ol 8.99E-02 5.22E-OS NP238 4.23E-07 l.13E-08 6.59E-09

0.

3.SSE-08 l.75E-05 2.38E-05 NP239 4.23E-08 3.99E-09 2.21E-09

o.
1. 25E-08 8. llE-06 l.65E-05 PU238 2.86E+OO 4.06E-Ol 7.22E-02
0.

3.IOE-01 3.12E-Ol 4.79E-05 PU239 3.31E+OO 4.50E-Oli 8.0SE-02

o.

3.44E-Ol 2.93E-Ol 4.37E-05 PU240 3.31E+OO 4.49E-01* 8.04E-02

o.

3.43E-Ol 2.93E-Ol 4.46E-05 PU24l+D 6.97E-02 3.57E-03 1.40E-03

0.

6.47E-03 2.60E-04 9.17E-07 PU242 3.07E+OO 4.33E-Ol

7. 75E-02
o.

3.31E-Ol 2.82E-Ol 4.29E-05 PU244 3.5.9E+OO 4. 96E~Ol 8.88E-02

o.

3.79E-Ol 3.23E-Ol 6.39E-05 AM241 LQ6E+oo: 4.07E-Ol 7.IOE-02

o.

S.32E-Ol l.OSE-01 4.88E-05 AM242M f.,:_g~E~gg ~:~~~=&l 7.15E-02

o.

5.30E-Ol 4.21E-02 6.14E-05 AM243 6.95E-02

0.

5.2IE-Ol 9.91E-02 5. 72.[-05 CM242 2 /l'2E:~.OZ... 2' *. l4:E-02 1.41E-03

0.

6.40E-03 6.76E-02 5.21E-05 CM243 8.45£-...0l 3.SOE-01 5.00E-02

0.

_./2.34E-Ol 1.09E-01 5.13E-05 CM244 6.46E-Ol 3.03E-01 3.BSE-02

a.

l.BlE-01 l.05E-Ol 4.96E-05 CM245 1.32E+OO 4. HE-01 7.53E-02

0.

3.52E-Ol\\ 1.0lE-01 4.63E-05 CM246 1.3-lE+OO 4.llE-01 7.52E-02

o.

3.SIE-01,l.03E-Ol 4.54E-05 CM247+D 1.28E+OO 4.04E-Ol 7.41E-02

o.

3.46E-Ol. l.OlE-01 5.97E-05 CM248 l.06E+Ol 3.33E+OO

6. llE-01
o.

2.85E+OO 8~32E-Ol 9.63E-04 CF252

1. 29E+OO o.

3.07E-02

o.
0.

3.43E-Ol 1.89E-04 52 Rev 6 5/08/92

TABLE 1.7 (contd)

ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3*

BElO Cl4 Nl3 FIS NA22 NA24 P32 AR39 AR4I CA4I SC46

, CRSI MNS4 MNS6 FESS FES9 COS7 COSS C060 Nl59 Nl63 Nl6S CU64 ZN6S ZN69M+D ZN69 SE79 BRS2 BRS3+D BRS4 BRSS KRS3M KRSSM KRSS KRS7 KRSS+D KRS9 RBS6 RBS7 RBS8 RBS9+0 SRS9+0 SR90+D SR91+0 SR92+D

0.

I.SSE-07 I.9SE-04 3.06E-OS 2.27E-06 4.26E-07 6.27E-09 6.27E-09 4.71E-07 0.

I.JOE-OS l.30E-OS I.2SE-06 I.2SE-06 I.65E-04 9.64E-06

0.
0.
0.
0.

3.S3E-OS 0.

5.51E-OS I.07E-04

0.
o.
0.

4.9SE-06

0.

I.SSE-IO 3.07E-06 2.I2E I.47E-06 3.47E-06

0.

S.6SE-OS

0.

I.9SE-07

0.

I.44E-06 4.06E-06 l.46E-06 S.40E-OS 3.93E-06 l.92E-IO 2.62E-ll

0.

I.S3E-IO 4.05E-06 I.29E-05 l.02E-09 2.45E-09 4.23E-12 S.14E-12

0.

3.83E-07

o..
o.
0.
0.
0.
o.
0.
0.
0.
o.
o.
0.

g

~~'~{~ i:..

o.,.f

    • \\~/:~o~.-

o "'*"'

c'."?.: : h69E-05 O*~{i~

-, - 9.86E-06

0.

4.84E-08

0.

l.20E-08 3.SOE-05 0.

l.24E-02 0.

7.74E-09 0.

S.43E-10 O.

I. 5SE-07

.4. 96E-06 4.26E-07 6.27E-09 S.I9E-OS I.30E-05 l.28E-06 6.26E-06

0.
0.

.4. I3E-06 3.llE-05 I. 25E-08 7.87E-07 2.29E-11 4.93E-07 I.32E-06 S.39E-08 2.59E-07 l.85E-06 6.77E-07 I.SlE-06 1.I4E-11 7.69E-11 5.82E-06 2.24E-10 5.65E-13 6.09E-08 l.69E-06 3.0IE-OS 3.91E-08 l.60E-09

0.
0.
0.
0.
0.
0.

7.37E-06 3.21E-06 2.41E-OS 2.12E-OS l.09E-06 7.62E-04 3.13E-10 3.64E-11 I. SSE-07

0.

4.26E-07 6.27E-09

0.

1.30E-05 1.28E-06

0.
0.
0.
0.
0.

7.44E-09

0.
0.
0.
0.
0.
0.
0.

o~

o.
0.
0.
0. o.
o.
0.
0.
0.
0.
0.
0.
0.
o.
0.
0.
0.
0.
0.
0.
o.
0.
o.
0.
0.

I.58E-07 I.SSE-07 O.

2.22E-04 4.26E-07 4.26E-07 6.27E-09 6.27E-09

0.
0.

I.30E-05 I.30E-05 I.28E-06 I.28E-06

o.
0.
0.

2.0SE-09

0.

S.06E-09

0.

3.83E-06 9.99E-05 0.

2.85E-09 I.SOE-06 I.23E-06 l.75E-04 I.63E-IO l.lSE-06

0.

9.0IE-06

0.

I.27E-04

0.

4.62E-05

0.

I.16E-04

0.

7.46E-04

0.

S.20E-06

0.

2.23E-05

0.

7.00E-07 S.78E-IO S.4SE-07 S.62E-06 I.OSE-04 I.4SE-09 2.38E-06 5.27E-I2 l.lSE-07 5.69E-07 4.47E-05

0.
0.
0.

- o.

0.
0.
0.
0.
0.

5.19E-10 o~

2.91E-09

0.

2.4IE-09

0.

l.53E-08

0.

3.13E-08

0.

2.13E-08.

o.
0.

/0.

0.
o.

\\

o~

0.

\\ o.

0.

,I.75E-04

0.

t.20E-03 O.

4~56E~06

0.

2.06E-06

  • Includes a 50% increase to account for percutaneous transpiration.

S3 I. 58E-07 I. 67E-05 4.26E-07 6.27E-09 9.24E-09 l.30E-05 l.2SE-06 I. OSE-05

0.

0.

2.86E-07 3.23E-05 4.lSE-07

9. 67E::06 2.S3E;os 7.54E:::o7 2.35E~05
3. 93E~06 1.33E-05 3.56E-05 6.llE-07 l.67E-06 l.54E-06 6.I2E-06 6.6SE-06 l.71E-05 2.04E-09 3.33E-06 1.30E-06 2.90E-08 2.05E-I3
0.
0.
0.
0.
0.
0.
0.

2.0SE-06 2.BSE-07

4. ISE-I9 l.16E-2I 4.37E-05 9.02E-05 2.39E-05 5.3SE-06 Rev 6 5/08/92

~....

  • ~-.

TABLE 1.7 (contd)

ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 2.61E-07 0.

7.0IE-09

0.
0.

2.12E-05 6.32E-05 Y91M+D 3.26E-ll O.

l.27E-12

0.
0.

2.40E-07 l.66E-10 Y91 5.7SE-05 0.

l.SSE-06

0.
0.

2.13E-04 4.SIE-05 Y92 l.29E-09 0.

3.77E-ll

0.
0.

l.96E-06 9.19E-06 Y93 l.ISE-OS 0.

3.26E-10

0.
0.

6.06E-06 5.27E-05 ZR93+0 5.22E-05 2.92E-06 l.37E-06

0.

l.llE-05 2.13E-05 l.SIE-06 ZR95+0 l.34E-05 4.30E-06 2.91E-06

0.

6.77E-06 2.21E-04 l.SSE-05 ZR97+0 l.21E-OS 2.45E-09 l.13E-09

0.

3.71E-09 9.S4E-06 6.54E-05 NB93M 3.lOE-05 l.OlE-05 2.49E-06

0.

l.16E-05 3.llE-05 2.38E-06 NB95 l.76E-06 9.77E-07 5.26E-07

0.

9.67E-07 6.31E-05 I.JOE-OS NB97 2.7SE-ll 7.03E-12 2.56E-12

0.

8.18E-12 3.00E-07 3.02E-08 M093

0.

l.17E-06 3.17E-08

0.

3.SSE-07 5.llE-05 3.79E-06 M099+0

0.

l.SlE-08 2.87E-09 O.

3.64E-08 l.14E-05 3.lOE-05 TC99M l.29E-13 3.64E-13 4.63E-12

0.

5.52E-12 9.SSE-08 5.20E.. -:-07 TC99 3.13E-OS 4.64E-08 l.25E-08

0.
  • 5.85E-07 l.OlE-04 7.54E;.06 TClOl 5.22E-15 7.52E-15 7.38E-14
0.

l.35E-13 4.99E-08 l.36E~21 RU103+0 l.91E-07 a.

8.23E-08

a.

7.29E-07 6.31E-05 l.38E:os RUIOS+O 9.8SE-ll a.

3.89E-ll

a.

l.27E-10 l.37E-06 6.02E:-06 RU106+0 8.64E-06 0.

l.09E-06

0.

l.67E-05 l.17E-03 l.14E-04 RHIOS 9.24E-10 6.73E-10 4.43E-10

  • 0.

2.86E-09 2.41E-06 l.09E-05 PD107

a.

8.27E-OS 5.87E-09 o~

6.57E-07 9.47E-06 7.06E-07 PD109

a.

4.63E-10 l.16E-10

a.

2.35E-09 l.85E-06 l.52E-05 AGIIOM+O l.35E-06 l.25E-06 7.43E-07

0.

2.46E-06 5.79E-04 3.78E-05 AGlll 4.25E-OS l.78E-08 8.87E-09

0.

5.74E-08 2.33E-05 2.79E-05 CD113M

a.

l.54E-04 4.97E-06

a.

l.71E-04 2.08E-04 l.59E-05 CDllSM

. a.

2.46E-05 7.95E-07

a.

l.98E-05 l.76E-04 4.SOE-05 SN123 3.02E-05 6.67E-07 9.82E-07 5.67E-07 0.

2.SSE-04 3.92E-05 SN125+0 l.16E-06 3.12E-08 7.0JE-08 2.59E-08 0.

7.37E-05 6.SlE-05 SN126+0 l.58E-04 4.ISE-06 6.00E-06 l.23E-06 0.

l.17E-03 l.59E-05 SB124 3.90E-06 7.36E-08 l.55E-06 9.44E-09 0.

3.lOE-04 5.0SE-05 SB125+0 6.67E-06 7.44E-08; l.58E-06 6.75E-09 0.

2.lSE-04.I.26E-05 SB126 4.50E-07 9.13E-09; l.62E-07 2.75E-09 0.

9.57E-05 6.0lE-05 SB127 3.3oE..:oa 7.22E-10 l.27E-08 3.97E-10 0.

2.0SE-05 3.77E-05 TE125M 4.27E~07 l.98E-07 5.84E-08 l.31E-07 l.55E-06 3.92E-05 8.83E-06 TE127M+D 1.58£~06 7.21E.-07 l.96E-07 4.llE-07 5.72E-06 l.20E-04 l.87E-05 TE127 L:lS£¥10:, 8.0JE:.11 3.87E-ll l.32E-10 6.37E-10 8.14E-07 7.17E-06 TE129M+D b:21E;;.:06 5.. 84E-07 1.98E-07 4.30E-07 4.57E-06 l.45E-04 4.79E-05 TE129 6~i2'2E~Jl2. 2.99E-12 1.SSE-12 4.87E-12 2.34E-ll 2.42E-07 l.96E-08 TE131M+D 8i:?l,A:E2,o~;- 5.45E-09 3.63E-09 6.88E-09 3.86E-08 l.82E-05 6.9.S'E-..:as TE131+0 L39E.;t2'. 7.44E-13 4.49E-13 l.17E-12 /S.46E-12 1. 74E-07 2.30E-09 TE132+0 3.2SE-08 2.69E-08 2.02E-08 2.37E-08' l.82E-0-7 3.60E-05 6.37E-05 TE133M+D 7.24.E-12 5.40E-12 4.17E-12 6.27E..:12 3.74E-ll\\ 5.SlE-07 5.49E-08 TE134+0 3.84E-12 3.22E-12 1.57E-12 3.44E-12 2.lSE-11 \\4.343-07 2.97E-ll 1129 2.48E-06 2.llE-06 6.91E-06 5.54E-03 4.53E-06 'O.

2.22E-07 1130 5.72E-07 l.68E-06 6.60E-07 l.42E-04 2.61E-06 O~

9.61E-07 1131+0 3.ISE-06 *4.47E-06 2.56E-06 l.49E-O~ 7.66E-06 O.

7.SSE-07 54 Rev 6 5/08/92

~..

  • < ~ *:*..

TABLE 1.7 (contd}

ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 l.45E-07 4.07E-07 l.45E-07 l.43E-05 6.48E-07 0.

5.08E-08 1133+0 l.08E-06 l.85E-06 5.65E-07 2.69E-04 3.23E-06 0.

l.llE-06 1134 8.05E-08 2.16E-07 7.69E-08 3.73E-06 3.44E-07 0.

l.26E-10 1135+0 3.35E-07 8.73E-07 3.21E-07 5.60E-05 l.39E-06 0.

6.56E-07 XE131M

0.
0.
0.
0.
0.

l.40E-09 0.

XE133M

0.
0.
0.
0.
0.

1.89E-09 0.

XE133

0.
0.
0.
0.
0.

l.57E-09 0.

XE135M

0.
0.
0.
0.
0.

2.22E-09 0.

XE135

0.
0.
0.
0.
0.

4.05E-09 0.

XE137

0.
0.

O.

0.
0.

1.74E-08 0.

XE138+D

0.
0.
0.
0.
0.

2.44E-08 0.

CS134M+D l.59E-08 3.20E-08 l.72E-08

0.

1.83E-08 2.93E-09 7.92E-09 CS134 4.66E-05 i.OGE-04 9.lOE-05 O.

3.59E-05 l.22E-05 1.30E-06 CS135 l.46E-05 l.29E-05 5.99E-06

0.

5.llE-06 l.57E-06 2.llE-07 CS136 4.88E-06 l.83E-05 l.38E-05

0.
  • l.07E-05 l.50E~06 l.46E-06 CS137+D 5.98E-05 7.76E-05 5.35E-05
0.

2.78E-05 9.40E-06 l.05E~06 CS138 4.14E-08 7.76E-08 4.0SE-08

0.

6.00E-08 6.07E-09 2.33E~I3 CS139+D 2.56E-08 3.63E-08 l.39E-08

0.

3.0SE-08 2.84E-09 5.49E-31 BA139 l.17E-10 8.32E-14 3.42E-12

0.

7.78E-14 4.70E-07 l.12E-07 BA140+D 4.88E-06 6.13E-09 3.21E-07

0.

2.09E-09 l.59E-04 2.73E-OS BA14l+D 1.25E-11 9.41E-15 4.20E-13 O~

8.75E-15 2.42E-07 l.45E-17 BA142+D 3.29E-12 3.38E-15 2.07E-13. 0.

2.86E-15 1.49E-07 1.96E-26 LA140 4.30E-08 2.17E-08 5.73E-09

0.
0.

1.70E-05 5.73E-05 LA141 5.34E-10 l.66E-10 2.71E-11

0.
0.

1.35E-06 7.31E-06 LA142 8.54E-ll 3.88E-ll 9.65E-12

0.
0.

7.91E-07 2.64E-07 CE141 2.49E-06 l.69E-06 1.91E-07

0.

7.83E-07 4.52E-05 l.50E-05 CE143+D 2.33E-08 l.72E-08 1.91E-09

0.

7.60E-09 9.97E-06 2.83E-05 CE144+0 4.29E-04 1.79E-04 2.30E-05

0.

l.06E-04 9.72E-04 l.02E-04 PR143 l.17E-06 4.69E-07 5.80E-08

0.

2.70E-07 3.51E-05 2.50E-OS PR144 3.76E-12 l.56E-12 l.91E-13

0.

8.81E-13 l.27E-07 2.69E-18 ND147+D 6.59E-07 7.62E-07: 4.56E-08

0.

4.45E-07 2.76E-05 2.16E-05 PM147 8.37E-05 7.87E-Q6'.

3.19E-06

o.

l.49E-05 6.60E~o5 5.54E-06 PM148M+D 9.82E::os 2.5-4E-06 l.94E-06

0.

3.85E-06 2.14E-04 4.ISE-05 PM148 3.84E-07 6.37E-08 3.20E-08

0.

l.20E-07 3.91E-05 5.80E-05 PM149 3.44f;.08 4.87E-09 I. 99E-09

0.

9.19E-09 7. 21E-06 2. SOE-OS PMISI 8.5.0£*~:09' 1.42E.,.Q9 7.21E-10

0.

2.55E-09 3.94E-06 2.00E-05 SMISI 8~*59(~os*. I. 48E*OS

3. 55E-06
o.

I.66E-OS 4.45E-05 3. 25E-06 SM153 L*:zoe~*oa. 1.42E-08 l.04E-09

0.

4.59E-09 4.14E-06 l.58E~os EU152 2~38*£:'~'().4:; _. 5.* 41E-05

4. 76E-05
0.

3.35E-04 3. 43E-04 I. 59E-05 EU154 7;40E~Of 9.IOE-05 6.48E-05

0.

-4.36E-04 5.84E-04 3.40E-05 EU155 l.OIE-04 l.43E-05 9.21E-06 O.

6.59E-05 9.46E-05 5.95E-06 EU156 l.93E-06 1.48E-06 2.40E-07

0.

9.9SE-07\\\\ 8.56E-05 4.50E-05 TB160 2.21E-05 0.

2.75E-06

0.

9.IOE-06

  • l.92E-04 2.68E-05 H0166M 3.37E-04 l.05E-04 8.00E-05
0.

l.57E-04 '3.94E-04 l.59E-05 Wl81 6.23E-09 2.03E-09 2.17E-10

0.
0.

1.71E-06 2.53E-07 WISS l.95E-07 6.47E-08 6.81E-09

0.
0.

5.57E-05 l.07E-05 Wl87 l.06E-09 8.SSE-10 3.IOE-10

0.
0.

3.63E-06 l.94E-05 55 Rev 6 5/08/92 J

TABLE 1.7 {contd}

ADULT INHALATION DOSE COMMITMENT FACTORS (MREM~SOY PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY TH ROID KIDNEY LUNG GI-LLI PB210+D 2.64E-02 6.73E-03 8.37E-04

o.

2.12E-02 2.62E-02 3.65E-05 8!210+0

0.
1. 59E-06 1.32E-07
0.

1.92E-05 l. llE-03 2.95E-05 P0210 3.97E-04 8.60E-04 9.58E-05

o.

2.95E-03 3.14E-02 4.19E-05 RN222+D

0.
0.
0.
0.
o.

2.05E-06 0.

RA223+D 1.SOE-04 2.77E-07 3.60E-05

0.

7.85E-06 2.55E-02 2.84E-04 RA224+D

1. 98E-05 4.78E-08 3.96E-06
0.

l.35E-06 8.77E-03 3.0IE-04 RA225+D 3.00E-04 3.56E-07 5.99E-05

0.

1.0IE-05 2.92E-02 2. 71E-04 RA226+D 1.25E-01 2.39E-06 9.14E-02

0.

6.77E-05 1.17E-Ol 2.94E-04 RA228+D 4.41E-02

1. 23E-06 4.78E-02
0.

3.48E-05 l.61E-Ol 5.00E-05 AC225 4.23E-04 5.82E-04 2.84E-05

0.

6.63E-05 2.21E-02 2.52E-04 AC227+D 2.30E+OO 3.05E-01 1.36E-01

0.

9.82E-02 2.41E-Ol 5.0SE-05 TH227+D 2.17E-04 3.92E-06 6.25E-06

0.

2.22E-05 3.77E-02 3.34E-04 TH226+D 2.00E-01 3.39E-03 6.77E-03

0.

1.89E-02 l.OIE+OO 3.49E-04 TH229 8.88E+OO l.33E-01 4.36E-Ol

0.

6.52E-Ol 3.49E+OO 3.17E-04 TH230 2.29E+OO l.31E-Ol 6.36E-02

0.
  • 6.40E-Ol 6.21E-Ol 3.73E~o5 TH232+D 2.56E+OO l.12E-Ol 9.04E-02
0.

5.47E-Ol 5.96E-Ol 3.17E-05 TH234

1. 63E-06 9.56E-08 4.70E-08
0.

5.41E-07 1.89E-04 7.03E;,05 PA231+D 5.0SE+OO 1.91E-01 l.98E-Ol

0.
1. 07E+OO 5.75E-02 4.44E.:05 PA233 1.21E-06 2.42E-07 2.09E-07
0.

9.15E-07 3.52E-05 1.02E-05 U232+D 5.14E-02 0.

3.66E-03

0.

5.56E-03 2.22E-Ol 4.21E-05 U233+D 1.09E-02 0.

6.60E-04

0.

2.54E-03 5.32E-02 3.89E-05 U234

1. 04E-02 a.

6.46E-04

a.

2.49E-03 5.22E-02 3.SIE-05 U235+D l.OOE-02

0.

6.07E-04

0.

2.34E-03 4.90E-02 4.84E-05 U236 1.00E-02 0.

6.20E-04

0.

2.39E-03 5.00E-02 3.57E-05 U237 3.67E-08 0.

9.77E-09

0.
1. 51E-07 l.02E-05 1.20E-05 U238+D 9.58E-03 0.

5.67E-04

0.

2.lSE-03 4.58E-02 3.41E-05 NP237+0 l.69E+OO

1. 47E-Ol 6.87E-02
0.

5.lOE-01 5.22E-02 4.92E-05 NP238 2.96E-07 8.00E-09 4.61E-09

0.

2.72E-08 l.02E-05 2.13E-05 NP239 2.87E-08 2.82E-09 l.55E-09

0.

8.75E-09 4.70E-06 1. 49E-05 PU238 2.74E+OO 3.87E-Ol 6.90E-02

0.

2.96E-Ol l.82E-Ol 4.52E-05 PU239 3.19E+OO 4.31E-Ol ; 7.75E-02

a.

3.30E-Ol l.72E-Ol 4.13E-05 PU240

3. lSE+_OO 4.30E-Ol ' 7.73E-02
0.

3.29E-Ol l.72E-Ol 4.21E-05 PU24l+D 6.41E-02 3.28E-03 1.29E-03

0.

5.93E-03 1. 52E-04 8.65E-07 PU242 2.95E+O~ 4.15E~Ol 7.46E-02

0.

3.17E-Ol l.65E-Ol 4.05E-05 PU244 3.45E+OQ:.*4.J6E-Ol 8.54E-02

0.

3.64E-Ol 1.89E-Ol 6.03E-05 AM241 l.OlE:f.Oo* 3.59E-Ol 6.71E-02

0.

5.04E-Ol 6.06E-02 4.GOE-05 AM242M l.02£+oo;. 3.46E:.OI 6.73E-02

0.

5.0IE-01 2.44E-02 5.79E-05 AM243 1 ~QlE+O.O:.. ; _3. 47E-Ol 6.57E-02

0.

4.95E-Ol 5.75E-02 5.40£.,05 CM242 l.48E.:.'02'("L51E.:.02 9.84E-04

0.

4.48E-03 3.92E-02 4.91E-05 CM243 1.a&e~*or':. -2~91E-01 4.61E-02

0.

/2.15E-Ol 6.31E-02 4.84E-05 CM244 5.90E'-Ol 2.54E-Ol 3.51E-02

0.

l.64E-O~ 6.06E-02 4.68E-05 CM245

1. 26E+OO l.59E-Ol 7.14E-02
o.

3.33E-Ol 5.85E-02 4.36E-05 CM246 l.25E+OO 3.59E-Ol 7.13E-02

0.

3.33E-01 \\5.96E-02 4.29E-05 CM247+D l.22E+OO 3.53E-Ol 7.03E-02

0.

3.28E-Ol S.. SSE-02 5.63E-05 CM248 1.0lE+Ol 2.91E+OO 5.79E-Ol

0.

2.70E+OO 4~*82E-Ol 9.09E-04 CF252 9.78E-Ol

0.

2.33E-02

0.
o.
1. 99E-Ol l.78E-04 56 Rev 6 5/08/92

TABLE 1.8 EXTERNAL DOSE FACTORS FOR STANDING ON CO~TAMINATION GROUND (DFG 11 (MREM/HR PER PCI/M l ELEMENT TOTAL BODY SKIN H-3 C-14 Na-24 P-32 Cr-51 Mn-54 Mn-56 Fe-55 Fe-59 Co-58 Co-60 Ni-63 Ni-65 Cu-64 Zn-65 Zn-69 Br-83 Br-84 Br-85 Rb-86 Rb-88 Rb-89 Sr-89 Sr-91 Sr-92 Y-90 Y-9lm Y-91 Y-92 Y-93 Zr-95 Zr-97 Nb Mo-99:

Tc-99in Tc-101 Ru-103

-Ru-105 Ru-106 Ag-_llOm Te-125m Te-127m Te-127 0.0 0.0 2.50E-08 0.0 2.20E-10 5.80E-09 l.lOE-08 0.0 8.00E-09 7.00E-09 I. 70E-08 0.0 3.70E-09 I. 50E-09 4.00E-09 0.0

6. 40E-ll
1. 20E-08 0.0 6.30E-10 3.50E-09 l.50E-08 5.60E-13 7.lOE-09 9.00E-09*

2.20E-12 3.SOE-09 2.40E-ll l.60E-09 5.70E-10 5.00E-09 5.50E-09 5.IOE-09 I. 90E-09 9.60E-10 2.70E-09 3.60E-09 4.50E-09 l.50E-09

  • I.SOE-OS '

3.50E-ll

l. IOE-12 l.OOE-11 57

/

0.0 0.0 2.90E-08 0.0 2.60E-10 6.80E-09 I. 30E-08 0.0 9.40E-09 8.20E-09 2.00E-08 0.0 4.30E-09 1.70E-09 4.60E-09 0.0 9.30E-ll l.40E-08 0.0 7.20E-10 4.00E-09 l.SOE-08 6.50E-13 8.30E-09 l.OOE-08 2.60E-12 4.40E-09

2. 70E-ll I. 90E-09 7.80E-10 5.80E-09 6.40E-09 6.00E-09 2.20E-09 l.IOE-09 3.00E-09 4.20E-09 5.lOE-09

~SOE-09 2.JOE-08 4.aoE-11 l.30E:..12

l. lOE.:-11 Rev 6 5/08/92 J

TABLE 1.8 (continued)

EXTERNAL DOSE FACTORS FOR STANDING ON CO~TAMINATION GROUND CDFG 1l (MREM/HR PER PCI/M l ELEMENT Te-129m Te-129 Te-13lm Te-131 Te-132 I-130 I-131

  • I-132 I-133 I-134 1-135 Cs-134 Cs-136 Cs-137 Cs-138 Ba-139
  • Ba-140 Ba-141 Ba-142 La-140 La-142 Ce-141 Ce-143 Ce-144 Pr-143 Pr-144 Nd-147 W-187 Np-239 TOTAL BODY 7.70E-10 7.lOE-10 8.40E-09 2.20E-09 l.70E-09 1.40E-08 2.BOE-09
1. 70E-08 3.?0E-09 l.60E-08
1. 20E-08
1. 20E-08 L50E-08 4.20E-09 2.lOE-08 2.40E-09 2.lOE-09 4.30E-09 7.90E-09 l.50E-08
1. 50E-08 5.50E-10 2.20E-09 3.20E-10 0.0 2.00E-10 l.OOE-09 3.lOE-09 9.50E-10 58 SKIN 9.00E-10 8.40E-10 9.90E-09 2.60E-06 2.00E-09
1. 70E-08 3.40E-09 2.00E-08 4.50E-09 l.90E-08 l.40E-08 l.40E-08
1. 70E-08 4.90E-09 2.40E-08 2~70E-09 2.40E-09 4.90E-09 9.00E-09
1. 70E-08 l.80E-08 6.20E-10 2.50E-09 3.?0E-10 0.0 2.30E-10 l.20E-09 3.60E-09
l. IOE-09 Rev 6 5/08/92

Nuclide Ag-llOm Ar-41 Ba-139 Ba-140 Br-82 C-14 Ce-141 Ce-144 Co-57 Co-58 Co-60 Cr-51 Cs-134 Cs-136 Cs-137 Cs-138 Fe-55 Fe-59 H-3 1-131 1-132 1-133 1-134 1-135 1 Kr-83m Kr-85 Kr-85m Kr-87 Kr-88 Kr-89 La-140 Mn-54 Mn-56 Mo-99 N-13 Na-24 Nb-95 Ni-65 "Np-239 Rb-88 Ru.-103 Sb-124 Sb-125 TABLE 1.9 1991 PALISADES GASEOUS DESIGN OBJECTIVE ANNUAL QUANTITIES Organ GI Tract-T Total Body GI Tract-C Lung-C Total Body-I Bone-C

  • GI Tract-T GI Tract-T GI Tract-T GI Tract-T GI Tract-T GI Tract-A,T Liver-C Total Body-I Bone-C.

Total Body-I Bone-C GE Tract-T Total Body-C Thyroid-I Thyroid-C Thyroid-C Thyroid-C Thyroid-C Skin SK in Total Body; Skin Total Body Total,Body

. ~-- ' GI' Tract.-T

~~?,~:<.GI Tract-T

'"\\r;;;.;&I -Tract-C i-:-:61 Tract-T

)~~- _-Total Body-C

    • ,_
      --:'-*Total Body-C GI Tract-A GL Tr-ac.t-C
  • GI Tract-T Total Body-C GI Tract-A GI Tract-T GI Tract-T Dose Factor mrem/Ci l.05E+OO 2.75E-04 2.38E-03 7.18E-02 1.16E-03
1. 07E-Ol l.15E-Ol 3.06E+OO 7.74E-02 l.37E-Ol 7.83E-Ol 2.14E-03 6.29E+OO 4.68E-02 6.15E+OO l.64E-05
1. 88E-Ol 2.19E-Ol
1. 23E-04 4.68E+OO 8.28E-03 l.65E-Ol 2.17E-03 3.39E-02 6.66E-07 6.0IE-05 3.63E-05 6.45E-04 4.57E-04 5.16E-04 2.0IE-02 2.21E-Ol 5.08E-03 l.llE-02 2.67E-50 6.63E-04 /,

6.75E~02-'

3.46E-03 5.44E-03 l.51E-05 l.07E-Ol 7.04E-Ol

3. 97E-Ol*

59 Design Objective Annual Quantity (Ci) l.43E+Ol l.82E+04 6.30E+03 2.09E+02 4.31E+03 l.40E+02 l.30E+02 4.90E+OO 1.94E+02 l.09E+02

1. 92E+Ol 7.0IE+03 2.38E+OO l.07E+02 2.44E+OO 3.05E+05 7.98E+OI 6.85E+OI 4.07E+04 3.21E+OO l.81E+03 9.09E+OI 6.91E+03 4.42E+02 2.25E+07 2.SOE+OS l.38E+OS 2.33E+04 l.09E+04 9.69E+03 7.46E+02 6.79E+OI 2.95E+03 1.35E+03 l.87E+50 7.54E+03 2.22E+02 4.34E+03 2.76E+03 3.31E+05

', l.40E+02 2.13E+Ol 3.78E+Ol Rev 6

  • 5/08/92

..~ ~-.-

Nuclide Sr-89 Sr-90 Sr-91 Sr-92 Tc-99m Tc-101 Te-127 Xe-13lm Xe-133 Xe-133m Xe-135 Xe-135m Xe-137 Xe-138 Zn-65 Zr-95

.:**_ ~:-

- -.. ~.. -*~~

TABLE 1.9 (continued~

1991 PALISADES GASEOUS D SIGN OBJECTIVE ANNUAL QUANTITIES Dose Factor Organ mrem/Ci Bone-C 8.26E+OO Bone-C 3.40E+02 Bone-I l.68E+OO GI Tract-C 9.99E-03 GI Tract-T 2.53E-04 GI Tract-I 3.48E-05 GI Tract-T 3.33E-03 Skin 2.65E-05 Total Body 9.13E-06 Skin 5.54E-05 Total Body 5.62E-05 Total Body 9.69E-05 Skin 5.94E-04 Total Body 2.74E-04 Total Bodl-C 4.16E-Ol GI Tract-2.89E-Ol 60 Design Objective Annual Quantity (Ci}

l.82E+OO 4.41E-02 8.93E+OO I. 50E+03 5.93E+04 4.31E+05 4.50E+03 5.66E+05 5.48E+05

2. 7JE+05
  • r~*

8.90E+04 5.16E+04 2.53E+04 l.82E+04 I. 20E+Ol 5.19E+Ol Rev 6 5/08/92

.~-...

--~*.. :':....

--:~;..**~

~~...

I I.

LIQUID EFFLUENTS A.

CONCENTRATION

1.

RETS Requirements Specification 3.24.3.2 of the Radiological Effluent Technical Specifications (RETS) requires that the concentration of radioactive material released at any time from the site to unrestricted areas shall be limited to the Maximum Permissible Concentration (MPC) specified in 10 CFR 20, Appendix B, Table II, Column 2 for nuclides other than dissolved or entrained noble gases.

For dissolved or entrained noble gases, the concentration shall be limited to 2E-04 µCi/ml total activity.

To ensure compliance, the following appr6ach will be used for each~

release.

2.

Prerelease Analysis Most tanks will be recirculated through two volume changes prior to sampling for release to the environment to ensure that a representative sample is obtained.

The appropriate recirculation time for those tanks too large to provide two volume changes will be the time that the suspended particulate concentrat i o.n reaches steady state. Either a one-time test, or prior sampling data, may be used to determine appropriate recirculation time.

Prior to rele_ase, a grab sample will be analyzed for each release, and the concentration of each radionuclide determined.

~f,'.~:~t~:f:~.i> -

  • -;ft __ _

c = I: ~i-i=l 61

\\

I (2.1)

Rev 6 5/08/92

where:

c

=

Total concentration in the liquid effluent at the release point, µCi/ml.

Concentration of a single radionuclide i, µCi/ml.

3.

Maximum Permissible Concentration (MPC) - Sum of the Ratios The MPC-Fraction (Rj) for each release point will be calculated by the relationship definea by Note I of Appendix B, 10 CFR 20:

where:

C;

=

=

Effluent concentration of radionuclide i, µCi/ml.

The MPC of radionuclide i, as *specified in Section 2.1.1,

µCi/ml.

The Total MPC-Fraction for the release point.

(2.2)

The sum of the ratios at the discharge to the releases from any or all concurrent releases.

will assure this criterion is met:

lake must be s I due to the The following relationship f 1 (R1-l) + f2 (~-1 ) + f 3 (R3-1)

~ F (2.3) where:

  • =
  • The effluent flow rate (gallon~/minute) for the respective releases, determined by Plant personnel.

The Total MPC-Fractions for the respective releases as determined by Equation 2.2.

Minimum required dilutio~-flow rate. Normally, a conservatively high dilution flow\\rate is used, that is, flow rate used= (b;)(F) where b, ts a conservative factor greater than 1.0.

62 Rev 6 5/08/92

B.

INSTRUMENT SETPOINTS

1.

Setpoint Determination The setpoint for each liquid effluent monitor will be established using Plant instructions. Concentration, flow rate, dilution, principal gamma emitter, geometry and detector efficiency are combined to give an equivalent setpoint in counts per minute (cpm).

The identification number for each liquid effluent radiation detector is contained in Figure 2-2.

The respective alarm/trip setpoints at each release point will be set such that the sum of the ratios at each point, as calculated by Equation 2.2, will not be exceeded.

The value of R is directly related to the total concentration calculated by Equation 2.1.

An~

increase in the concentration would indicate an increase in the value of R.

A large increase would cause the limits specified in Section 2.1.l to be exceeded..

The minimum alarm/trip* setpoint value is equal to the release concentration, but for ease of operation it may be desired that the setpoint (S) be set above the effluent concentration (C) by the same factor (b) utilized in setting dilution flow.

That is:

s =bx c Liquid effluent flow paths and release points are indicated in Figure 2.1.

2.

Composite Samplers (2.4)

Ef~l)'.(Qht pathways, Turbine Sump and Service Water, are equipped with co:o't~friuous compositors to meet the requirements of Technical Sp~cH'lc.ation Table 4. 24-3.

These compositors are adjustable and __ _

normally set in a time mode and collect,.--a" 30 ml sample directly from the effluent every 10 minutes, 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> a-/day.

A reP-resentative sample

\\

\\*

63 Rev 6 5/08/92

is collected daily from the compositor and saved for the weekly, monthly analysis requirements of Technical Specification Table 4.24-3.

In the event that a compositor is not operational, effluent releases via this pathway may continue provided that grab samples are collected and analyzed for gross radioactivity at least once per 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> per Technical Specification Table 3.24-1, action 30.

3.

Post-Release Analysis C.

DOSE A post-release analysis will be done using actual release data to ensure that the limits specified in Section I were not exceeded.

A composite list on concentrations (Ci), by isotope, will be used with the actual liquid radwaste (f) and dilution (F) flow rates (or volumes) during the release.

The data will be substituted into Equation 2.~ to demonstrate compliance with the limits in Section I. This data and setpoi nts will be recorded.*in auditabl e records by Pl ant personnel.

  • I.

RETS Requirement Specification 3.24.4.l the Radiological Effluent Technical Specification (RETS) requires that the quantity of radionuclides released by limited such that the dose or dose commitment to an individual from radioactive materials in liquid effluents release to unrestricted areas from the reactor (see Figut;e 2-1) will not exceed:

a.

During any calendar quarter, 1.5 mrem to the total body and 5 mrem

... _.to.any organ, and t~t¥{.;)~'.--..

bl*:~f:]:~:,Qu'fJng any calendar year, 3 mrem to the total body and 10 mrem to

. /~~~iahy,organ.

To ensure compliance, quantities of activity of 'eilch radionuclide released will be summed for each release and accumulated for each quarter as follows in Section 2.

64 Rev 6 5/08/92

2.

Release Analysis Calculations shall be performed for each batch release, and weekly for continuous releases according to the formula:

where:

Ai

=

Cumulative quarterly activity of nuclide i identified in liquid release (Ci}.

Design objective annual quantity of radionuclide i from Table 2.2.

(2.5)

Radionuclides may be omitted from the summation if they fall under the criteria of allowed omission specified by Note 5 to Appendix B, 10 CFR 20.

The design basis quantities are derived in such a conservative manner that doses may be greatly overestimated by this technique.

As a consequence of this conservatism, and in light of historically consistent operations with releases well below annual design basis quantities, the Palisades Plant Technical Specifications do not require monthly dose proj~ctions. Instead, if at any time, calculations by Equation (2.5) results in values greater than-0.5 for a given quarter or 1.0 for year-to-date, the NRC LADTAP code will be run to ensure that Speci f_i cation 3. 24. 4.1 has been met.

  • &~:~tf;:,:_"'

Vi~~.Y~~: for the design ~as i ~ quant i ~ i es (Ci), and the dose per Curie (l:J,¢ACe.}_l for each nuclide 1 shown in Table 2.2, were calculated a*s __ _

follows* fn Sections 2.1 and 2.2.

-*-'I/Of' 65 Rev 6 5/08/92

--~"'.*.

a.

Water Ingestion The dose to an individual from ingestion of radioactivity from any source as described by the following equation:

i Dj E (DCF) ij x Ii i=l where:

(2.6)

Dj

=

Dose for the jth organ from radionuclides releases, mrem.

j

=

The organ of interest.

(DCF) ij

=

Ingestion dose commitment factor for the jth org~n from the ith radionuclide mrem/pCi, see Table 2.1.

Activity ingested of the ;th radionuclide, pCi.

Ii is described by:

I (A1)(V)(365)

(1E06) i =.

(1000) (d)

(2. 7) where:

365 =

Days per year.

An~ual activity released of ;th radionuclide, µCi.

  • -. V. _ * -*

Average rate of water consumption (2000 ml/d - adult, 1400 ml/d - teen and child, 900 ml/d - infant, ICRP 23,

.,,;.* :c.:_., _;:*:**

3 58}

-~~*,~:*:..*.. - --

-:.,~- p *
  • 1~~;d:~ =~

Dilution water flow for year, ml.

_:,}:~;;~~d~~-.:2:7-: :. Dispersion factor from qJscharge to nearest drinking water supply.

' \\

\\

1E06..

Conversion µCi to pCi.

66 Rev 6 5/08/92

The dose equatiort then becomes:

i (3.65EOS)(V)

~

Dj =

d

~ (DCF) ij x A1 mrem 1=1 (2.8}

b.

Fish Ingestion

c.

The dose to an individual from the consumption of fish is described by Equation 2.10.

In this case the activity ingested of the ;th, radionuclide (I;) is described by:

A1B1F(lE09)

I

.= pCi 1 -

lSd where:

=

=

Annual released of ;th radionuclide, µCi.

Fish concentration factor of ;th radionuclide (see Table 2.0}. *

µCi/gm

µCi/ml (2.9}

F

=

Amount of fish eaten per year (21 kg adult, 16 kg teen, 6.9 kg child, none infant.)

15

=

d

=

IE09 =

Dispersion factor from discharge to fish exposure point.

Dilution water flow for year, ml.

Conversion of µCi and Kgm to gross *.

Substitution of Equation 2.9 into Equation 2.6 gives:

(2.10}

A complete analysis utilizing the NRC-*computer c~~e. LADTAP with the total source* release will be done annually in con~unction with the annual environmental report. This analysis will

\\

67 Rev 6 5/08/92

provide estimates of dose to the total body and various organs in addition to the dose limiting organs considered in the method of Section 2.

The following approach is utilized on LADTAP.

The dose to the jth organ from m radionuclides, Oj, is described by:

m Dj = I: Dij mrem i=l m

= I:

(DCF) ij x Ij mrem i=l where:

=

Dose to the j~h organ from the. ;th radionuclide, mrem.

(2.11)

=

The organ of interest (bone, GI tract, thyroid, liver, ~dney, lung or tot~l body).

(DCF) ij

=

Adult ingestion dose commitment factor for the jth organ from the ;th radionuclide, mrem/pCi (see Table 2.1).

=.

Activity ingested of the ;th radionuclide, µCi.

I; for water ingestion is described by:

A1 Vr I1 = vd

µCi and for fish ingestion I; is described by:

\\

68 (2.13)

Rev 6 5/08/92

-.'.~~-£:~

where:

A; v

=

=

Activity release of jth radionuclide during the year, µCi.

Average rate of water consumption (2000 ml/d}.

r

=

v

=

d

=

=

F

=

Number of days during the year (365 d}.

Dispersion factor from point of discharge to point of exposure.

Dilution water volume (ml}.

Fish concentration factor of the ;th radionuclide, Amount of fish eaten per day (57. 5 gm/d}.

D.

O_PERABILITY OF LIQUID RADWASTE EQUIPMENT

µCi/gm

µCi/ml The Palisades liquid radwaste system is designed to reduce the radioactive materials in liquid wastes prior to their discharge (by recycle or shipment for disposal} so that radioactivity in liquid effluent releases to unrestricted areas (see Figure 2-1} will not exceed Specification 3.24.4.1.

Maintaining the cumulative fraction if allowable release for each batch release and weekly for continuous releases assures compliance with this requirement.

In addition, 13 years of operating experience {to the date this ODCM was first adopted} has shown that design basis quantities never have been exceeded.

E.

RELEASE RATE FOR OFFSITE MPC (500 mRem/yr) 10 CFR 20.106 requires!radioactive effluent releases to unrestricted areas be less than-the limits specified in Appendix B, Table II when averaged over a period not to exce.ed one year. Concentrations at this level, if ingested for one ye~~-,> l!'H-l result in a dose of 500 mi 11 i rem to the total body or its equiv'al~_nlf;tt'o internal organs.

In addition, IO CFR 50.36a requires that the releas~~q:~~radioactive materials be kept as low as is reasonably achievable.

Append~1tko/iJ'_~;,t;o_ ~O CFR 50 provides the numerical 1'.,.. ~,?-::;-.. ~~... -**.

69

\\ \\ *\\

Rev 6 5/08/92

guidelines on limiting conditions for operations to meet the as low as is reasonably achievable requirement.

The LADTAP code has been run to determine the dose due to drinking water at plant discharge concentration (I,000 x nearest drinking water intake concentration.)

The source term used is given in Table I.I. Dose to the most limiting organ of the person hypothetically drinking this water is 3.88E-03 mrem.

The release rate which would result in a dose rate equivalent to 500 mrem/year (using the more conservative total body limit) is the curies/year given in Table I.I (I62) times 500/3.88E-03 or 2.IE07 Ci/yr =

0.66I Ci/sec.

III. URANIUM FUEL CYCLE DOSE A.

SPECIFICATION In accordance with Specification 3.24.8.I, if either liquid or gaseous quarterly releases exceed the quantity which would cause offsite doses more

~han twice the limit of Specifications 3.24.4.I, 3.24.5.2 or 3.24.5.3, !hen the cumulative dose contributions from combined release plus direct radiation sources (from the reactor unit and radwaste storage tanks) shall be calculated.

The dose is to be determined for the member of the public protected to be the most highly exposed to these combined sources.

B.

ASSUMPTIONS I.

' 2.

The full time resident determined to be maximally exposed individual (excluding infant) is assumed also to be a fisherman. This individual is assumed to drink water and ingest local fish at the rates specified in Sections II C.2.1 and II C.2.2.

Amount of shore line fishing (at accessible shoreline adjacent to site security fence) is conservatively assumed as 48 hours5.555556e-4 days <br />0.0133 hours <br />7.936508e-5 weeks <br />1.8264e-5 months <br /> per quarter (average of approximately I/2 hour per day each day of the 70 Rev 6 5/08/92

quarter} for the second and third quarters of the year, 36 hours4.166667e-4 days <br />0.01 hours <br />5.952381e-5 weeks <br />1.3698e-5 months <br /> for the fourth quarter and 16 hours1.851852e-4 days <br />0.00444 hours <br />2.645503e-5 weeks <br />6.088e-6 months <br /> for the first quarter.

C.

DOSE CALCULATION Maximum doses to the total body and internal organs of an individual shall *be determined by use of LADTAP and GASPAR computer codes, and doses to like organs and total body summed.

Added to this sum will be a mean dose rate, calculated or measured for the shoreline due to plant present curing the quarter in question, times the assumed fishing time.

040 = DG + DL + (Rr)(T}

where:

(2.15)

T

= 40 CFR 190 dose (mrem}

= Limiting dose to an individual from gaseous source term (mrem}

= Limiting dose to an individual from liquid source term (mrem}

= Mean dose rate calculated to be applicable to Lake Michigan shoreline adjacent to plant site (mrem/hr}

= Assumed shoreline fishing time for the quarter in questions (hours).

IV.

RADWASTE SYSTEM MODIFICATIONS A.

DEFINITION OF MAJOR RADWASTE SYSTEM MODIFICATION I.

Purpose The purpose of th~s definition is to assure that Technical Specification 6.20-will be,*satisfied under clearly identifiable circumstances, and w;th the objective that current radwaste system capabilities are not jeop~rd;ized* *. -> *

,'.]?~~!'.'~~~>~..

71

\\

\\

\\

Rev 6 5/08/92

' -~ -~.-. *r : *

  • ~ :..
2.

Definition A major radwaste system modification is a modification which would remove (either by bypassing or physical removal) or replace with less efficient equipment, any components of the radwaste system:

a.

Letdown filters or demineralizers

b.

Vacuum degasifier

c.

Miscellaneous or clean waste evaporators

d.

The present waste gas compressor/decay tank system

e.

Fuel pool filters/demineralizers

f.

Radwaste polishing demineralizers

g.

Radwaste solidification system Improvements or additions to improve efficiency will not be considered major modifications unless a complete substitution of equipment or systems is made with equipment of unrelated design.

Examples would be,

1) replacement of mechanical degasifier with steam, jet degasifier,
2) replacement of waste gas system with cryogenic system,-3) replacement of asphalt solidification with cement system, and 4) change from deep bed resins to Powdex, etc.

\\

72

\\

Rev 6 5/08/92

' \\

\\

\\

\\

\\

\\

\\

'l

\\

~'

~

I 13 I

I B

I I

I I

I

~\\

I

\\

-t' I

/

\\

c,

\\

I

~ HHW \\

HNf I

/ /

~,

\\

I NW

\\

I HI

'1 I,

\\ /J I

. (;

/

)

. I I..

GASlOUHFFLUENlS

~*~

I 'Y STACK 78' ~le*.

f

\\ \\ ~-** -.

A.

~... ;j.:*'/'.r:-.~ - -

llOUIDl>1$CHARCiE

-f.,.1 /I.'"'**-;;**.,...::.:... *.-..

SU~FACf ~.. t¥.

r

~" \\,*

/**1/*'"

1 ---

I wsw r 1 1

/

1 ts1

/

/

6 14

...,,..~ -

,,., /

  • 'r I

\\

\\

, ", /,,.fi I,' ','

\\ \\\\ " '- '-

/ t 1

uw i

\\. m

\\

v.
. \\ \\

/)

/

\\

\\

!I I

\\

\\

I.'

I

\\

\\

UffflCSTRICTCb AREA I

\\

.. 19\\

SI IF llm.llt0"'1'f I

\\

\\

/

I I

.N.


.. ~.........

,*.. 215 111F.1~ns

  • -~*-

. I

~* rl t' '

.I.'":'

  • s1t£ ENVIRONMENT llD STATIONS PALISADU Nl.ICUAR PLAN1 SITf 90UN0AflY FIGl.IRE 7-1 l.DN O'I QJ co c::: C>

U1

I I..

PALISADES RADWASTE EFFLUENTS - LIQUID

((JM..

W.l\\~.r~

'.iYSH_M TntATEIJ WASTF.

TM,KS!ll

---.. ~------

PRIMARY SYSTEM ST Off AGE TANK T90 TnJP l!i FLOW CONTRlll r---,

I

-l-. ___ _.,._-J.._....., __

......J RE llM!I L-1'....._,_

j r.*15Cfll.MffOIJS WASTE SYS1EM N

tr>mn WASl[J

~

1.AUNDTIY U11LITY U::

SYS I EM WA TF. R SfORACiE mnnrn W4STE TANI(

lANk 1-!lf TURBINE BlDG DRAINS TURltlNE SUMP STtAMGEN BlOWOOWN TANK RED8JJ

\\

SERVICE __.._..._

WAIER fl'.. -..

I

~.. r-=

q~ I RAKE SERVICE WATER __,.__..._ ___

.....,.~_lA_K_E _tN.;..lE;..;.T_-"'

I.ON O'I Q) 00 0::::0 U"l

ELEMENT H c NA p

CR MN FE co NI cu ZN BR RB SR y

ZR NB MO TC RU RH TE I

cs BA-LA CE.

PR ND.

w NP TABLE 2.0 BIOACCUMULATION FACTORS aCi/gm oer aCi/ml 7S FRESHWATER FISH 9.0E-01 4.6E 03 I.OE 02 I.OE OS 2.0E 02 4.0E 02 I.OE 02 S.OE 01 I.OE 02 S.OE 01 2.0E 03 4.2E 02 2.0E 03 3.0E 01 2.SE 01 3.3E 00 3.0E 04 I. OE 01 I. SE 01 I. OE 01 I. OE 01 4.0E 02 I. SE 01 2.0E 03 4.0E 00 2.SE 01 I.OE 00 2.SE 01 2.SE 01 l.2E 03 I.OE 01 Rev 6 5/08/92

TABLE 2.1 INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3

0.

3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.083-07

  • BElO l.71E-05 2.49E-06 5.16E-07
0.

l.64E-06 0.

2.78E-OS Cl4 2.37E-05 5.06E-06 S.06E-06 S.06E-06 S.06E-06 S.06E-06 S.06E-06 Nl3 5.85E-08 5.85E-08 S.8SE-08 S.83SE-08 S.8SE-08 5.8SE-08 S.8SE-08 Fl8 S.19E-06 0.

4.43E.07

0.
0.
0.

1.22E-06 NA22 9.83E-05 9.83E-05 9.83E-OS 9.83E-OS 9.83E-05 9.83E-05 9.83E-OS NA24 l.OIE-05 l.OIE-OS l.OIE-OS l.OIE-OS l.OIE-05 l.OIE-05 l.OIE-OS P32 l.70E-03 l.OOE-04 6.59E-05

0.
0.
0.

2.30E-OS AR39

0.
0.
0.
0.
0.
0.
0.

AR41

0.
0.
0.
0.
0.
0.
0.

CA41 3.74E-04 0.

4.0BE-OS

0.
0.
0.

l.91E-07 SC46 3.75E-08 5.41E-08 l.69E-08

0.

3.56E-08 0.

3.53E-OS CR51

0.

O.

i.4iE-08 9.20E-09 2.0IE-09 l.79E-08 4.llE-07 MN54

0.

l.99E-OS 4.51E-06

0.

4.41E-06. 0.

7.31E-06 MN56

0.

8.18E-07 l.41E-07

0.

7.03E-07 0.

7.43E~OS FESS l.39E-05 8.98E-06 2.40E-06

0.
0.

4.39E-06 l.14E~06 FES9 3.08E-05 5.38E-05 2.12E-05

0.
o.

l.59E-05 2.S7E~os C057

0.
l. lSE-06
1. 87E-06
0.
0.
0.
3. 92E::.o6 COSS
0.

3.60E-06 8.98E-06

0.
0.
0.

8.97E-06 C060

0.

l.08E-05 2.SSE-OS

0.
0.
0.

2.S7E-05 NI59 4.78E-05 l.45E-05 8.17E-06

0.
0.
0.

7.16E-07 NI63 6.34E-04 3.92E-05 2.20E-05

0.
0.
0.

l.95E-06 NI65 4.70E-06 5.32E-07 2.42E-07

0.
0.
0.

4.0SE-05 CU64

0.

6.09E-07 2.82E-07

0.

l.03E-06 0.

l.25E-05 ZN65 l.84E-05 6.31E-05 2.91E-05

0.

3.06E-05 0.

5.33E-05 ZN69M+D l.50E-06 3.06E-06 2.79E-07

0.

l.24E-06 0.

4.24E-05 ZN69 9.33E-08 l.68E-07 l.25E-08

0.

6.98E-08 0.

l.37E-05 SE79

0.

2.IOE-05 3.90E-06

0.

2.43E-05 0.

5.58E-07 BR82

0.
0.

l.27E-05

0.
0.
0.
0.

BR83+D

0.
0.

3.63E-07

0.
0.
0.
0.

BR84

0.
0.

3.82E-07

0.
0.
0.
0.

BRSS

0.
0.

l.94E-08

0.
0.
0.
0.

KR83M

0.
0.
0.
0.
0.
0.
0.

KR85M

0.

O.

0.
0.
0.
0.
0.

KR85

0.
0.
0.
0.
0.
0.
0.

KR87

0.

O.

0.
0.
0.
0.
0.

KRSS+D

0.

. 0.

0.

0.

0.

0.

0.

KR89

0.

..0.

0.
0.
0.
0.
0.

RB86 0

.,"1.70E-04 8.40E-05

0.
0.
0.

4.3S-E-06 RB87 o~**,*;;.8~88E.;OS 3.52E-05 o.*

... o.

0.

5.98E-07 RBSS

0.

4.98E-07 2.73E-07

0.

.* 0.

\\

0.

4.85E-07 RB89+0 O.

2.86E-07 l.97E-07

0.
0.

\\ 0.

9.74E-08 SR89+0 2.5lE-03 0.

7.20E-05

0.
0.

\\0.

5.16E-05 SR90+0 l.85E-02 0.

4.71E-03

0.
0.

~.

2.31E-04 SR9l+D 5.00E-05 O.

l.BlE-06

0.
0.

O.

5.92E-05 SR92+D l.92E-05 O.

7.13E-07

0.
0.
0.

2.07E-04 76 Rev 6 5/08/92

TABLE 2.1 INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 8.69E-08 0.

Y91M+O 8.IOE-10 0.

Y91 l.13E-06 0.

Y92 7.6SE-09 0.

Y93 2.43E-08 0.

ZR93+0 l.93E-07 9.18E-08 ZR9S+O 2.06E-07 S.02E-08 ZR97+0 l.48E-08 2.S4E-09 N893M l.23E-07 3.33E-08 N895 4.20E-08 l.73E-08 N897 4.S9E-10 9.79E-ll M093

0.

S.6SE-OS M099+0

0.

3.40E-OS TC99M l.92E-09 3.96E-09 TC99 l.08E-06 l.46E-06 TCIOI 2.27E-09 2.86E-o9*

RU103+0 l.48E-06 0.

RUIOS+O l.36E-07 0.

RU106+0 2.41E-OS 0.

RHIOS l.09E-06 7.13E-07 P0107

0.

l.19E-06 P0109

0.

l.SOE-06 AGllOM+D 9.96E-07 7.27E-07 AGlll S.20E-07 2.02E-07 C0113M

0.

l.77E-OS COllSM

0.

l.42E-OS 5Nl23 2.49E-04 3.89E-06 5Nl2S+O 7.41E-OS l.38E-06 5Nl26+0 S.S3E-04 7.26E-06 58124 2.14E-OS 3.lSE-07 S812S+O l.23E-05 l.19E-07i 58126 8.06E:06 l.SSE-07:

58127 2.23E-06 3.98E-08 TE125M 2.33E-05 7.J9E~06 TE127M+O 5.SSE~os~ lr94E-05 TE127 l.. Q:OE~Q6, _;3~3sE:.07 TE129M+D h,OOE:~0~4+ *3.43E-05 TE129 2~.,4Eb.'01 9. 79£,..08 TE131M+O r:s2£~'0S;. -6.12E-06 TE131+0 l:'76E'.;:()7: '6. SOE:-08 TE132+D 2.0aE:::os* l.03E-05 TE133M+D 3.91E-07 l.79E-07 TE134+D 2.67E-07 l.34E~07 1129 2.86E-05 2.12E-05 1130 6.00E-06 l.32E-05 1131+0 3.59E-05 4.23E-05 2.33E-09 2.76E-ll 3.0IE-08 2.ISE-10 6.62E-10 5.54E-08 3.56E-08 1.16E-09 1.04E-08 l.OOE-08 3.S3E-ll l.82E-06 6.63E-06 5.IOE-08 4.SSE-07 2.83E-08 4.9SE-07 4.SSE-08 3.0IE-06 4.79E-07 8.45E-08 3.62E-07 4.81E-07 l.07E-07 6.52E-07 4.93E-07 6.SOE-06 3.29E-06 I.SOE-OS 6.63E-06 2.53E-06 2.91E-06 6.90E-07 3.15E-06 7.0SE-06 2.15E-07

1. S4E-OS 6.63E-08 5.0SE-06 4.94E-08 9.61E-06
1. 71E-07 l.38E-07 I.SSE-OS 5.30E-06 l.86E-05
o.
0.
o.
0.
0.
o.
o.
o.
0.
o.
0.
o.
o.
o.
o.
0.

2.71E-07 O.

0.

5.41E-08 0.

O.

2.S6E-09 0.

0.

3.25E-08 0.

0. \\

l.24E-08 0.

0.

7.65E-ll 0.

O.

l.13E-05 0.

0.

5.0SE-05 0.

0.

4.26E-08 2.07E-09

0.

l.23E-05 l.42E-07 O.

3.40E-08 l.S6E-09

0.

3.0SE-06 0.

O.

l.OOE-06 0.

0.

2.85E-OS 0.

0.

l.98E-06 0.

0.

6.79E-06 0.

0.

5.SlE-06 0.

O.

l.04E-06 O.

0.

4.22E-07 O.

0.

l.34E-05 0.

0.

7.41E-06 0.

3.91E-06 0.

0.

l.36E-06 0.

0.

l.91E-06 0.

O.

S.68E-08 0.

l.34E-OS l.S4E-08 0.

7.72E-06 6.19E-08 0.

5.07E-06 2.84E-08 0.

l.15E-06 7.84E-06 0.

O.

1.69E-05 l.44E-04 0.

8.14E-07 2.44E-06 0.

3.84E-05 2.50E-04 0.

2.38E-07 7.07E-07 0.

l.24E-05 4.21E-05 0.

1. S7E-07 / '4. SOE-07 0.

1.S2E°-05 6.44E-05 0.

3.4SE-07 1.22E-06\\. 0.

2.39E-07 9.03E-07 \\0.

I,36E-02 2.51E-05

~.

l.48E-03 1.4SE-05 o~

l.39E-02 4.94E-05 0.

77

1. 20E-04 2.70E-06 8.IOE-05 l.46E-04
1. 92E-04 2.39E-OS 2.SOE-OS
1. 62E-04 3.98E-06
1. 46E-05 3.09E-OS l.21E-06 l.12E-05 l.ISE-06 6.31E.,.06 4.86E:.07 1.aoE~os S.41E-05 l.83E-04
1. 77E-OS 9.46E-07 3.68E-05
3. 77E-OS 4.82E-OS 2.66E-OS 8.09E-OS 6.SSE-05
1. llE-04 2.52E-05 6.60E-05 1.64E-05 8.35E-05 5.91E-OS l.llE-05 2.36E-05 2.IOE-05 5.97E-05

. 2.27L-OS l.03E-04

7. llE-06 3.81E-OS
1. 93E-05 3.06E-06 4.24E-07 2.83E-06 l.SIE-06 Rev 6 5/08/92

\\

t.... -

~., *:-.:: -* -:..- -

-~ --

TABLE 2.1 INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 l.66E-06 3.37E-06 l.20E-06 l.58E-04 3.76E-06 0.

2.73E.06 1133+0 l.25E-05 l.82E-05 5.33E-06 3.31E-03 2.14E-05 0.

3.0BE-06 1134 8.69E-07 l.78E-06 6.33E-07 4.15E-05 l.99E-06 0.

l.84E-06 1135+0 3.64E-06 7.24E-06 2.64E-06 6.49E-04 8.07E-06 0.

2.62E-06 XE131M

0.
0.
0.
0.
0.
0.
0.

XE133M

0.
0.
0.
0.
0.
0.
0.

XE133

0.
0.
0.
0.
0.
0.
0.

XE135M

0.
0.
0.

O.

0.
0.
0.

XE135

0.
0.
0.
0.
0.
0.
0.

XE137

0.
0.
0.
0.
0.
0.
0.

XE138+0 0.

0.
0.
0.
0.
0.
0.

CS134M+O l.76E-07 2.93E-07 l.48E-07

0.

l.13E-07 2.60E-08 2.32E-07

. CS134 3.77E-04 7.03E-04 7.lOE-05

0.

l.BlE-04 7.42E-05 l.91E-06 CS135 l.33E-04 l.21E-04 6.30E-06

0.

3.44E-05 1.31E-05 4.37E.-07 CS136 4.59E-05 l.35E-04 5.04E-05

0.

. 5.38E-05 l.lOE-05 2.05E~06 CS137+0 5.22E-04 6.llE 4.33E-05

0.

l.64E-04 6.64E-05 1.91E~06 CS138*

4.81E-07 7.82E-07 3.79E~07

0.

3.90E-07 6.09E-08 l.25e~o6 CS139+0 3. lOE-07 4. 24E-07 l.62E-07

0.

2.19E-07 3.30E-08 2.66E'-08 BA139 8.81E-07 5.84E-10 2.55E-08

0.

3.51E-10 3.54E-10 5.58E-05 BA140+0 l.71E-04 l.71E-07 8.81E-06

0.

4.06E-08 l.OSE-07 4.20E-05 BA141+0 4.25E-07 2.91E-10 l.34E-08

0.

l.75E-10 l.77E-10 5.19E-06 BA142+0 l.84E-07 l.53E-10 9.06E-09

0.

8.81E-ll 9.26E-ll 7.59E-07 LA140 2.llE-08 8.32E-09 2.14E-09

0.
0.
0.

9.77E-05 LA141 2.89E-09 8.38E-10 l.46E-10

0.
0.
0.

9.61E-05 LA142 l.lOE-09 4.04E-10 9.67E-ll

0.
0.

O.

6.86E-05 CE141 7.87E-08 4.80E-08 5.65E-09

0.

l.48E-08 0.

2.48E-05 CE143+0 l.48E-08 9.82E-06 l.12E-09

0.

2.86E-09 0.

5.73E-05 CE144+0 2.98E-06 l.22E-06 l.67E-07

0.

4.93E-07 0.

l.71E-04 PR143 8.ISE-08 3.04E-08 4.03E-09

0.

l.13E-08 0.

. 4.29E-05 PR144 2.74E-10 l.06E-10 l.38E-ll

0.

3.84E-ll 0.

4.93E-06 N0147+0 5.53E-08 5.68E-OS; 3.48E-09

0.

2.19E-08 0.

3.60E-05 PM147 3.88[~07 3.27E-oa:

l.59E-08

0.

4.88E-08 0.

9.27E-06 PM148M+O l.65E-07 4.18E-08 3.28E-08

0.

4.80E-08 0.

5.443-05 PM148 6.32E-08 9.13E-.09 4.60E-09

0.

l.09E-08 0.

9.74E-05 PM149 l.3_8E-~-08' l.81E~09 7.90E-10

0.

2.20E-09 0.

4.86E-05 PM151 6!~1'8E~:09' -9~01E-10

4. 56E-10
0.

1.07E-09 0.

4.17E-05 SM151 2.,g_p£,,;07;~- 6.67E-08 l.44E-08

0.

4.53E-08 0.

5.58E-06 SM153 r.-Z2E~og,~ 5.97E-09 4.58E-10

o.

l.25E-09 0.

3.12E-~05 EU152 6/l.,e~*ot 1.79E-07 l.SIE-07

0.

5.02E-07 o.

1.59E-05 EU154 -

2~64E.-o6* -3.67E-07 2.20E-07 O.

  • '9.95E-07 0.

4.58E-05 EU155 5.42E-07 6.25E-08 3.23E-08

0.

l.40E-07 0.

8.37E-05 EU156 l.14E-07 7.06E-08 l.12E-08

0.

3.26E-08'. 0.

6.67E-05 18160 2.59E-07 0.

3.24E-08

0.

7.37E-08 \\ 0.

3.45E-05 H0166M l.25E-06 2.69E-07 2.13E-07

0.

3.57E-07 'O.

0.

Wl81 8.SSE-08 2.72E-08 3.04E-09

0.
0.

G.

3.82E-07 WISS 3.62E-06 l.13E-06 l.29E-07

0.
0.
0.

l.62E-05 Wl87 9.03E-07 6.28E-07 2.17E-07

0.

'. - 0.

0.-

3.69E-05 78 Rev 6 5/08/92

TABLE 2.1 INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG Gl-LLI PB210+D 5.28E-02 l.42E-02 2.38E-03

0.

4.33E-02 0.

5.62E-05 8!210+0 4.16E-06 2.68E-05 3.58E-07

0.

2.0SE-04 0.

5.27E-05 P0210 3.IOE-03 5.93E-03 7.41E-04

0.

l.26E-02 0.

6.61E-05 RN222+D

0.
0.
  • O.
0.
0.
0.
0.

RA223+D 4.41E-02 6.42E-05 8.82E-03

0.

l.17E-03 O.

3.43E-04 RA224+D l.46E-02 3.29E-05 2.91E-03

0.

6.00E-04 0.

3.86E-04 RA225+D 5.78E-02 6.42E-05 l.15E-02

0.

l.19E-03 0.

3.24E-04 RA226+D 6.20E-Ol 4.76E-05 5.14E-Ol

0.

8.71E-04 0.

3.44E-04 RA228+D 4.32E-Ol 2.58E-05 4.86E-Ol

0.

4.73E-04 0.

5.86E-05 AC225 3.92E-05 5.03E-05 2.63E-06

0.

3.69E-06 0.

4.36E-04 AC227+D 4.49E-03 7.67E-04 2.79E-04

0.

l.56E-04 0.

8.50E-05 TH227+D l.20E-04 2.0IE-06 3.45E-06

0.

7.41E-06 0.

5.70E-04 TH228+D 2.47E-03 3.38E-05 8.36E-05

0.

l.SSE-04 0.

5.84E-04 TH229 l.48E-02 l.94E-04 7.29E-04

0.

9.29E-04 0.

5.31E-04 TH230 3.80E-03 l.90E-04 l.06E-04

0.
  • 9.12E-04 0.

6.24E-05 TH232+D 4.24E-03 l.63E-04 l.65E-04

0.

7.79E-04 0.

5.31E~os TH234.

6.92E-07 3.77E-08 2.00E-08

0.

l.39E-07 0.

l.19E-04 PA23l+D 7.57E-03 2.50E-04 3.02E-04

0.

l.34E-03 0.

7.44E*05 PA233 3.IIE-08 6.09E-09 5.43E-09

0.

l.67E-08 0.

l.46E-05 U232+D 2.42E-02 0.

2.16E-03

0.

2.37E-03 0.

7.04E-05 U233+D 5.08E-03 0.

3.87E-04

0.

l.OSE-03 0.

6.SIE-05 U234 4.88E-03 0.

3.80E-04

0.

l.06E-03 0.

6.37E-05 U235+D 4.67E-03 0.

3.56E-04

0.

9.93E-04 0.

8.IOE-05 U236 4.67E-03 0.

3.64E-04

0.

l.OIE-03 0.

5.98E-05 U237 4.95E-07 0.

l.32E-07

0.

l.23E-06 0.

2.llE-05 U238+D 4.47E-03 0.

3.33E-04

0.

9.28E-04 0.

5.71E-05 NP237+D 2.53E-03 l.93E-04 l.OSE-04

0.

6.34E-04 0.

8.23E-05 NP238 l.24E-07 3.12E-09 l.92E-09

0.

6.81E-09 0.

4.17E-05 NP239 l.llE-08 9.93E-10 5.61E-10

0.

l.98E-09 0.

2.87E-05 PU238 l.34E-03 l.69E-04 3.40E-05

0.

l.21E-04 0.

7.57E-05 PU239 l.45E-03 1.77E-04; 3.54E-05

0.

1.28E-04 0.

6.91E-05 PU240 1.45E-03 l.77E-04: 3.54E-05

0.

1.28E~04 0.

7.04E-05 PU241+D 4.38E~05 1.90E-06 8.82E-07

0.

3.17E-06 0.

1.45E-06 PU242 l.35E-03 l.70E-04 3.41E-05

0.

1.23E-04 0.

6.77E-05 PU244 1.57E-03. l.95E-04 3.91E-05

0.

1.41E-04 0.

1.0IE-04 AM241 l.53E::,;()3* 7.ISE-04 l.09E-04

0.

6.SSE-04 0.

7.70E-05 AM242M 1.58£~03* 7.02E-04 1.13E-04

0.

6.64E-04 0.

9.69E-05 AM243 L:SlE:.<()a 6.SSE-04 1.06E-04

0.

6.36E-04 0.

9.03I::-05 CM242 I.'31E~o*4. l.24E-04 9.IOE-06

0.

2.62E-05 0.

8.23E-05 CM243 1.45£".;:03 6.88E-04 8.98E-05

0.

. 3.27E-04 0.

8.IOE-05 CM244 l.22E-03 6.16E-04 7.59E-05

0.

, 2.71E-04 0.

7.84E-05 CM245 l.SSE-03 Z.49E-04 1.13E-04

0.

4.32E-04'-. 0.

7.30E-05 CM246 l.87E-03 7.49E-04 1.13E-04

0.

4.31E-04 °' 0.

7.17E-05 CM247+0 l.82E-03 7.36E-04 l.IIE-04

0.

4.24E-04 -0.

9.43E-05

.CM248 l.SlE-02 6.07E-03 9.16E-04

0.

3.50E-03 O~

l.52E-03 CF252 l.24E-03 0.

2.95E-05 0

0.
0.

2.99E-04 79 Rev 6 5/08/92

TABLE 2.1 CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 BEIO Cl4 Nl3 FIS NA22 NA24 P32 AR39 AR41 CA41 SC46 CRSl MNS4 MNS6 FESS FE59 COS7 COSS C060 NIS9 Nl63 Nl6S CU64 ZN65 ZN69M+D ZN69 SE79 BRS2 BRS3+D BRS4 BRSS KRS3M KR8SM KR8S KR87 KR88+D KR89 RB86 RB87 RB88 RB89+D SR89+0 SR90+0 SR91+0 SR92+D

0.

2.03E-07 1.35E-OS l.57E-06 1.21E-05 2.42E-06 3.lOE-08 3.lOE-08 2.49E-06 0.

5.88E-OS 5.88E-OS S.SOE-06 5.SOE-06 8.2SE-04 3.86E-05

0.
0.
0.
0.

3.47E-04 0.

1.97E-08 2.70E-OS

0.
0.
0.

1.07E-OS

0.

3.34E-07 l.lSE-05 6.lOE-06 1.65E-05 2.67E-OS

0.

4.93E-07

0.

1.SOE-06

0.

S.29E-06 4.02E-OS 1.07E-05 S.38E-04 2.88E-OS 2.22E-06 2.09E-07

0.

2.4SE-07 1.37E-OS 3.6SE-OS 7.lOE-07 l.21E-06 4.38E-08 6.33E-08

0.

8.43E-06

o.
o.
0.
0.
0.
o.

0

0.
0.

0 *.

o.

. 0.

0......

O* *...

o;:c* **',~:,.*

  • o. *
  • 0 :
~:~_:_

0 oL~ '~"i{;i,:.. 'o:

0 ~;;;~!~,c~-~""'"

6. 70£-0S o'~*::<_:\\.. * **_. 3. 95E-OS
0.

~*

. 1.90E-07

0.

l.17E-07 1.32E-03 0.

1.70E-02 0.

2.40E-05 0.

9.03E-06 0.

2.03E-07 3.39E-07 2.42E-06 3.lOE-OS 2.47E-07 5.SSE-OS 5.SOE-06 3.lSE-05

0.
0.

3.79E-OS 1.04E-OS S.90E-09 2.SSE-06 7.54E-OS

1. S9E-06 1.33E-05 9.98E-0.7 5.51E-06
1. 56E-OS 6.S2E-06 1.S3E-05.
1. 22E-07 1.4SE-07 2.27E-OS 1.43E-07 S.85E-09 1.S7E-06 7.SSE-06
1. 71E-07
1. 98E-07 9.12E-09
0.
0.
0.
0.
o.
0.

4.12E-OS

1. S3E-OS 1.32E-07
1. 04E-07 3.77E-05 4.31E-03 9.06E-07 3.62E-07 2.03E-07 2.03E-07 O.

1.llE-06 2.42E-06 2.42E-06 3.lOE-OS 3.lOE-OS

0.
o.

5.SSE-05 5.SSE-05 5.SOE-06 5.SOE-06

o.
0.
0.
0.
0.
o.
0.
o.
0.

2.30E-OS 4.94E-09 1.35E-09

0.

3.00E-06

0.

4.04E-07

0.
0.
o.
o.
0.
0.
0.
0.
o.
o.
0.
0.
0.
0.
o.
o.
0.

S.92E-07

0.

2.30E-OS

0.

7.03E-07

0.

3.84E-08

0.

1.37E-OS

o.
o.
o.
o.
o.
o.
o.
o.
0.
o.
0.
o.
0.
o.
o.
o.
o.

. o.

0.
0.
o.
o.
o.

. *o.

2.03E-07

o.

2.42E-06

3. lOE-08
o.

5.88E-05 S.SOE-06

o.
0.
o.
o.
o.

9.02E-09

o.
o.

3.45E-06 7.74E-06

o.
0.
0.
0.
0.
o.
o.
0.
0.
o.
o.
o.
o.
o.
o.
0.
o.
o. o.
o.
o.
o.
o.
o.

/ o.

o.
o.
o.
o.
0.
o.
o.
o.
o.
0.

\\ o.

\\, 0.

\\ o.

    • o.

().. o.

so 2.03E-07 2.75E-05 2.42E-06 3.lOE-OS 6.74E-07 5.SSE-05 S.SOE-06 2.2SE-05

0.
o.
1. 90E-07 3.95E-05 4.72E-07 8.98E-06 4.84E:-05 l.13E'-06
2. 78E-05
4. 04f-06
1. 05E-05 2.93E-05 7.IOE-07
1. 94E-06 2.S6E-05 l.ISE-05 6.41E-06 3.94E-05 3.99E-06 S.S3E-07
o.
o.
o.
0.
o.
0.
o.
o.
o. o... --

4.31E-06 S.92E-07 9.32E-09 1.02E-09 S.llE-05 2.29E-04 S.30E-05

1. 71E-04

_ Rev 6 5/08/92

TABLE 2.1 CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG Gl-LLI Y90 4.llE-08 0.

1.IOE-09

0.
0.
0.

1.17E-04 Y91M+D 3.82E-10 0.

1.39E-ll

0.
0.
0.

7.48E-07 Y91 6.02E-07 0.

l.61E-08

0.
0.
0.

8.02E-05 Y92 3.60E-09 0.

1.03E-10

0.
0.
0.

1.04E-04 Y93 1.14E-08 0.

3.13E-10

0.
0.
0.

1.70E-04 ZR93+0 l.67E-07 6.25E-08 4.45E-08

0.

2.42E-07 0.

2.37E-05 ZR95+0 1.16E-07 2.55E-08 2.27E-08

0.

3.65E-08 -0.

2.66E-05 ZR97+0 6.99E-09 l.OIE-09 5.96E-10

0.

l.45E-09 0.

l.53E-04 N893M l.05E-07 2.62E-08 8.6IE~09

0.

2.83E-08 0.

3.95E-06 NB95 2.25E-08 8.76E-09 6.26E-09

0.

8.23E-09 0.

l.62E-05 NB97 2.17E-10 3.92E-ll l.83E-ll

0.

4.35E-ll 0.

l.21E-05 M093

0.

2.41E-05 8.65E-07

0.

6.35E-06 0.

l.22E-06 M099+0

0.

. l.33E-05 3.29E-06 O.

2.84E-OS

0.

l.lOE-05 TC99M 9.23E-10 l.SIE-09 3.00E-08

0.

2.63E-08 9.19E-10 l.03E-06 TC99 S.3SE-07 S.96E-07 2.14E-07

0.

7.02E-06 S.27E-08 6.25E:-06.

TCIOI l.07E-09 l.12E-09 l.42E-08

0.

l.91E-08 S.92E-10 3.S6E:o9 RU103+0 7.31E-07 0.

2.BIE-07

0.

1.84E-06 0.

l.89E~os RUIOS+D 6.4SE-08 0.

2.34E-08

0.

5.67E-07 o.

4.21E~os RU106+0 l.17E-05 0.

l.46E-06

0.

I.SSE-OS 0.

l.82E-04 RHIOS S.14E-07 2.76E-07 2.36E-07

0.

l.IOE-06 0.

l.71E-05 PD107

0.

4.72E-07 4.0IE-08 O~

3.9SE-06 0.

9.37E-07 PD109

0.

S.67E-07 l.70E-07

0.

3.04E-06 0.

3.35E-05 AGIIOM+D S.39E-07 3.64E-07 2.91E-07

0.

6.78E-07 0.

4.33E-05 AGlll 2.48E-07 7.76E-08 5.12E-08

0.

2.34E-07 0.

4.75E-05 CD113M

0.

l.02E-OS 4.34E-07

0.

l.OSE-OS 0.

2.63E-05 C0115M

0.

5.89E-06 2.SIE-07

0.

4.38E-06 0.

8.0IE-05 5Nl23 l.33E-04 l.6SE-06 3.24E-06 1.75E-06 0.

0.

6.52E-05 5Nl25+0 3.SSE-05 S.3SE-07 l.S9E-06 5.55E-07 0.

0.

l.IOE-04 5Nl26+0 3.33E-04 4.ISE-06 9.46E-06 l.14E-06 0.

0.

2.SOE-05 58124 l.llE-OS l.44E-07 3.89E-06 2.4SE-08 0.

6.16E-06 6.94E-05 5812S+O 7.16E-06 S.S2E-08; l.SOE-06 6.63E-09 0.

3.99E-06 l.71E-OS 58126 4.40E~06 6.73E-08 !

l.SSE-06 2.SSE-08 0.

2.IOE-06 8.87E-05 58127 l.06E-06 l.64E-08 3.68E-07 l.ISE-08 0.

4.60E-07 S.97E-OS TE12SM l.14E-05 3.09£-06 l.S2E-06 3.20E-06 0.

0.

l.IOE-05 TE127M+O 2.89E--05 7.78E-06 3.43E-06 6.91E-06 8.24E-OS 0.

2.34E-05 TE127 4.. llE~:07 1. 27£-07

1. OIE-07
3. 26E-07 1.34E-06 0.

1.84E-05 TE129M+D 4.8*7E;'os:: l.36E-OS

7. S6E-06
1. S7E-OS I. 43E-04 0.
s. 94E-OS TE129 I.3;4E~0.7:- 3.74E-08 3.18E-08 9.S6E-08 3.92E-07 0.

8.34[-06 TE131M+D 7.2QE';.;'06' 2.49£-06 2.6SE-06 5.12E-06 2.41E-OS 0.

1.0iE-04 TE131+0 8.. Joe.,.oa* 2.SJE-08 2.47E-08 6.3SE-08 '2.SlE-07 o.

4.36E-07 TE132+0 l.OlE-05 4.47E-06 S.40E-06 6.SIE~06 4.lSE-05 0.

4.SOE-OS TE133M+D l.87E-07 l.S6E-08 9.37E-08 l.4SE-07 7.18E-O~\\ 0.

S.77E-06 TE134+0 l.29E-07 S.80E-08 7.74E-08 l.02E-07 5.37E-07 \\0.

S.89E-07 Il~g

~:~~~=8~ ~:~~~=8~

~:~~~=g~

~:~g~:g~ ~:~~~=8~ _g:

~:~~~=g~

1131+0 l.72E-05 l.73E-OS 9.83E-06 5.72E-03 2.84E-OS 0.

l.54E-06 81 Rev 6 5/08/92

~' *:.......

~_;.:-:*.

TABLE 2.1 CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 8.00E-07 l.47E-06 6.76E-07 6.82E-05 2.25E-06 0.

l.73E-06 1133+0 5.92E-06 7.32E-06 2.77E-06 l.36E-03 l.22E-05 0.

2.95E-06 1134 4.19E-07 7.78E-07 3.58E-07 l.79E-05 l.19E-06 0.

5.16E-07 II35+0 l.75E-06 3.I5E-06 I.49E-06 2.79E-04 4.83E-06 0.

2.40E-06 XEI3IM

0.
0.
0.
0.
0.
0.
0.

XEI33M

0.
0.
0.
0.
0.
0.
0.

XEI33

0.
0.
0.
0.
0.
0.
0.

XE135M

0.
0.
0.
0.
0.
0.
0.

XEI35

0.
0.
0.
0.
0.
0.

O.

XE137

0.
0.
0.
0.
0.
0.
0.

XEI38+0 0.

0.
0.
0.
0.
0.
0.

CSI34M+O 8.44E-08 I.25E-07 8.I6E-08

0.

6.59E-08 I.09E-08 I.58E-07 CSI34 2.34E-04 3.84E-04 8.IOE-05

0.

I.19E-04 4.27E-05 2.07E-06 CSI35 8.JOE-05 5.78E-05 5.93E-06

0.

2.04E-05 6.BIE-06 4.33E-07 CSI36 2.35E-05 6.46E-05 4.ISE-05

0.

3.44E-05 5.IJE-06 2.27E~o6

.CSI37+0 3.27E-04 3.IJE-04 4.62E-05

0.

l.02E-04 3.67E-05 1.96[;..06 CSI38*

2.28E-07 3.17E-07 2.0IE-07

0.

2.23E-07 2.40E-08 1.46E~07 CSI39+0 1.45E-07 1.6IE-07

7. 74E-08
0.

1.21E-07 1.22E-08 1.45E--11 BAI39 4.I4E-07 2.2IE-IO l.20E-08

0.

I.93E-IO I.JOE-IO 2.39E-05 BAI40+0 8.31E-05 7.28E-08 4.85E-06

0.

2.37E-08 4.34E-08 4.2IE-05 BA141+0 2.00E-07 I.I2E-10 6.5I£-09

0.

9.69E-ll 6.58E-10 l.14E-07 BAI42+0 8.74E-08 6.29E-ll 4.88E-09

0.

5.09E-1I 3.70E-ll l.I4E-09 LA140 l.OlE-08 3.53E-09 l.19E-09

0.
0.
0.

9.84E-05 LA141 l.35E-09 3.I7E-10 6.88E-Il

0.
0.
0.

7.05E-05 LA142 5.24E-IO I.67E-IO 5.23E-II

0.
0.
0.

3.31E-05 CEI4I 3.97E-08 I.98E-08 2.94E-09

0.

8.68E-09 0.

2.47E-05 CEI43+0 6.99E-09 3.79E-06 5.49E-IO

0.

l.59E-09 0.

5.SSE-05 CE144+0 2.08E-06 6.52E-07 I.lIE-07

0.

3.61E-07 0.

I.70E-04 PR143 3.93E-08 l.18E-08 1.95E-09

0.

6.39E-09 0.

4.24E-05 PR144 l.29E-10 3.99E-ll 6.49E-12

0.

2.llE-11. 0.

8.59E-08 N0147+D 2.79E-08 2.26E-08i l.75E-09

o.

I.24E-08' 0.

3.58E-05 PM147 3.18E.'.'.'07 2.2.7E-08!

1.22E-08

0.

4.0lE-08 0.

9.19E-06 PM148M+D l.03E-07 2.0SE-08 2.0SE-08

0.

3.04E-08 0.

5.78E-05 PM148 3.02E~os 3.63E-09 2.35E-09

0.

6.17E-09 -0.

9.70E-05 PM149 6.* ~-~E;+:O~> 6~90E~l0 3.74E-10

0.

1.22E-09 0.

4.71E-05 PM151 z:*~:9aEf~9': 3.SSE'-10 2.31E-10

0.

6.02E-10 0.

4.03E-05 SM151 2}:~6E~,07>::.3:*81E-08

1. 20E-08
0.
3. 94E-08 0.
5. 53E-06 SM153 3_,;i~65,E+"o9:/.2~.27E-09 2.19E-10
0.

6.91E-10 0.

3.Q2E_"'.05 EU152 6~'!115E~&7:,~ L.l2E-07 l.33E-07

0.
4. 73E-07 O.

l.84E-05 EU154 2*~~3.0E'-'cJ.6: 2/01.E-07 l.89E-07

0.
  • '9.09E-07 0.

4.81E-05 EU155 4.82.E-07' 3.47E-08 2.72E-08

0.

l.30E-01 0.

8.69E-05 EU156 5.62E-08 3.0lE-08 6.23E-09

0.

l.94E-08, 0.

6.83E-05 TB160 1.66E-07 0.

2.06E-08

0.

4.94E-08 \\ 0.

3.68E-05 H0166M l.OSE-06 2.26E-07

  • l.91E-07
0.

3.22E-07 'Q.

0.

Wl81 4.23E-06 l.04E-08 l.43E-09

0.
0.

o~

3.79E-07 WISS l.73E-06 4.32E-07 6.0SE-08

0.
0.
0.

l.61E-05

  • Wl87 4.29E-07 2.54E-07 l.14E-07
0.
0.
0.

3.57E-05 82 Rev 6 5/08/92

  • ~'

TABLE 2.1 CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+0 4.75E-02 1.22E-02 2.09E-03

0.

3.67E-02 0.

5.57E-05 81210+0 l.97E-06 l.02E-05 1.69E-07

0.

l.15E-04 0.

5.17E-05 P0210 l.52E-03 2.43E-03 3.67E-04

0.

7.56E-03 0.

6.55E-05 RN222+D 0.

0.
0.
0.
0.
0.
0.

RA223+D 2.12E-02 2.45E-05 4.24E-03

0.

6.50E-04 0.

3.3SE-04 RA224+D 6.S9E-03 l.25E-05 l.3SE-03

0.

3.31E-04 0.

3.7SE-04 RA225+D 2.SOE-02 2.50E-05 5.59E-03

0.

6.62E-04 0.

3.21E-04 RA226+D 5.75E-Ol l.S4E-05 4.72E-Ol

0.

4.SSE-04 0.

3.41E-04 RA22S+D 3.SSE-01 9.99E-06 4.32E-Ol

0.

2.65E-04 0.

5.SlE-05 AC225 I.SSE-OS l.94E-05 l.26E-06

0.

2.07E-06 0.

4.31E-04 AC227+D 4.12E-03 6.63E-04 2.SSE-04

0.

l.46E-04 0.

S.43E-05 TH227+0 5.SSE-05 7.96E-07 l.69E-06

0.

4.22E-06 0.

5.63E-04 TH22S+D 2.07E-03 2.65E-05 7.00E-05

  • 0.

l.3SE-04 0.

5.79E-04 TH229 l.3SE-02 l.SIE-04 6.SOE-04

0.

S.S4E-04 0.

5.27E-04 TH230 3.SSE-03 l.7SE-04 9.91E-05

0.
  • S.67E-04 0.

6.19E~05 TH232+D 3.96E-03 l.52E-04 3.0IE-04

0.

7.41E-04 0.

5.27E~OS TH234

  • 3.42E-07 l.SlE-OS 9.SSE-09
0.

S.OlE-OS 0.

l.1SE~04 PA23l+D 7.07E-03 2.34E-04 2.SIE-04

0.

l.2SE-03 0.

7.37E~05 PA233 l.SlE-OS 2.S2E-09 3.16E-09

0.

l.04E-OS 0.

l.44E-05 U232+D l.76E-02 0.

. l.26E-03

0.

l.34E-03 0.

6.9SE-05 U233+0 3.72E-03 0.

2.25E-04 O~

6.IOE-04 0.

6.45E-05 U234 3.57E-03 0.

2.21E-04

0.

5.9SE-04 0.

6.32E-05 U235+D 3.42E-03 0.

2.07E-04

0.

5.61E-04 0.

S.03E-05 U236 3.42E-03 0.

. 2.12E-04

0.

5.73E-04 0.

5.92E-05 U237 2.36E-07 0.

6.27E-OS

0.

6.SlE-07 0.

2.0SE-05 U23S+D 3.27E-03 0.

l.94E-04

0.

5.24E-04 0.

5.66E-05 NP237+D 2.36E-03 l.SlE-04 9.79E-05

0.

6.0SE-04 0.

8.16E-05 NP238 5.83E-08 l.ISE-09 9.0SE-10

0.

3.76E-09 0.

4.04E-05 NP239 5.25E-09 3.77E-10 2.65E-10

0.

l.09E-09 O~

2.79E-05 PU238 l.25E-03 l.56E-04 3.16E-05

0.

l.lSE-04 o.

7.SOE-05 PU239 l.36E-03 l.65E-04i 3.31E-05

0.

l.22E-04 0.

6.SSE-05 PU240 l.36E~03 l.65E-04:

3.31E-05

0.

l.22E-04 0.

6.98E-05 PU24l+D 4.00E-05 l.72E~06 S.04E-07

0.

2.96E-06 0.

l.44E-06 PU242 l.26E-03 l.59E-04 3.19E-05 O~

l.17E-04 0.

6.71E-05 PU244 l.47E-03. l.82E-04 3.65E-05

0.

l.35E-04 0.

l.OOE-04 AM241 I.43E~*o3 6.40E-04 l.02E-04

0.

6~23E-04 0.

7.64E-05 AM242M 1AlE~o3: 6.25E-04 1.04E-04

0.

6.30E-04 0.

9.61E-05 AM243 L.41£#:0.3 6.-14E-04 9.83E-05

0.

6.06E-04 0.

8.95£,.._05 CM242 s.soe-.;os 0 6.* 73E~os s.a4E-06

o.

I.S7E-os o.

s. I6E-os CM243 1.3~E-03 6.03E-04 8.24E-05
0.

/l.OSE-04 O.

8.03E-05 CM244 1.llE-03 5.36E-04 6.93E-05

0.

2.54E-~ *o.

7.77E-05 CM245 1.76E-03 6.64E-04 l.OSE-04

0.

4.llE-~~\\ 0.

7.24E-05 CM246 l.74E-03 6.64E-04 1.05E-04

0.

4.lOE-04

-0~

7.llE-05 CM247+D l.70E-03 6.53E~04 1.-03£-04

0.

4.04E-04

'Q~

9.35E-05 CM248 l.41E-02 5.38E-03 8.52E-04

0.

3.33E-03 0\\

l.SlE-03 CF252 l.07E-03 0.

2.54E-05 O.

0.
0.

2.96E-04 83 Rev 6 5/08/92

-""~;.,

~*

" : *. tr TABLE 2.1 TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 BEIO C14 N13 FIS NA22 NA24 P32 AR39 AR41 CA41 SC46 CRSI MNS4 MNS6 FESS FES9 COS7 COSS C060 NIS9 NI63 NI65 CU64 ZN6S ZN69M+D ZN69 SE79 BRS2 BRS3+D BRS4 BRSS

. KRS3M KRSSM KRSS KR87 KRSS+D KRS9 RBS6 RBS7 RBSS RBS9+D SRS9+D SR90+D SR91+D SR92+D

0.

1.06E-07 4.4SE-06 6.94E-07 4.06E-06 S.12E-07 1.ISE-OS 1.ISE-OS S.64E-07 0.

2.34E-OS 2.34E-OS 2.30E-06 2.30E-06 2.76E-04 1.71E-OS

0.
0.
0.
0.

l.97E-04 0.

7.24E-09 1.41E-OS

0.
0.
0.

S.90E-06

0.

1.SSE-07 3.7SE-06 2.6SE-06 5.87E-06 l.37E-OS

0.

2.3SE-07

0.

9.72E-07 0

2.SIE-06 1.32E-OS 4.66E-06 1.77E-04 1.2SE-05 7.49E-07 9.S7E-OS

0.

1.ISE-07 S.76E-06 2.00E-OS 2.40E-07 S.66E-07 1.47E-08 2.SOE-08

0.

3.73E-06

o.
0.
0.
o.
o.
0.
0.
0.
o.
0.
0.
o.

f liJ~~**.*. 1~ 9$E-05 o- -:*'

0-'* ****

l" 75E-05 o:'****' * - a*:s2E-os

0.

5.SOE-08 4.40E-04 0.

8.30E-03 0.

8.07E-06 0.

3.0SE-06 0.

1.06E-07 1.13E-07 S.12E-07 1.ISE-OS 9.47E-OS 2.34E-OS 2.30E-06

1. 07E-OS
0.
0.

2.13E-OS 4.ISE-09 3.60E-09 1.17E-06 2.SIE-OS 6.2SE-07 S.29E-06 3.99E-07 2.24E-06 6.33E-06 2.24E-06 6.00E-06 4.36E-OS S.41E-OS 9.33E-06 S.19E-OS 1.96E-09 6.27E-07 3.04E-06 S.74E-OS 7.22E-OS 3.0SE-09 0 *

0.
0.
0.
0.
0.

1.40E-OS

6. llE-06 4.S4E-08 3.S9E-OS 1.26E:-OS 2.0SE-03 3.21E-07 1.30E-07 I. 06E-07
0.

8.12E-07 I. ISE-08

o.

2.34E-OS 2.30E-06

o.
0.
o.
o.
o.

2.00E-09

o. o.
o.
o.
o.
o.
o.
o.
0.
o.
o.
o.
o.
o.
o.
0.
o.
0.
o.
0.
0.
o.
o.
0.
o.
0.
o.
o.
0.
o.
o.
0.
0.

S4

1. 06E-07 5.30E-07 S.12E-07 I.15E-OS
0.

2.34E-OS 2.30E-06

o.
o.
o.
o.

1.3SE-08 7.S9E-10 1.76E-06 2.00E-07

0.
o.
o.
0.
o.
0.
0.
o.

2.91E-07

1. 2SE-OS 3.44E-07 1.S3E-08 6.SOE-06
o.
o.
o.
o.
0.
o.
o.
o.
o.
o.
o.

1.06E-07

0.

8.12E-07 1.ISE-OS

o.

2.34E-05 2.30E-06

0.
0.
0.
0.
0.

5.14E-09

0.
0.
1. 70E-06 4.32E-06
o.
o.
0.
o.
0.
o.
o.
o.
o.
o.
0.
o.
0.
o.
0.
o.
0.
o.
0.
o.
0.
o.
o.
  • o.
o.
o.
0.
o.

\\

0.

\\\\ 0.

\\ o.

o.
o.

\\ 0.

a.
o.

1.06E-07 2.84E-05 8.12E-07 1.15E-OS 7.78E-OS 2.34E-05 2.30E-06 2.32E-OS

0.
0.

1.9SE-07 4.80E-OS 6.05E-07 1.21E-OS

1. 04E"-OS l.16E-06 3.24E-05
4. 44E:-o6 1.34E-OS 3.66E-OS 7.31E-07
1. 99E-06 5.193-06 S.92E-06 S.47E-06 3.llE-05 S.16E-OS 5.70E-07
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.

4.41r:..05 6.llE-07 7.30E-15 S.43E-17 S.24E-05 2.33E-04 3.66E-OS 7.77E-OS Rev 6 5/08/92

-~-_' -'

TABLE 2.1 TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG Gl-LLI Y90 l.37E-08 0.

3.69E-10

0.
0.
0.

1.13E-04 Y91M+D l.29E-10 o.

4.93E-12

0.
0.
0.

6.09E-09 Y91 2.0lE-07 0.

5.39E-09

0.
0.
0.

8.24E-05 Y92 l.21E-09 O.

3.50E-ll

0.
0.
0.

3.32E-05 Y93 3.83E-09 0.

l.05E-10

0.
0.
0.

1.17E-04 ZR93+0 5.53E-08 2.73E-08 1.49E-08

0.

9.65E-08 0.

2.58E-05 ZR95+0 4.12E-08 l.30E-08 8.94E-09

0.

1.91E-08 0.

3.00E-05 ZR97+D 2.37E-09 4.69E-10 2.16E-10

0.

7.llE-10 0.

l.27E-04 NB93M 3.44E-08 l.13E-08 2.83E-09

0.

l.32E-08 0.

4.07E-06 NB95 8.22E-09 4.56E-09 2.51E-09

0.

4.42E-09 0.

l.95E-05 NB97 7.37E-ll 1.83E-11 6.68E-12

0.

2.14E-ll 0.

4.37E-07 M093

0.

l.06E-05 2.90E-07

0.

3.04E-06 0.

l.29E-06 M099+D

0.

6.03E-06 l.15E-06

0.

l.38E-05 0.

l.OSE-05 TC99M 3.32E-10 9.26E-10 1.20E-08

0.

1.38E-08 5.14E-10 6.08E-07 TC99 l.79E-07 2.63E-07 7.17E-08

0.
  • 3.34E-06 2.72E-08 6.44E~06 TC101 3.60E-10 5.12E-10 5.03E-09
0.

9.26E-09 3.12E-10 8.75E~17 RU103+D 2.55E-07 o.

l.09E-07

0.

8.99E-07 0.

2.13E~05 RU105+D 2.lSE-08 0.

8.46E-09

0.

2.75E-07 0.

l.76E-05 RU106+D 3.92E-06 0.

4.94E-07

0.

7.56E-06 0.

l.88E-04 RH105 l.73E-07 l.25E-07 8.20E-08

0.

5.31E-07 0.

l.59E-05 PD107

0.

2.08E-07 l.34E-08

b.

1~88E-06 0.

9.66E-07 PD109

0.

2.51E-07 5.70E-08

0.

l.45E-06 0.

2.53E-05 AGllOM+D 2.05E-07 l.94E-07 1.18E-07. 0.

3.70E-07 0.

5.45E-05 AGlll 8.29E-08 3.44E-08 l.73E-08

0.

l.12E-07 0.

4.80E-05 CD113M

0.

4.51E-06 l.45E-07

0.

4.99E-06 0.

2.71E-05 CD115M

0.

2.60E-06 8.39E-08

0.

2.08E-06 0.

8.23E-05 5Nl23 4.44E-05 7.29E-07 l.OSE-06 5.84E-07 o.

0.

6.71E-05 5Nl25+D l.19E-05 2.37E-07 5.37E-07 l.86E-07 0.

0.

l.12E-04 5Nl26+D l.16E-04 2.16E-06 3.30E-06 5.69E-07 0.

0.

2.58E-05 58124 3.87E-06 7.13E-08 l.51E-06 8.78E-09 0.

3.38E-06 7.80E-05 58125+0 2.48E-06 2.71E-08:

5.SOE-07 2.37E-09 0.

2.18E-06 l.93E-05 58126 l.59E-06 3.25E-08i 5.71E-07 8.99E-09 0.

l.14E-06. 9.41E-05 58127 3.63E~07 7.76E-09 l.37E-07 4.0SE-09 0.

2.47E-07 6.16E-05 TE125M 3.83E-06 l.38E-06 5.12E-07 l.07E-06 0.

0.

l.13E-05 TE127M+D 9.67E-06 3.43E-06 l.15E-06 2.30E-06 3.92E-05 0.

2.41E-05 TE127 1.5.8E.'."07 5.60E-08 3.40E-08 l.09E-07 6.40E-07 0.

l.22E-05 TE129M+D I.':63'E4os 6.0SE-06 2.58E-06 5.26E-06 6.82E-05 0.

6.12E-05 TE129 4~~*sE:F08. l.67E-08 l.09E-08 3.20E-08 l.SSE-07 o.

2.45E-07 TE131M+D 2}4:4£.'~06' 1.17E-06 9.76E-07 l.76E-06 l.22E-05 0.

9.l9F05 TE13l+D 2~'79E-08 1.15E-08 8.72E-09 2.15E-08.-l.22E-07 0.

2.29E-09 TE132+D 3.49E-06 2.21E-06 2.08E-06 2.33E-a&* 2.12E-QS 0.

7.00E-05 TE133M+D 6.44E-08 3.66E-08 3.56E-08 5.llE-08 3.62E-oi 0.

l.48E-07 TE134+D 4.47E-08 2.87E-08 3.00E-08 3.67E-08 2.74E-07\\ 0.

l.66E-09 1129 4.66E-06 3.92E-06 6.54E-06 4.77E-03 7.0lE-06 \\O.

4.57E-07 1130 1.03E-06 2.98E-06 1.19E-06 2.43E-04 4.59E-06

~.

2.29E-06 1131+0 5.85E-06 8.19E-06 4.40E-06 2.39E-03 l.41E-05 0.

l.62E-06 85 Rev 6 5/08/92

TABLE 2.1 TEEN INGESTION DOSE COMMITMENT FACTORS (MREM,50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THY OID KIDNEY LUNG GI-LLI 1132 2.79E-07 7.30E-07 2.62E-07 2.46E-05 l.15E-06 0.

3.18E-07 1133+0 2.0IE-06 3.41E-06 l.04E-06 4.76E-04 5.98E-06 0.

2.58E-06 1134 l.46E-07 3.87E-07 l.39E-07 6.45E-06 6.lOE-07 0.

5.IOE-09 1135+0 6.lOE-07 l.57E-06 5.82E-07 l.OlE-04 2.48E-06 0.

l.74E-06 XE131M

0.
0.
0.
0.
0.
0.
0.

XE133M

0.
0.
0.
0.
0.
0.
0.

XE133

0.
0.
0.
0.
0.

-0.

0.

XE135M

0.
0.
0.
0.
0.
0.
0.

XE135

0.
0.
0.
0.
0.
0.
0.

XE137

0.
0.
0.
0.
0.
0.
0.

XE138+D 0.

0.
0.
0.
0.
0.
0.

CS134M+O 2.94E-08 6.09E-08 3.13E-08

0.

3.39E-08 5.95E-09 4.05E-08 CS134 8.37E-05 l.97E-04 9.14E-05

0.

6.26E-05 2.39E-05 2.45E-06 CS135 2.78E-05 2.55E-05 5.96E-06

0.

9.73E-06 3.52E-06 4.46E~07 CS136 8.59E-06 3.38E-05 2.27E-05

0.

. l.84E-05 2.90E-06 2.72E~~06 CS137+D l.12E-04 l.49E-04 5.19E-05

0.

5.07E-05 l.97E-05 2.12E~06 CS138

  • 7.76E-08 l.49E-07 7.45E-08
0.

l.lOE-07 l.28E-08 6.76E'~II CS139+D 4.87E-08. 7.17E-08 2.63E-08

0.

5.79E-08 6.34E-09 3.33E~23 BA139 l.39E-07 9.78E-ll 4.05E-09

0.

9.22E-ll 6.74E-ll l.24E-06 BA140+D 2.84E-05 3.48E-08 l.83E-06

0.

l.lSE-08 2.34E-08 4.38E-05 BA14l+D 6.71E-08 5.0lE-11 2.24E-09

0.

4.65E-ll 3.43E-ll l.43E-13 BA142+D 2.99E-08 2.99E-ll l.84E-09

0.

2.53E-ll l.99E-ll 9.lSE-20 LA140 3.48E-09 l.71E-09 4.55E-10

0.

O.

0.

9.82E-05 LA141 4.SSE-10 l.40E-10 2.31E-ll

0.
0.
0.

2.48E-05 LA142 l.79E-10 7.95E-ll l.98E-ll

0.
0.
0.

2.42E-06 CE141 l.33E-08 8.SSE-09 l.02E-09

0.

4.lSE-09 0.

2.54E-05 CE143+D 2.35E-09 l.71E-06 l.91E-10

0.

7.67E-10 0.

5.14E-05 CE144+D 6.96E-07 2.SSE-07 3.74E-08

0.

l.72E-07 0.

l.75E-04 PR143 l.31E-08 5.23E-09 6.52E-10

0.

3.04E-09 0.

4.31E-05 PR144 4.30E-ll l.76E-ll 2.lSE-12

0.

l.OlE-11 0.

4.74E-14 ND147+D 9.38E-09 l.02E-08i 6.llE-10

0.

5.99E-09 0.

3.68E-05 PM147 l.05E~07 9.96E-09; 4.06E-09

0.

l.90E-08 0.

9.47E-06 PM148M+D 4.14E-08 l.OSE-08 8.21E-09

0.

l.59E-08 0.

6.61E-05 PM148 l.02E-08 l.66E-09 8.36E-10

0.

3.00E-09 0.

9.90E-05 PM149 2.HE~~og 3:.0SE;*lO 1.25E-10

0.

5.SlE-10 0.

4.49E-05 PM151 9.S7E~l0:.. l.63E-~10 8.25E-ll

0.

2.93E-10 0.

3.66E-05 SM151 s~*~3E'~~oa.. ;_*l.68E-08 3.94E-09 0..

1.84E-08 0.

5.70E-06 SM153 l.2*2£~.og;_.:.. *l.OlE-09 7.43E-ll

0.

3.30E-10 0.

2.SSE-05 EU152 2~:~45£~0'1 *s~9oE*~os 5.20E-08

0.

2.74E-07 0.

2.17E-05 EU154 7.9lE~07. 1.02£".:.07 7.19E-08

0.

,.'*4.56E-07 0.

5.39E-05 EU155 1.74E~07. 1.68£-08 1.04E-08

0.

6.57E-0'8 0.

9.63E-05 EU156 1.92E-08 l.44E-08 2.35E-09

0.

9.69E-09\\ O.

7.36E-05 TB160 6.47E-08 0.

8.07E-09

0.

2.56E-08 \\0.

4.19E-05 H0166M 3.57E-07 l.lOE-07 7.96E-08

0.

l.61E-07 0.

O.

Wl81 l.42E-08 4.SSE-09 4.79E-10

0.
0.

O~

3.90E-07 WISS 5.79E-07 l.91E-07 2.02E-08

0.
0.
0.

l.65E-05 Wl87 1.46E-07 l.19E-07 4.17E-08

0.
0.
0.

3.22E-05 86 Rev 6 5/08/92

TABLE 2.1 TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+0 l.81E-02 5.44E-03 7.0lE-04

0.

l.72E-02 O.

5.74E-05 81210+0 6.59E-07 4.51E-06 5.66E-08 O.

5.48E-05 0.

5.15E-05 P0210 6.09E-04 l.07E-03 1.23E-04

0.

3.60E-03 0.

6.75E-05 RN222+D

0.
0.
0.
0.
0.
0.

O.

RA223+D 7.llE-03 l.08E-05 1.42E-03

0.

3.lOE-04 0.

3.43E-04 RA224+D 2.31E-03 5.52E-06 4.61E-04

0.

l.58E-04 0.

3.71E-04 RA225+D 9.37E-03 l.lOE-05 l.87E-03 O.

3.15E-04 0.

3.27E-04 RA226+D 3.22E-Ol 8.13E-06 2.39E-Ol O.

2.32E-04 0.

3.51E-04 RA228+D l.37E-Ol 4.41E-06 l.51E-Ol

0.

l.26E-04 0.

5.98E-05 AC225 6.29E-06 8.59E-06 4.22E-07

0.

9.85E-07 0.

4.36E-04 AC227+D 2.05E-03 3.03E-04 l.22E-04

0.

8.81E-05 0.

8.68E-05 TH227+D l.96E-05 3.52E-07 5.65E-07 O.

2.0lE-06 0.

5.75E-04 TH228+D 6.80E-04 l.14E-05 2.30E-05

0.

6.41E-05 0.

5.97E-04 TH229 8.39E-03 l.26E-04 4.llE-04

0.

6;10E-04 0.

5.43E-04 TH230 2.16E-03 l.23E-04 6.00E-05

o.

' 5.99E-04 o.

6.38E~05 TH232+D 2.42E-03 l.05E-04 l.63E-04

0.

5.llE-04 o.

5.43E~05 TH234.

l.14E-07 6.68E-09 3.31E-09

0.

3.81E-08 0.

l.21E.:-04 PA23l+D 4.31E-03 l.62E-04 l.68E-04

0.

9.lOE-04 0.

7.60E~05 PA233 7.33E-09 l.41E-09 l.26E-09 O.

5.32E-09 0.

l.61E-05 U232+D 5.89E-03 0.

4.21E-04

0.

6.38E-04 0.

7.19E-05 U233+D l.24E-03 0.

7.543-05

0.

2.90E-04 0.

6.65E-05 U234 l.19E-03 0.

7.39E-05

0.

2.85E-04 0.

6.51E-05 U235+D l.14E-03 0.

6.94E-05

0.

2.67E-04 0.

8.28E-05 U236 l.14E-03 0.

7.09E-05

0.

2.73E-04 0.

6.llE-05 U237 7.89E-08 0.

2.lOE-08

0.

3.24E-07 0.

2.09E-05 U238+D l.09E-03 0.

6.49E-05

0.

2.50E-04 0.

5.83E-05 NP237+D l.44E-03 l.25E-04 5.85E-05

0.

4.33E-04 0.

8.41E-05 NP238 l.95E-08 5.22E-10 3.04E-10

0.

l.79E-09 0.

3.83E-05 NP239 l.76E-09 l.66E-10 9.22E-ll

0.

5.21E-10 0.

2.67E-05 PU238 7.21E-04 l.02E-04 l.82E-05 O.

7.SOE-05 0.

7.73E-05 PU239 s~27E-04 l.12E-04; 2.0lE-05

0.

8.57E-05 0.

7.06E-05 PU240 8.26E-04 l.12E-04:

2.0IE-05

0.

8.56E-05 0.

7.19E-05 PU24l+D l.84E:os 9.42E-07 3.69E-07

o.

l.71E-06 o.

I.48E-06 PU242 7.6_6E-04 1.08.E-04 l.94E-05

0.

8.25E-05 0.

6.92E-05 PU244 8,.95£.:_04 :1:23E-04 2.22E-05

0.

9.45E-05 0.

l.03E-04 AM241

  • 9,;~~EiOA\\. 3.29E-04
5. 75E-05
0.

4.31E-04 O.

7.87E-05 AM242M s:~;*ZOE~~o4;. 3.. 19E-04 5.SOE-05

0.

4.30E-04 0.

9.90E-05 AM243 8:~6.0E1~04,.: 3-.17E-04 5.62E-05

0.

4.22E-04 0.

9.23E:-05 CM242 2;~\\9JE7'#.Q5;. 2~97E-05 1.95E-06

0.

8.89E-06 0.

8.40E-05 CM243 61;g1,E4'()~~~*2.86E-04 4.09E-05

0.

/*I.91E-04 O.

8.28E-05 CM244 5~32E*~o*4-2.49E-04 3.19E-05

0.

- l.49E-04 0.

8.00E-05 CM2~5 l.07E-03 3.33E-04 6.lOE-05 O.

2.85E-04\\ 0.

7.46E-05 CM246 1.06E-03 3.32E-04 6.09E-05

0.

2.84E-04 \\_ O.

7.33E-05 CM247+D l.03E-03 3.27E-04 6.00E-05

0.

2.SOE-04 \\0.

9.63E-05 CM248 8.60E-03 2.69E-03 4.95E-04

0.

2.llE-03 O~

I.55E-03 CR252 3.SIE-04 0.

8.37E-06

0.

O.

0.

3.05E-04 87 Rev 6 5/08/92

~ '~ >' -

TABLE 2.1 ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 BEIO Cl4 Nl3 FIS NA22 NA24 P32 AR39 AR41 CA41 SC46 CRSI MN54 MN56 FESS FE59 C057 COSS C060 NI59 NI63 NI65 CU64 ZN65 ZN69M+D ZN69 SE79 BRS2 BRS3+D BRS4 BRSS KRS3M KRS5M KRS5 KRS7 KRSS+D KRS9 RB86 RB87 RB88 RB89+D SR89+0 SR90+0 SR91+0 SR92+0

0.

3.18E-06 2.84E-06 8.36E-09 6.24E-07

1. 74E-05
1. 70E-06
1. 93E-04
0.
0.

1.83E-05 5.SlE-09

0.
0.
0.

2.75E-06 4.34E-06

0.
0.
0.

9.76E-06 1.30E-04 5.28E-07

0.

4.84E-06 l.70E-07 l.03E-08

0.
0.
o.
0.
0.
0.
o.
0.

~~f~;

0.
0.
o.

3.0SE-04 7.58E-03 5.67E-06 2.15E-06 1.05E-07 4.91E-07 5.68E-07 8.36E-09

.o.

1. 74E-05
1. 70E-06 1.20E-05
0.
0.
0.
1. 07E-08
0.

4.57E-06

1. ISE-07 I. 90E-06 l.02E-05 1.75E-07 7.45E-07 2.14E-06 3.35E-06 9.0lE-06 6.86E-08 8.33E-08 I. 54E-05 4.08E-07 l.97E-08 2.63E-06
0.
o.
0.
0.
0.
0.
o.
0.
o.
0.
2. llE-05 l.23E-05 6.0SE-08 4.0IE-08
0.
0.
0.
0.

1.0SE-07 7.94E-08 5.68E-07 8.36E-09 6.92E-08 l.74E-05 l.70E-06 7.46E-06

0.
0.

2.00E-05

3. llE-09 2.66E-09 8.72E-07 2.04E-08 4.43E-07 3.91E-06 2.91E-07 1.67E-06 4~72E-06 1.63E-06 4.36E-06 3.13E-08 3.91E-08 6.96E-06 3.73E-08 l.37E-09 4.39E-07 2.26E-06 4.02E-08 5.21E-08 2.14E-09
o.
0.
o.
0.
o.
o.

9.83E-06 4.2SE-06 3.21E-08 2.82E-OS S.84E-06 l.86E-03 2.29E-07 9.30E-08 1.0SE-07 l.OSE-07 1.05E-07

0.

3.71E-07 0.

5.6SE-07 5.68E-07 5.68E-07 8.36E-09 8.36E-09 8.36E-09

0.
0.
0.

1.74E-05 1.74E-05 l.74E-05 1.70E-06 l.70E-06 l.70E-06

0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.

9.99E-09 0.

1.59£-09 5.S6E-10 3.53E-09

0.

l.36E-06 0.

0.

l.46E-07 0.

0.
0.

1.06E-06

0.
0.

2.85E-06

0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
o.
0.
0.
0.
0.
0.
0.
0.

2.IOE-07 0.

0.

l.03E-05 0.

0.

2.47E-07 0.

0.

l.28E-08 0.

0.

4.SSE-06 0.

0.
0.
o.
0.
o.
0.
0.
0.
0.
o.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
0.
o.
0.
o.
o.
o.
0.

..--o.

0.
0.
0.

\\

0.
0.
0.
o.
0.
0.

\\O.

0.
0.

'O

0.
o.

o:

0.
0.
0.

88

1. OSE-07 2.6SE-05 5.6SE-07 8.36E-09
1. SSE-08 l.74E-05
1. 70E-06 2.17E-05
0.
0.

l.84E-07 5.21E-05 6.69E-07 I. 40E-05 3.67E-06

  • 1.09E-06 3.40E-05 4.44E-06 l.SlE-05 4.02E-05 6.90E-07 l.SSE-06
1. 74E-06 7.IOE-06 9.70E-06 2.49E-05 2.96E-09 5.38E-07 2.59E-06 5.79E-08 4.09E-13
0.
o.
o.
o.
0.
0.
0. -----

4.16E-06 5.76E-07 8.36E-19 2.33E-21 4.94E-05 2.19E-04 2.70E-05 4.26E-05 Rev 6 5/08/92

~.*~

TABLE 2.1 ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 9.62E-09 0.

2.58E-10

0.
0.

O.

1.02E-04 Y91M+D 9.09E-11 0.

3.52E-12 O.

0.

O.

2.67E-10 Y91 l.41E-07 0.

3.77E-09

0.

O.

0.

7.76E-05 Y92 S.45E-10 0.

2.47E-ll

0.
0.
0.

l.48E-05 Y93 2.68E-09 0.

7.40E-ll

0.
0.
0.

8.SOE-05 ZR93+D 4.ISE-08 2.34E-09 l.09E-09 O.

8.87E-09 0.

2.43E-06 ZR95+D 3.04E-08 9.75E-09 6.60E-09 O.

l.53E-08 0.

3.09E-05 ZR97+D l.6SE-09 3.39E-10 l.SSE-10

0.

5.12E-10 0.

l.OSE-04 NB93M 2.SSE-OS S.32E-09 2.0SE-09

0.

9.57E-09 0.

3.84E-06 NB95 6.22E-09 3.46E-09 l.S6E-09

0.

3.42E-09 0.

2.IOE-05 NB97 5.22E-ll l.32E-ll 4.S2E-12

0.

l.54E-ll 0.

4.S7E-08 M093

0.

7.SlE-06 2.03E-07

0.

2.13E-06 0.

l.22E-06 M099+D

0.

4.31E-06 8.20E-07

0.

9.76E-06 O.

9.99E-06 TC99M 2.47E-10 6.9SE-10 S.S9E-09

0.

l.06E-OS 3.42E-10 4.13E-07 TC99 l.25E-07 l.S6E-07 5.02E-OS

0.
  • 2.34E-06 I.SSE-OS 6.0SEr06 TClOl 2.54E-10 3.66E-IO*

3.59E-09

0.

6.59E-09 1.S7E-10 1.IOE'-21 RU103+D l.SSE-07 0.

7.97E-OS

0.

7.06E-07 0.

2.16E~05 RUIOS+D l.54E-OS 0.

6.08E-09

0.

l.99E-07 0.

9.42E~06 RU106+D 2.75E-06 0.

3.4SE-07

0.

5.31E-06 0.

l.7SE-04 RH105 l.21E-07 S.SSE-OS 5.S3E-OS

0.

3.76E-07 0.

l.41E-05 PD107

0.

l.47E-07 9.40E-09

0.

l.32E-06 0.

9.llE-07 PD109

0.

l.77E-07 3.99E-OS

0.

l.OIE-06 0.

l.96E-05 AGllOM+D l.60E-07 l.4SE-07 S.79E-OS

0.

2.91E-07 0.

6.04E-05 AGlll 5.SIE-08 2.43E-OS l.21E-OS

0.

7.S4E-OS 0.

4.46E-05 CD113M

0.

3.ISE-06 l.02E-07

0.

3.SOE-06 O.

2.56E-05 CDllSM

0.

l.84E-06 5.S7E-OS O.

l.46E-06 0.

7.74E-05 SN123 3.llE-05 5.ISE-07 7.59E-07 4.38E-07 0.

0.

6.33E-05 SN125+D. S.33E-06 l.68E-07 3.7SE-07 l.39E-07 0.

0.

l.04E-04 SN126+D 8.45E-05 l.67E-06 2.40E-06 4.92E-07 0.

0.

2.43E-05 SB124 2.SOE-06 5.29E-08 1.llE-06 6.79E-09 O.

2.ISE-06 7.95E-05 SB125+D l.79E-06 2.00E-08; 4.26E-07 1.82E-09 0.

1.3SE-06 l.97E-05 SB126 l.ISE-06 2.34E-08' 4.ISE-07 7.04E-09 O.

7.0SE-07 9.40E-05 SB127 2.saE:o7 5.6SE-09 9.90E-OS 3.IOE-09 0.

1.53E-07 5.90E-05 TE125M 2.68E-06* 9.71E-07 3.59E-07 S.06E-07 1.09E-05 0.

l.07E-05 TE125M+O 6.J.7E.;06 *2.42E-06 8.25E-07 l.73E-06 2.75E-05 0.

2.27E-05 TE127 lA*:OE*~ot" 3.9SE-08 2.3SE-08 8.lSE-OS 4.4SE-07 o.*

8.6SE-06 TE129M+O LI1 15.e;~Q'.5_. 4.29E-06 l.S2E-06 3.95E-06 4.SOE-05 o.

5.79E-05 TE129 3~c'l4E~o*a l.18E-08 7.65E-09 2.41E-08 l.32E-07 o.

2.37E_-OS TE131M+O t.l3:E~06'., _ 8.* 46E-07 7.OSE-07 1.34E-06 S.57E-06 0.

8.40E-05 TE131+0 l.9Z£4()8': S.23E-09 6.22E-09 1.62E-08... '8.63E-08 0.

2.79E-09 TE132+0 2.52E-06 l.63E-06 l.53E-06 1.80E-06. l.57E-05 O.

7.71E-05 TE133M+D 4.62E-08 2.70E-08 2.60E-OS 3.91E~08 2.67E-O'A. 0.

6.64E-08 TE134+0 3.24E-08 2.12E-OS I.JOE-OS 2.SJE-08 2.0SE-07\\ 0.

3.59E-ll 1129 3.27E-06 2.SlE-06 9.21E-06 7.23E~03 6.04E-06 *o.

4.44E-07

. 1130 7.56E-07 2.23E-06 S.SOE-07 1.S9E-04 3.48E-06 Q..

1.92E-06 1131+0 4.16E-06 5.95E-06 3.41E-06 l_.95E-0.3 1.02E-05 O.

l.57E-06 89 Rev 6 5/0S/92

TABLE 2.1 ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 2.03E-07 5.43E-07

1. 90E-07 1.90E-05 8.65E-07 o.
1. 02E-07 1133+0 1.42E-06 2.47E-06 7.53E-07 3.63E-04 4.31E-06 0.

2.22E-06 1134

1. 06E-07 2.88E-07
1. 03E-07 4.99E-06 4.58E-07 0.

2.51E-10 1135+0 4.43E-07 1.16E-06 4.28E-07 7.65E-05 1.86E-06 0.

1.31E-06 XE131M

0.
0.
0.
0.
0.
0.
0.

XE133M

0.
0.
0.
0.
0.
0.
0.

XE133

0.
0.
0.
0.
0.
0.
0.

XE135M

0.
0.
0.
0.
0.
0.
0.

XE135

0.
0.
0.
0.
0.
0.
0.

XE137

0.
0.
0.
0.
0.
0.
0.

XE138+0 0.

0.
0.
0.
0.
0.
0.

CS134M+D 2.13E-08 4.48E-08 2.29E-08

0.

2.43E-08 3.83E-09 1. 58E-08 CS134 6.22E-05 1.48E-04 1.21E-04

o.

4.79E-05 1. 59E-OS 2.59E-06 CS135 1.9SE-05 I.BOE-OS 7.99E-06

0.

6.BlE-06 2.04E-06 4.21E-07 CS136 6.SlE-06 2.S7E-OS I.SSE-OS

0.

1.43E-OS 1. 96E-06 2.92E-06 CS137+0 7.97E-OS 1. 09E-04 7.14E-OS

0.

3.70E-OS l.23E-OS 2.llE-06 CS138.

6.S2E-08 l.09E-07 5.40E-08

0.

8.0IE-08 7.91E-09 4.65E-13 CS139+0 3.41E-08 5.0BE-08

1. BSE-08
0.

4.07E-08 3.70E-09 l. IOF-30 BA139 9.70E-08 6.91E-ll 2.84E-09

0.

6.46E-ll 3.92E-ll 1. 72E-07 BA140+0 2.03E-OS 2.SSE-08 l.33E-06

0.

8.67E-09 1. 46E-08 4.lBE-05 BA141+0 4. 71E-08 3.S6E-ll

1. S9E-09
0.

3.31E-ll 2.02E-ll 2.22E-17 BA142+0 2.13E-08 2.19E-ll 1.34E-09

0.

l.85E-ll 1.24E-ll 3.00E-26 LA140 2.SOE-09 1. 26E-09 3.33E-10

0.
0.
0.

9.2SE-OS LA141 3.19E-10 9.90E-ll 1.62E-ll

0.
0.
0.

1.18E-OS LA142 1.28E-10 S.82E-ll 1.45E-ll

0.
0.
0.

4.2SE-07 CE141 9.36E-09 6.33E-09 7.lBE-10

0.

2.94E-09 0.

2.42E-OS CE143+0

1. 6SE-09
1. 22E-06 l.3SE-10
0.

S.37E-10 0.

4.S6E-05 CE144+0 4.BBE-07 2.04E-07 2.62E-08

0.

1.21E-07 0.

1. 6SE-04 PR143 9.20E-09 3.69E-09 4.56E-10
0.

2.13E-09 0.

4.03E-05 PR144 3.0lE-11

1. 25E-ll
1. 53E-12
0.

7.0SE-12 0.

4.33E-18 N0147+D 6.29E-09 7.27E-09*

4.35E-10

0.

4.25E-09 0.

3.49E-OS PM147 7.54E-08 7.09E-09i 2.87E-09

0.

l.34E-08 0.

8.93E-06 PM148M+O 3.07E:oa 7.95E-09 6.0SE-09

0.

l.20E-08 0.

6.74E-05 PM148 7.17E-09 l.19E-09 5.99E-10

0.

2.25E-09 0.

9.35E-05 PM149 1.52£-09 2.lSE-10

8. 78E-ll
0.

4.06E-10 o.

4.03E-05 PM151 6~.91E;10 l.17E-10 5.91E-ll

0.

2.09E-10 0.

3.22E-OS SM151 6~190E;:oa l.19E-08 2.SSE-09

0.

1.33E-08 0.

5.25E-06 SM153 8 ~ SJE:~* lO.

  • 7.lSE-10 5.22E-ll
0.

2.31E-10 0.

2.55E-OS EU152 1 ~*95Et0.7 4.44E-08 3.90E-08

0.

2.75E-07 0.

2.56E-05 EU154 6.lSE;;.07 7.56E-08 5.38E-08

0.

.* *J.62E-07 0.

5.48E-05 EU I SS 8.60E-08 1. 22E-08 7.87E-09

0.
5. 63E-Q8 0.

9.60E-06 EU156 l.37E-08 l.06E-08 l.71E-09

0.

7.0SE-0~ o.

7.26E-05 TB160 4.70E-08 0.

5.86E-09

0.

l.94E-08\\. O.

4.33E-05 H0166M 2.70E-07 8.43E-08 6.40E-08

0.

l.26E-07 0.

0.

Wl81 9.91E-09 3.23E-09 3.46E-10

0.
0.
n.

3.68E-07 WISS 4.0SE-07 l.35E-07 l.42E-08

0.
0.
0.
1. S6E-05 Wl87 l.03E-07 8.61E-08 3.0lE-08
0.
0.
0.

2.82E-OS 90 Rev 6 5/08/92

TABLE 2.1 ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/SOY PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG Gl-LLI PB210+0 l.53E-02 4.37E-03 5.44E-04

0.

1.23E-02 0.

5.42E-05

  • 81210+0 4.61E-07 3.18E-06 3.96E-08
0.

3.83E-05 0.

4.75E-05 P0210 3.56E-04 7.56E-04 8.59E-05

0.

2.52E-03 O.

6.36E-05 RN222+0 0.

0.
0.
0.
0.
0.
0.

RA223+D 4.97E-03 7.65E-06 9.94E-04

0.

2.17E-04 0.

3.21E-04 RA224+D l.61E-03 3.90E-06 3.23E-04

0.

1.lOE-04 0.

3.40E-04 RA225+D 6.56E-03 7.78E-06 1.31E-03 O.

2.21E-04 0.

3.06E-04 RA226+D 3.02E-01 5.74E-06 2.20E-Ol O.

1.63E-04 0.

3.32E-04 RA228+D l.12E-Ol 3.12E-06 1.21E-Ol

0.

8.83E-05 0.

5.64E-05 AC225 4.40E-06 6.06E-06 2.96E-07

0.

6.90E-07 0.

4.07E-04 AC227+D l.87E-03 2.48E-04 1.llE-04

0.

8.00E-05 0.

8.19E-05 TH227+D l.37E-05 2.48E-07 3.95E-07

0.

1.41E-06 0.

5.40E-04 TH228+D 4.96E-04 8.40E-06 1.68E-05

0.

4.67E-05 0.

5.63E-04 TH229 7.98E-03 l.19E-04 3.91E-04

0.

5.75E-04 0.

5.12E-04 TH230 2.06E-03 l.17E-04 5.70E-05

0.

5.65E-04 0.

6.02E~05 TH232+D 2.30E-03 l.OOE-04.

l.50E-04

0.

4.82E-04 0.

5.12E~05 TH234

  • 8.0IE-08 4.71E-09 2.31E-09
0.

2.67E-08 0.

1.13E~;.04 PA231+D 4.IOE-03 l.54E-04 l.59E-04

0.

8.64E-04 0.

7.17E;.05 PA233 5.26E-09 l.06E-09. 9.12E-10

0.

3.99E-09 0.

1.64E-05 U232+D 4.13E-03

0.

2.95E-04

0.

4.47E-04 0.

6.78E-05 U233+D 8.71E-04 0.

5.28E-05

0.

2.03E-04 0.

6.27E-05 U234 8.36E-04 0.

5.17E-05

0.

l.99E-04 0.

6.14E-05 U235+D 8.0IE-04 0.

4.86E-05

0.

l.87E-04 0.

7.81E-05 U236 8.0IE-04 0.

4.96E-05

0.

l.91E-04 0.

5.76E-05 U237 5.52E-8

0.

l.47E-08

0.

2.27E-07 0.

l.94E-05 U238+D 7.67E-04 0.

4.54E-05

0.

l.75E-04 0.

5.50E-05 NP237+D l.37E-03 l.19E-04 5.54E-05

0.

4.12E-04 0.

7.94E-05 NP238 l.37E-08 3.69E-10 2.13E-10

0.

l.25E-09 0.

3.43E-05 NP239 l.19E-09 I.17E-10 6.45E-11

0.

3:65E-10 0.

2.40E-05 PU238 6.80E-04 9.58E-05 l.71E-05

0.

7.32E-05 0.

7.30E-05 PU239 7.87E-04 l.06E-04:

l.91E-05

0.

8.IIE-05 O.

6.66E-05 PU240 7.85E-04 l.06E-04:

1.91E-05

0.

8.IOE-05 0.

6.78E-05 PU24l+D l.65E-05 8.44E-07 3.32E-07

0.

l.53E-06 0.

l.40E-06 PU242 7.29E-04 l.02E-04 l.84E-05

0.

7.81E-05 0.

6.53E-05 PU244 8.5ZE~04

  • l.17E-04 2.llE-05
0.

8.95E-05 0.

9.73E-05 AM241 8.l9Ei04 2.SSE-04 5.41E-05

0.

4.07E-04 0.

7.42E-05 AM242M S.2lE~04*. 2.78E-04 5.43E-05

0.

4.0SE-04 0.

9.34E-05 AM243 a~tsE.~.04 2.78E-04 5.30E-05

0.

3.99E-04 0.

8.70E~05 CM242 2:'06El;OS 2.IOE-05 1.37E-06

0.

6.22E-06 0.

7.92E-05 CM243 6.39E;;*oot 2*.41E-04 3.75E-05

0.

, 1.75E-04 0.

7.SIE-05 CM244 4.83E-04 2.07E-04 2.87E-05

0.

I.34E-04 0.

7.55E-05 CM245 l.02E-03 2.87E-04 5.76E-05 O.

2.69E-04\\ 0.

7.04E-05 CM246 l.OIE-03 2.87E-04 5.75E-05

0.

2.68E-04 'O.

6.91E-05 CM247+0 9.84E-04 2.83E-04 5.67E-05

0.

2.64E-04 *a.

9.09E-05 CM248 8.ISE-03 2.33E-03 4.67E-04

0.

2.ISE-03 d~

1.47E-03 CF252 2.64E-04 0.

6.29E-06

0.
0.
0.

2.SSE-04 91 Rev 6 5/08/92

-._ *- ".... *-... :..;:.~*

~: __...

  • '11

~

Nuclide Half-Life H-3 12.3 yr Na-24 15 h Sc-46 83.9 d Cr-51 27.8 d Mn-54 303 d Fe-55 2.6 yr Mn-56 2.576 h Co-57 270 d Co-58 71.3 d Fe-59 45.6 d Co-60 5.26 hr Cu-64 12.8 Ni-65 2.56 h Zn-65 245 d Br-84 31.8 mo Rb-86 1.02 mo Rb-88 17.8 mo Sr-89 52.7 d Sr-90 27.7 hr Sr-91 9.67 Sr-92

2. 71 h Y-92 3.53 h Nb-95 35 d,- : "

7 Zr-95

&s'*-sfcf" -- :

\\}.,

""i;**.

Nb-97 7~~1~~;'.~--

Zr-97 11 'ti<

.,,r,u

£;;.-".,,*"*

Mo-99

&&;~Y"-ti-Tc-99m 6.05 h Ru-103 39.5 d Ag-llOm 255 d TABLE 2.2 PALISADES Liquid Effluent Design Objective Annual Quantity Dose Conversion Factors {mremLCil IndividualLOrgan I. 75E-06 Adult/TB 5.44E-03 Teen/TB 2.02E-02 Teen/TB I. 56E-03 Adult/GI (LLI) 3.50E-02 Teen/TB 4.48E-03 Child/Bone l.86E-03 Teen/TB 4.39E-03 Teen/TB I. 03E-02 Teen/TB 4.08E-02 Adult/GI (LLI) 4.71E-Ol Teen/TB I.32E-03 Teen/GI (LLI) 5.82E-04 Teen/TB l.83E-Ol Teen/TB 2.02E-03 Teen/TB 3.06E-Ol Child/TB 6.92E-04 Teen/TB I. 56E-Ol Child/Bone 2.71E-OO Adult/Bone L 16E-03 Teen/TB I. 51E-03 Teen/TB 2.69E-04 Teen/TB 7.24E+OO Adult/GI (LLI) 6.17E-03 Teen/TB 6.95E-04 Teen/TB 9.28E-04 Teen/TB I. llE-03 Teen/Kidney I.42E-04 Teen/TB

\\

2.74E-03 Teen/TB

\\

7.75E-02 Teen/TB

\\

\\

92 Design Objective Annual Quantity

{Curies}

1. 71E+06 551.5 148.5 6,410.0 85o7 2,232.0 1,612.0 683.4 291.3 245.1 6.37 7,575.0 5_, 154. 0 16.4 1,485.2 9.80 4,335.3 64.1 3.69 2,586.0 1,986.8 11, 150.0 1.38 486.2 4,316.6 3;232.8 -

9,009.0 21,126.8 1,094.9 38.7 Rev 6 5/08/92

Nuclide Half-Life Cd-113m 13.6 yr Sb-124 60 d Sb-125 2.7 yr Te-127 9.4 h Te-127m 109 d Te-129m 34.l d I-130 12.3 h I-131 8.05 d Te-13lm

  • 30 h I-132 2.26 h Te-132
77. 7 h I-133 20.3 h Cs-134 2 yr 1-134 52 mo I-135 6.68 h Cs-136 13.7 d Cs-137 30 yr Cs-138 32.2 mo Ba-139 82.9 mo Ba-140 12.8 d La-140 40.22 h Ce-141 32.5 d Ce-144 284 d Eu-152

~~;,~;~hr W-187

.;--~:-::.::.-

~-

Np-239 2.'346;*;-d_

~.-.\\.._*:;:<:.*-

TABLE 2.2 (continued)

PALISADES Liquid Effluent Design Objective Annual Quantity Dose Conversion Factors (mremLCi}

IndividualLOrgan 6.02E-02 Adult/GI (LLI}

l.51E-02 Teen/TB 5.llE-02 Teen/TB 7.38E-03 Teen/GI {LLI}

1.39E-01 Teen/Kidney 2.66E-01 Adult/GI (LLI}

1.17E-02 Child/Thyroid 3.27E-Ol Child/Thyroid 2.27E-Ol Adult/GI (LLI}

3.18E-05 Teen/TB 2.93E-Ol Adult/GI (LLI}

3.94E-02 Child/Thyroid 2.86E+OO Adult/TB 2.43E-03 Teen/TB

l. 64E-03 Child/Thyroid 4.13E-Ol Adult/TB
1. 71E+OO Adult~TB 2.31E-03 Teen/ B 4.66E-05 Teen/TB 7.96E-04 Teen/TB 1:85E-02 Adult/GI (LLI}

3.70E-04 Teen/TB 1.56E-03 Teen/TB 3.24E-Ol Teen/TB 1.98E-01 Adult/GI (LLI}

2.26E-03 Adult/GI (LLI}

' \\

93 Design Objective Annual Quantity

{Curies}

166.1 198.7 58.7 1,355.0 71.9 37.6 854.7 30.6 44.0 94,339.0 34.l 253.8 l.04 1;234.0 6,097.0 7.26

l. 75 1,298.0 64,377. 0 3,768.0 540.5 8,108.0 1,923.0 9.25 50.5 4,424.0 ----

\\

Rev 6 5/08/92

ATTACHMENT 7 Consumers Power Company Palisades Plant Docket 50-255 SEMIANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT CRITICAL RECEPTOR ITEMS August 27, 1992 1 Page

Distance Sector (Miles)

SSE 0.48 s

0.50 ESE 3.10 ENE 4.00 ENE 3.80 NOTE:

  • Based on TABLE l.4a 1991 PALISADES LAND USE CENSUS TABLE 10.11-3 Critical Receptor Items Location/Description Item Site Boundary N/A Residence, Palisades Park Residence/

3/4 mile West of 29th Garden Avenue and Blue Star intersection.

Newel, 73419 30th Ave Beef Covert, '(South side of Cattle road).

Cecil Hodge, 16971 72nd Dairy Street, 3.8 mile South of 16th Avenue and 72nd Street intersection (west side of 72nd Street).

Harlett, 19487 72nd Street Goat 1/4 mile South of 72nd Street CR 380 intersection.

Palisades 5-year composite meteorological 38

  • X/O ( s ec/m3 l l.40E-06 l.OOE-06 7.40E-08 6.40E-08 6.90E-08 data, 1983-1987.

Rev 6 5/08/92

~*

ATTACHMENT 8 Consumers Power Company Palisades Plant Docket 50-255 SEMIANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT 1991 PALISADES LAND USE CENSUS August 27, 1992 1 Page

TABLE 1.4 1991 PALISADES LAND USE CENSUS TABLE 10.11-1 Distance to the nearest residence, garden;. dairy/beef cattle and goat in SECTOR RESIDENCE GARDEN BEEF CATTLE DAIRY COW.

N

> 5 mi

> 5 mi

> 5 mi

> 5 mi NNE I.6 mi 3.8 mi

> 5 mi

> 5 mi NE I.8 mi I.8 mi

> 5 mi

> 5 mi ENE I.3 mi I.5 mi 4.0 mi 4.0 mi E

I. 0 mi

i. I mi 3.5 mi

> 5 mi ESE I.O mi 1.0 mi 3.I mi 4.0 mi SE

. 9 mi I.I mi 3.8 mi 4.3 mi SSE

.75 mi l.5 mi

> 5 mi

> 5 mi s

.5 mi

.5 mi

> 5 mi

> 5 mi SSW

.75 mi I.5 mi

> 5 mi

> 5 mi 37 each sector.

GOAT

> 5 mi

> 5 mi

> 5 mi 3.8 mi

> 5 mi

> 5 mi

> 5 mi

> 5 mi

> 5 mi

> 5 mi Rev 6 5/08/92

ATTACHMENT 9 Consumers Power Company Pali sades Pl ant Docket 50-255 SEMIANNUAL RADIOACTIVE EFFLUENT RELEASE REPORT SAFETY REVIEW August 27, 1992 I Page

1.

Does the item involve a FSAR?

FSAR Sections affected FSAR Sections reviewed

2.

Does the item involve a the FSAR?

FSAR Sections affected FSAR Sections reviewed PS&L Log No change to procedures as described in the

~.'Z"- ' fr*S:1 j&,~ a-:1~

change to the facility as described in N~

a.,

j 11. 5' 1 ~J-a~

Revision 5 Page l of l SE Re...-

3.

Does the item involve a test or experiment not described in the FSAR Sections affected O"l\\.e.

FSAR?

~

FSAR Sections reviewed

---a----,---~11-.~s~,__,iij...._~...---a---#-::l __________ __

4.

Does the ftem involve na ch::~to. tlle 'rechnical.---Spec*ification? --- **

TS Sections affected

~~

TS Sections reviewed


~'~*~l~i-------------------------------~

If any Safety Review question listed above is answered "YES", perform a written USQ Evaluation according to Section S'.3.

If all Safety Review questions listed above are answered NO, written USQ Evaluation is not required.

However, this Attachment shall accompany other review materials fo:

the item to document that a Safety Evaluation was not required.

~ 1 11/;w(er1 ReVi8W8dBY Date